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Abstract 
Microglia are the principal immune cells of the central nervous system and as such 
are crucial for maintaining integrity of the neuronal network in health and disease. 
Microglia become activated when they sense changes in their extracelluar 
environment which is accompanied by changes in morphology and gene 
expression. Acute microglial activation is important to mediate and resolve 
neuroinflammation. However, sustained activation of microglia is observed in 
chronic neuropathologies such as Alzheimer’s Disease and Parkinson’s Disease. 
It still remains controversial whether chronically activated microglial cells are 
neuroprotective or neurotoxic. Thus, a better understanding of the mechanisms of 
microglial activation is required. 
One aim of this project was to investigate the role of integrin receptor 
CD11b/CD18 (complement receptor 3, CR3) in microglial activation. CD11b is 
expressed by microglia and macrophages within the CNS and its expression up-
regulated on activated cells. This receptor has a prominent role in the immune 
response of closely related peripheral immune cells, but has been inadequately 
studied in microglia. 
Another aim was to develop non-viral vehicles in order to study microglial 
function by targeted gene transfer. These vehicles (‘immunogenes’) are based on 
monoclonal antibodies and could provide a safer alternative to viral gene transfer 
and increased cell type specificity. Targeted gene transfer into microglia with non-
viral vehicles has not been achieved so far. 
Part 1 of this project used the monoclonal α-CD11b antibody OX42 as tool to 
investigate CD11b function in vitro. Immunofluorescence studies identified a role 
of microglial CD11b in mediating microglial activation. OX42 antibody induced 
receptor clustering in the membrane, receptor internalization and lysosomal 
trafficking of internalized antibody. Evidence suggested that internalized CD11b 
receptor is recycled to membrane ruffles in activated microglia.  
 The OX42 antibody caused partial microglial activation as judged by 
macropore formation but it did not stimulate a strong immune response in terms of 
respiratory burst activity. In contrast, CD11b/CR3 triggered microglial activation 
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and a phagocytosis-induced respiratory burst when stimulated with particulate 
material (beads coated with intact OX42 antibody). This strong inflammatory 
response most likely also involved Fcγ-receptors (FcγR), because beads coated 
with OX42-F(ab’)2 antibody fragments that lack FcγR binding sites did not 
stimulate the respiratory burst although they were phagocytosed by microglia via 
CD11b/CR3. Particulate zymosan, an inflammatory stimulus that stimulates the 
lectin-binding site of CD11b, triggered a vigorous release of ROS demonstrating 
that the ability of microglial CD11b to activate the respiratory burst also depends 
on the binding site within the same receptor. 
These data suggested that intact OX42 antibody is useful for targeted non-
viral gene transfer into microglia. Thus, an OX42-immunoporter was synthesized 
in part 2 of this project, using the targeting ligand OX42 antibody conjugated to 
polyethyleneglycol (PEG)-engrafted polyethyleneimine (PEI). The OX42-
immunoporter was shown to bind plasmid DNA and the OX42-immunogene was 
then tested for specificity and transfection efficiency in mixed glia culture and in rat 
brain in vivo in comparison to non-targeting PEI-PEG. 
The OX42-immunogene was able to significantly reduce off-target 
transfection by PEI-PEG. Although non-targeting PEI-PEG transfected more cells 
than the OX42-immunogene, less than 20% of these cells were microglia. 
Unfortunately, the OX42-immunogene did not increase the rate of microglial 
transfection. Microglial cells that had taken up the OX42-immunogene displayed 
non-specific auto-fluorescence apparently associated with intracellular degradation 
of the immunogene in vitro and in vivo.  
A variety of experiments were conducted to elucidate the barriers to non-viral 
gene transfer into microglia. The OX42-immunogene triggered a strong immune 
response as judged by ROS production and CD11b exocytosis. Aggregation of the 
OX42-immunogene facilitated the stimulation of an immune response that likely 
involved FcγRs and caused destruction of the OX42-immunogene.  
In the presence of the endosomolytic agent chloroquine, the OX42-
immunogene transfected significantly more microglia indicating that endosomal 
escape is limited in microglia. However, the OX42-immunogene transfected other 
cells as well under this condition. This further highlighted the involvement of 
another receptor in internalization of the OX42-immunogene. Transfections of 
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mixed glia cultures with commercially available mannose-conjugated PEI (jetPEI®-
Macrophage) did not provide specificity for microglia either. 
This project identified a differential role of CD11b/CR3 in mediating the 
inflammatory response of microglia. Dependent on the stimulus, microglial cells 
can undergo gradual steps in activation via CD11b/CR3 in absence or presence of 
respiratory burst activity. The results of this project suggest that CD11b/CR3 could 
play an important role in the switch of the microglial phenotype from protective to 
toxic and contribute to neurotoxic ROS production in neuropathologies. 
Nevertheless, CD11b may be a good target for antibody-mediated gene transfer 
into microglia if FcγR-stimulation is avoided. Thus, targeted gene transfer may be 
accomplished with a second generation OX42-F(ab’)2-immunogene that lacks 
binding sites for FcγRs. 
 
 CHAPTER 1                
INVESTIGATING THE IMMUNE 
FUNCTIONS OF MICROGLIA
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1.1 Microglial Activation is the Key Event in the 
CNS Immune Response 
The central nervous system (CNS) is the most sophisticated of the body’s organs 
and represents the control center which governs all essential functions such as 
moving, breathing and thinking. Due to its central role in human physiology, any 
CNS malfunction can have most deleterious consequences affecting an 
individual’s life quality and expectancy. Not surprisingly, brain disorders therefore 
contribute most to healthcare expenses representing an estimated € 798 billion in 
direct and indirect costs in 2010 in Europe alone [350]. Therefore, the investigation 
of brain function is ultimately important in order to understand how neurological 
disorders develop and progress and new techniologies must be developed to 
enable more effective and more efficient treatments. 
Neuropathologies are among the human disorders that are most difficult to 
treat and this can be explained by the complex structure and interrelationship 
between the cells of the CNS. For decades, neurons have been the stars of 
neuroscience and the role of the other major group of CNS cells – the glial cells – 
in modulating neuronal function has been largly neglected. This is partly due to the 
fact that the CNS has for a long time been considered an immune-privileged 
organ, separated from the immune system by the blood-brain-barrier (BBB). 
Research in recent years has challenged this traditional view and demonstrated 
that normal neuronal function is closely dependent on proper functioning of the 
immune system [405,437]. 
Among the glial cells, microglia have emerged as central mediators of the 
innate and adaptive immune responses within the CNS, despite their relative small 
numbers, constituting 0.5-16.6% of the total cell population in humans dependent 
on the brain region [314]. Microglial cells control immune effector functions via a 
multitude of cell surface receptors including chemokine [45,307], cytokine 
[173,326,464], neurotransmitter [64,375] and pattern recognition receptors (PRR) 
[13,337,352]. Microglia utilize these receptors, for example, to communicate with 
neurons [71,181] and astrocytes [134,479] and to detect and remove foreign/toxic 
substances from the extracellular environment by phagocytosis [86,154,525]. 
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Thus, microglia are the principal immune cells of the CNS providing a link between 
the central nervous and peripheral immune system. 
The microglial immune response is intimately linked to the microglial 
activation state. Under normal conditions in vivo, microglia actively monitor the 
surrounding tissue (‘surveying’ [174] or ‘quiescent’ microglia) by extending and 
retracting their fine processes to detect disruptions in homeostasis and to sense 
pathological insults [104,335]. In neuropathology, microglia acquire an activated 
phenotype with enlarged cell soma and thicker processes (Figure 1-1). Activation 
proceeds in gradual steps until microglial cells eventually obtain an amoeboid form 
characterised by a round cell shape and absence of processes often associated 
with their phagocytic function [448]. Besides morphological changes, activated 
microglia also undergo a diverse set of functional changes that will be discussed 
later in more detail.  
1.1.1 The Relationship of Microglia with Cells of the Peripheral 
Immune System 
Microglial cells are often referred to as the resident macrophages of the CNS or 
‘brain macrophages‘, because they share a common myeloid lineage with 
peripheral immune cells such as neutrophils, dendritic cells, monocytes and 
macrophages [157,387]. Microglia are classified as mononuclear phagocytes 
originating from the yolk sac in the embryo. During embryonic development, 
amoeboid microglia populate the CNS, acquire a surveying/quiescent phenotype 
and reside there as resident immune cells throughout life [224].    
Their common lineage suggests functional similarities between microglia and 
tissue macrophages, but this depends on the microglial activation state. Quiescent 
microglia differ from peripheral macrophages in their ability to maintain their 
population and in their pattern of receptors and secreted messengers [107,174]. 
Although still controversial [476], microglial turnover in their quiescent state occurs 
predominantly locally by cell division (microgliosis) albeit at a very low rate 
[8,157,252,431,497]. In pathological situations where the BBB is compromised, 
bone-marrow-derived myeloid precursor cells may enter the CNS and acquire 
microglia-like functions [114]. The pool of of peripheral tissue macrophages, in 
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contrast, is replenished by circulating blood-derived monocytes that extravasate 
into the tissue rather than by proliferation [169].          
Under normal conditions, microglia are characterized by flow cytometry as 
CD11b+/CD45low as opposed to monocytes/macrophages that are 
CD11b+/CD45high [305,414]. However, microglial activation then entails a 
fundamental change in the microglial phenotype causing up-regulation of CD45 
expression, for instance, and making activated microglia functionally and 
morphologically very similar to peripheral tissue macrophages [32,73,169]. 
1.1.2  Functional Changes of Activated Microglia 
The activation of microglia not only involves morphological changes as previously 
mentioned. On a molecular level, microglial activation causes a drastic change in 
the expression of secreted messengers and surface receptors. Characteristically, 
activated microglia form large membrane pores (‘macropores‘) in vitro [38,318] 
which allows an influx of extracellular calcium and efflux of neurotoxic 
subastances, for example [304]. A sustained increase in intracellular calcium is 
linked to microglial activation [182,200,316] and membrane ruffle formation 
[184,347].  
Other functional outcomes of microglial activation can include chemotaxis 
[177,184,348], production and release of cytokines [146,173,180,201] and 
neurotrophic factors [127,461,462], attracting peripheral immune cells [26,27], 
generation of reactive oxygen species (ROS) in the respiratory burst [50,260,359], 
phagocytosis [137,240,331], apoptosis [144,479] and antigen presentation through 
major histocompatibility complex class I and II molecules (Figure 1-1) 
[199,365,511]. 
Many of these functions of activated microglia are modulated by extracellular 
purines (eg., adenosine triphosphate, ATP) or pyrimidines (eg., uridine 
diphosphate) that bind to purinergic P2X and metabotropic P2Y receptors [64]. 
Stimulation by ATP is physiologically relevant and often used as an in vitro model 
to investigate microglial function, because microglia encounter elevated ATP 
concentrations in the extracellular environment in vivo, for instance when released 
by damaged neurons [94,434]. Although cultured primary microglial cells do not 
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represent truly quiescent cells in vivo morphologically and functionally [1,56,388], 
the stimulation of microglia with ATP in vitro demonstrates that cultured microglia 
can be activated further to perform tasks associated with their immunological role. 
Studies conducted in vivo have identified a crucial role of activated microglia 
in the onset and progression of virtually every neuropathology [366]. However, 
until today controversy exists regarding whether microglial activation is beneficial 
or detrimental for neuronal tissue during inflammation. 
1.1.3 Mechanisms of Neuroprotective and Neurotoxic Microglial 
Activation 
Upon injury or insult, microglial cells initiate an acute inflammatory response 
important for host defence which involves ingestion of invading pathogens or toxic 
protein aggregates and degradation of these by production of reactive oxygen 
species (ROS) in the respiratory burst [85,158,244]. These pro-inflammatory 
mechanisms are clearly neuroprotective and a timely termination of the pro-
inflammatory stage is required to restore homeostasis in the CNS. However, 
chronic activation of pro-inflammatory microglia has been linked to neuronal cell 
death and the progression of neuropathologies. The signals that trigger the switch 
from the neuroprotective to neurotoxic microglial phenotype are largely unknown 
and are subject to intensive study. 
Recent reports suggest that activated microglia can acquire different 
phenotypes that are termed classically activated (M1) and alternatively activated 
(M2) microglia [51,405]. This terminology was originally developed in reference to 
inflammatory macrophages in peripheral tissues. Classical M1 macrophage 
activation is characterised by the secretion of pro-inflammatory cytokines that 
include tumor necrosis factor (TNF)-α, interferon (IFN)-γ and interleukin (IL)-1β 
[289]. The switch of a pro-inflammatory response to an anti-inflammatory 
environment is promoted by alternatively M2 activated macrophages and initiated 
by the anti-inflammatory cytokines IL-4 and IL-13. A second activation state that 
facilitates an anti-inflammatory response has been described and termed acquired 
deactivation. This macrophage phenotype can be stimulated by phagocytosis of 
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apoptotic cells [90,512] and characteristically causes secretion of the anti-
inflammatory cytokines IL-10 and transforming growth factor (TGF)-β [90,133,324].   
Many of the signals that regulate the macrophage activation states also 
modulate microglial activation. Although activation of microglia with TNF-α 
[245,443,447], IL-1β [145,176], IFN-γ [156,464], IL-4 and IL-13 [358,516], IL-10 
[21,121,529] and TGF-β [110,227] has been reported, a clear categorization in 
M1- and M2-like microglial cells has not been achieved thus far [405]. 
Nevertheless, due the complex composition of the microglial environment during 
neuroinflammation with factors that influence the microglial activation state (Figure 
1-1), it is likely that the microglial population is heterogeneous and exists in 
different but parallel activation states as observed in Alzheimer’s Disease (AD), for 
instance [93,405]. 
Therefore, whether microglial activation is neuroprotective or neurotoxic may 
depend on this delicate balance. In macrophages for example, the prevalence of 
classically activated macrophages over alternative activated macrophages in type 
2 diabetes is linked to insulin resistance [342] and in cancer, alternative 
macrophage activation can be detrimental [421]. Further, microglial cells that are 
activated by the pro-inflammatory cytokine IFN-γ induce neurogenesis [67] and are 
neuroprotective to organotypic hippocampal slice cultures [66], because they 
remove neurotoxic glutamate levels [417]. IL-1β-activated microglia are also 
neuroprotective as they support remyelination in mice [291]. 
These examples show that one single microglial activation state cannot 
indicate whether microglia are neuroprotective or neurotoxic. Rather, the 
appropriate microglial activation state is needed at any stage of disease 
progression, eg., pro-inflammatory in the initial stages of neuroinflammation, and 
this stage must be followed by the deactivation of pro-inflammatory microglia 
and/or the transition to an anti-inflammatory phenotype at the right time.  
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Figure 1-1: Microglia orchestrate the immune response in the CNS.  
Microglial cells express various cell surface receptors that sense changes in their extracellular 
environment. When microglia get activated they form large membrane pores (‘macropores’) and 
undergo drastic functional changes that are crucial for mediating neuroinflammation. Microglia may 
acquire an amoeboid phenotype dependent on the activation stimulus and this activation state is 
often associated with the phagocytic function of activated microglia. 
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A well-organized shift in microglial activation states may therefore be necessary to 
resolve inflammation which could be mediated by the activation of nuclear 
receptors [404], expression of micro-RNAs [377] or ubiquitination and degradation 
of proteins associated with classical activation [90]. Further, apoptosis of microglia 
in an anti-inflammatory environment mediated by IL-10/TGF-β (acquired 
deactivation) or IL-4/IL-13 (alternative deactivation) may support the restoration of 
homeostasis in the CNS [109,358,497,516]. 
An inadequate deactivation of microglia and prolonged classical activation 
could therefore facilitate pro-inflammatory microglial activation and the progression 
of neurodegenerative diseases such as AD or Parkinson’s Disease (PD). Both 
pathologies are characterized by the presence of activated microglia around the 
lesion site in AD [340] or substantia nigra and striatum in PD [505]. Both 
pathologies also share a common mechanism by which pro-inflammatory microglia 
continuously release ROS beyond the initial states of inflammation 
[112,188,311,341,368]. The activation of microglia in AD is a good example of the 
double-edged sword of microglial function. Although microglial phagocytosis is 
required for removal of amyloid aggregates in AD [86,98,154], sustained release of 
ROS is detrimental for neuronal function. 
The involvement of activated microglia in AD and PD illustrates the current 
dilemma in glia research that despite knowledge about the sort of neurotoxic 
factor(s) that are responsible for neuronal cell death, detailed information is still 
lacking about the underlying mechanisms that facilitate sustained microglial 
activation and ROS production. Thus, a better understanding of these 
mechanisms is required.  
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1.1.4 Integrin CD11b Mediates Cellular Activation 
One of the microglial receptors that is associated with neurotoxic ROS production 
is the CD11b receptor [50]. CD11b belongs to the integrin receptor family of 
heterodimeric transmembrane proteins that are expressed on CNS microglia and 
myeloid cells of the peripheral immune system [40,310]. The structural diversity of 
this receptor family is based on the combination of at least 18 α- and 8 β-subunit 
that can form non-covalent dimers [183]. The β2-subunit (CD18) characterizes β2-
integrins and forms dimers with CD11a (αL), CD11b (αM), CD11c (αX) and CD11d 
(αD). The CD11b integrin receptor is therefore also known as CD11b/CD18 and 
αMβ2 as well as macrophage antigen complex 1 (Mac-1) and complement receptor 
3 (CR3) [40].    
The intracellular domain of integrin receptors binds to a variety of proteins 
that link the receptors to the cytoskeleton of the cell and also provides a 
connection between the extracellular matrix (ECM) and the cell signalling 
machinery within the cell [450]. Integrin receptors can transduce signals bi-
directionally across the cell membrane. ‘Inside-out signalling’ of integrins is 
initiated by intracellular signals from other receptors, eg., TNF receptor [483] which 
causes integrin activation and conformational changes. Activated integrin 
receptors exhibit an increased affinity state which exposes previously masked 
binding sites and increases the binding affinity to extracellular ligands [3]. 
Extracellular integrin ligands then can trigger protein phosphorylation and 
intracellular signalling cascades by an event termed ‘outside-in signalling’ [3,495].  
There is ample evidence from peripheral immune cells that CD11b critically 
mediates cellular functions associated with the inflammatory response, including 
morphological changes, chemotaxis, apoptosis, phagocytosis and respiratory burst 
activity (reviewed in [40,440,450]). Activation of microglia is usually accompanied 
by up-regulated expression of CD11b on the cell membrane. In pathological states 
such as myocardial infarction, microglial CD11b expression remains elevated for 
several weeks [386]. This suggests an important function of CD11b in microglial 
activation.  
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Although CD11b plays an important role in the function of peripheral immune 
cells, the role of the CD11b integrin receptor in microglial function has been 
inadequately studied. Consistent with the observation that integrin function is 
linked to the cytoskeleton [17], murine microglia deficient in CD11b do not change 
significantly in morphology when activated in vitro and in vivo [188,363]. As for 
peripheral tissues, ECM proteins that are present in the CNS, eg,. laminin and 
fibronectin, can also modulate activation states of microglia [76,90,124] and 
regulate differentiation of microglial cells in vitro.  
Further, CD11b-deficient microglial cells demonstrate the absence of the 
respiratory burst when activated with lipopolysaccharide (LPS) [363] and mutant α-
synuclein protein [525] or treated with 1-methyl-4-phenyl-pyridium iodide which is 
an animal model for PD [188]. During pathological BBB breakdown, microglia can 
also be activated by blood proteins such as fibrinogen that enter the CNS and bind 
to CD11b [4,5,373,402]. Fibrinogen-induced microglial activation causes ROS 
production in microglia which leads to axonal damage [105].  
Taken together, these studies suggest that the microglial CD11b receptor 
can also modulate certain aspects of inflammation in the CNS and is a cause of 
oxidative stress in the CNS. Monoclonal antibodies has been extensively used to 
mimic ECM-CD11b interaction and investigate integrin function in peripheral 
immune cells [68]. Experiments performed in microglia with the monoclonal α-
CD11b antibody OX42 showed that OX42 induces mitosis and apoptosis in 
microglia in vivo [390] and triggers nitric oxide release in vitro [161]. Thus, the 
OX42 antibody may be useful to investigate CD11b function in microglia. 
Chapter 1: Investigating the Immune Functions of Microglia 
18 
 
1.1.5 The Role of Pattern Recognition Receptor CR3 in the 
Microglial Immune Response 
Besides its role as integrin receptor, CD11b is also involved in mediating the 
immune response via its function as a pattern recognition receptor (PRR). Pattern 
recognition receptors share the ability to recognize repetitive molecular structures 
on their ligands also known as pathogen-associated molecular patterns (PAMPs) 
[135]. For example, microglia express mannose receptors that detect 
mannosylated carbohydrate structures [435], scavenger receptors (SR) such as 
SR-BI that recognize polyanionic ligands [194] and Fcγ-receptors (FcγRs) that 
detect antibody-coated immune complexes [337]. Activation of PRRs with PAMPs 
is usually followed by phagocytosis and intracellular degradation of the internalized 
material. Thus, PRR are important for the role of immune cells as scavengers. The 
role of integrin CD11b in phagocytosis is usually linked to its function as 
complement receptor 3 (CR3). 
The microglial CR3 is involved in uptake of opsonized and unopsonized 
particles. Opsonisation of targets with complement/opsonins is an event that 
occurs as part of the complement activation during an immune response. The 
complement system represents the innate arm of the immune system and consists 
of more than 30 plasma proteins and membrane-bound receptors [392]. 
Opsonisation of target proteins facilitates clearance of toxic and foreign material by 
covalent attachment of complement 3b (C3b) which is the major opsonin in the 
human body and directs the opsonised particle to complement receptors [153]. 
Particle-bound C3b is cleaved by proteases to generate a complement protein 
termed ‘inactived C3b‘ (iC3b). Generation of iC3b directs iC3b-coated particles to 
receptors with high affinity for iC3b such as CR3 [478]. 
Complement factors can be locally produced by either neurons or glial cells 
and thus do not need to cross the BBB [321,478]. The complement system is 
crucial for a variety of microglial functions in the healthy CNS and in various 
neuropathologies. Inactivated C3b complement-mediated phagocytosis via the 
microglial CR3 is involved in pruning neuronal synapses important for synaptic 
plasticity, memory and learning [409,410,422,437,438,463]. Under pathological 
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conditions, the interaction of iC3b with microglial CR3 plays important roles in 
uptake of amyloid fibrils in AD [86,154,340], myelin phagocytosis [170,322] and 
microglial priming in multiple sclerosis [385]. Microglial priming appears to be an 
important mechanism by which microglia are stimulated to an activated state 
which makes them more responsive to subsequent stimuli. Primed microglia exert 
much stronger pro-inflammatory effects that possibly excacerbate 
neurodegeneration [100,118]. However, how the primed state of activated 
microglia relates to the microglial phenotypes remains to be investigated. 
Importantly, apoptotic neurons are taken up by microglial cells by 
phagocytosis which involves CR3 and iC3b [89,167,392]. As for peripheral 
macrophages [16], ingestion of iC3b-coated apoptotic cells is anti-inflammatory 
[167,191]. The anti-inflammatory role of CD11b/CR3 in complement-mediated 
phagocytosis is thus contrary to the proposed role of CD11b/CR3 in generating 
oxidative stress as discussed above.  
In conclusion, prolonged ROS production of classically activated microglia via 
CR3 is neurotoxic, but complement-mediated phagocytosis via CR3 is 
neuroprotective. A shift from an ‘anti-inflammatory CR3’ to a ‘pro-inflammatory 
CR3’ could cause the progression of neurodegenerative diseases due to 
dysfunction of CR3-mediated phagocytosis and/or the complement system 
[114,331,472]. Studying CD11b integrin function and the role of CR3 in 
phagocytosis in microglia is therefore crucial to discern under which conditions 
CD11b can mediate classical activation and ROS production or exert effects that 
lead to an immune response in absence of cytotoxicity. The OX42 antibody could 
be a powerful tool to shed light on the function of CD11b in microglial activation, 
because it binds to or close to the complement-binding site of CD11b 
[234,393,430] and hence mimics iC3b-CD11b/CR3 interactions. 
. 
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1.2 Hydrogen Peroxide - A Potential Mediator of 
Microglial Activation 
The production of reactive oxygen species (ROS) such as superoxide and 
hydrogen peroxide in the respiratory burst is characteristic of a strong immune 
response in microglia [174]. As discussed before, ROS production is important for 
host defence but prolonged exposure of neurons to an oxidative environment is 
toxic. Besides their apparent bactericidal role, ROS produced by microglia have 
been appreciated in recent years to mediate a variety of redox-sensitive 
intracellular signalling cascades [149,433], for instance to regulate gene 
expression [147,380], to modulate release of neurotransmitters [30,175] and to 
regulate apoptosis [287,444]. Importantly, hydrogen peroxide has recently been 
shown to be involved in the intracellular mechanisms that mediate microglial 
activation in vitro as discussed below. Because the pathophysiology of different 
neurodegenerative diseases may involve different mechanisms (i.e. receptors and 
secreted messengers), the modulation of hydrogen peroxide levels in activated 
microglia could therefore be a more general target to manipulate microglial 
function and investigate the role of activated microglia in chronic neuropathologies. 
1.2.1 Generation and Disposal of Hydrogen Peroxide 
Hydrogen peroxide (H2O2) is quantitatively the most important ROS [122] and can 
act in an autocrine and paracrine fashion due to its ability to cross cell membranes 
[346]. Basal levels of hydrogen peroxide are mainly obtained from the 
mitochondrial respiratory chain by spontaneous disproportionation of superoxide 
and the action of superoxide dismutase (SOD) enzymes [202]. Activated microglia 
produce large amounts of H2O2 [466] and this is due to the activation of NADPH 
oxidase (NOX) enzymes in the respiratory burst. 
The family of NOX enzymes consists of seven members and microglia 
express NOX1, NOX2 and NOX4 [433]. While NOX4 is constitutively expressed 
[175,261,297], the assembly of ROS producing NOX1 and NOX2 isoforms can be 
induced in the respiratory burst of microglia which is associated with classical 
microglial activation and neurotoxicity [82,85,244,407]. The assembled NOX 
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complexes catalyse oxygen conversion to superoxide. However, superoxide is a 
relatively short-lived ROS and dismutates into hydrogen peroxide either 
spontaneously or enzymatically by SODs [152]. Disposal of H2O2 occurs via the 
glutathione system [122], peroxide scavengers such as peroxiredoxins and 
thioredoxins [12,23,441] and the specific hydrogen peroxide scavenging enzyme 
catalase which is expressed by microglial cells [339]. The balance between H2O2-
producing and H2O2-scavenging enzymes thus controls the level of hydrogen 
peroxide that can act on redox-sensitive signalling cascades, for instance 
extracellular regulated kinase (ERK) 1/2 and phosphoinositide kinase 3 (PI3K) 
which regulate proliferation and pro-inflammatory gene expression 
[113,147,168,351]. 
1.2.2 The Role of Hydrogen Peroxide in Microglial Activation 
Hydrogen peroxide has emerged in recent years as a crucial intracellular 
messenger that regulates various aspects of microglial activation. 
Lipopolysaccharide (LPS)-induced cyclooxygenase-2 expression and release of 
prostaglandin-2 in microglia is redox-sensitive, because activated microglia from 
NOX2-deficient mice and wild-type microglia treated with the NOX inhibitor 
diphenyliodonium (DPI) produce less prostaglandin-2 compared to untreated 
microglia from wild-type mice [485]. DPI also reduces pro-inflammatory gene 
expression (IL-6, IL-1β and TNF-α) in microglia activated with LPS and IFN-γ [361] 
and fibrillar beta-amyloid peptide Aβ1-40 [208]. NOX2-/- microglia cultures show 
reduced levels of ROS and produce significantly less TNF-α mRNA in response to 
LPS [379,380]. Hydrogen peroxide is suggested to be involved in regulating the 
inflammatory gene expression, because the pro-inflammatory immune response is 
blocked by catalase [208,361,485] and catalase mimetics in vitro [208,485].  
NOX-derived hydrogen peroxide is also important for microglial proliferation 
in cultured cells. Proliferation of microglia stimulated with IL-1β and TNF-α is 
prevented by the NOX inhibitors DPI and apocynin. The same is observed with 
exogenous catalase and catalase mimetics that consume hydrogen peroxide 
produced by exogenous enzymes [208,281,282].  
Further, the up-regulated expression of CD11b which is characteristic of 
activated microglia is redox-sensitive. Hydrogen peroxide from NOX is a central 
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mediator in up-regulating CD11b expression, because exogenous catalase 
decreases CD11b expression in activated microglia in vitro and in vivo [400,401]. 
Additionally, exogenous H2O2 alone is sufficient to activate microglia and 
stimulation of CD11b expression is inhibited by catalase. 
Finally, the expression of inducible nitric oxide synthase (iNOS) which is 
characteristic of classically activated microglia [20,78,125,361] is dependent on 
hydrogen peroxide from NOX. Microglial cells with mutated NOX-enzyme produce 
less ROS which results in decreased iNOS production and DPI as well as 
exogenous catalase block iNOS expression in activated microglia [361]. Thus, 
hydrogen peroxide appears to be a central mediator of microglial activation and a 
potential target to manipulate microglial function. 
1.2.3 Over-Expression of Catalase could Reduce Oxidative 
Stress and Inhibit Classical Microglial Activation 
In order to investigate the role of activated microglia in chronic neurodegeneration, 
microglial function could be therefore modulated by removing excessive hydrogen 
peroxide produced in the respiratory burst of classically activated microglia. 
Reducing H2O2 levels directly by over-expressing the H2O2-specific scavenger 
catalase in microglia may be more promising to modulate microglial activation 
rather than targeting NOX, because several NOX enzymes can produce hydrogen 
peroxide, extracellular catalase cannot cross the cell membrane and simple 
treatment with catalase mimetics is not specific for microglia. Microglial specificity 
is desired, because hydrogen peroxide can cross the cell membrane and act on 
other cells. Over-expression of catalase specifically in microglia could be achieved 
by targeted gene transfer. This methodology could be used to investigate the 
significance of hydrogen peroxide in microglial function in vivo as most previous 
studies were conducted in vitro. 
From the previous discussion it becomes clear, however, that prevention of 
classical microglial activation by reduction of H2O2 levels may not necessarily 
confer neuroprotection, because the pro-inflammatory response is beneficial in the 
short term [242]. However, targeting the excessive production of ROS in chronic 
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neurodegeneration may restore the redox-balance and help to reduce oxidative 
stress [85] and potentially inhibit classical microglial activation.  
There are several lines of evidence suggesting that an anti-oxidative/anti-
inflammatory treatment of classically activated microglia may reduce neurotoxicity. 
Inhibition of NOX2 in classically activated microglia after LPS challenge promotes 
an alternative microglial phenotype in vivo suggesting that inhibition of NOX2  can 
promote an anti-inflammatory state [101,116,179,227,262,499]. Treatment with 
anti-oxidants or TGF-β1 is neuroprotective by decreasing ROS levels, inhibiting 
microglial activation and attenuating iNOS expression in vitro [25,218]. Further, 
immunosuppressive substances such as glucocorticoids reduce the production of 
pro-inflammatory cytokines [436] and deactivation of classically microglial 
activation with galectin-1 is neuroprotective in vivo 
[79,123,136,178,456,457,505,517]. Lastly, inhibiting microglial activation and 
proliferation with minocycline, a tetracycline antibiotic, shows some 
neuroprotection in vitro and in vivo [296]. 
Although all of these anti-oxidative/anti-inflammatory treatments have been 
demonstrated to be neuroprotective to some degree, none of them are specific for 
microglia. Therefore, the contributions of microglia to these neuroprotective effects 
are unknown. Modulating microglial activation on a molecular level by targeted 
over-expression of the hydrogen peroxide-scavenging enzyme catalase could 
address the specific role of microglial function in various neuropathologies. The 
investigation of the microglial function in the immune system by targeted gene 
transfer may identify novel targets for treatment of neurodegeneration. Further, it 
may also establish a new technology that could be used to deliver genes into 
microglia for therapeutic purposes.  
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1.3 Modulation of Microglial Function by Targeted 
Non-Viral Gene Delivery with Antibodies 
Gene delivery vehicles for in vivo applications can be broadly classified into viral 
and non-viral vehicles. Viral vehicles have been used for many decades to transfer 
genes into cells of the CNS due to their exceptional high transfection efficiency. 
Throughout their development, improvements have been gradually implemented to 
generate recombinant viral vectors for specific cell targeting, with impaired viral 
replication and improved safety [384]. However, viruses have to be extensively 
modified to achieve these goals and deleterious effects on infected cells remain 
[35,266].  
Alternative approaches with non-viral vectors may circumvent many issues 
which still exist with viral gene delivery techniques such as immunotoxicity and 
laborious production. The simplicity and flexibility of using chemical synthesis to 
design non-viral vectors and reduced toxicity gives bioconjugates an advantage 
over viral vectors and accounts for continued efforts to develop alternative vector 
types for research and gene therapy [58,162]. 
Clearly, the development of safe and specific gene vehicles is desired to 
address the large unmet medical need to treat neuropathologies [108]. The 
complex aetiology of neuropathologies involves all cell types of the CNS including 
microglia. It is evident that a thorough understanding of microglial function is 
essential to understand the onset, progression and eventual treatment of 
disorders. Thus, modulating microglial function on a genetic level by targeted gene 
transfer is a powerful tool for basic research and gene therapy. However, specific, 
microglia-targeting gene transfer in vivo has not been achieved as yet.  
1.3.1 Strategies to Transfect Microglial Cells 
An optimal gene vehicle for microglial cells delivers the transgene specifically into 
microglia to avoid off-target effects, causes stable and long-lasting gene 
expression and does not trigger an immune response. Viral methods have proven 
to be more effective than non-viral techniques in transducing microglial cells so far. 
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However, the effective use of viral vehicles for gene therapy has been hampered 
by evoked immune responses and significant cytotoxicity levels besides lack of 
specificity for microglia which overshadows their exceptional high transfection 
efficiency [7,63,491].  
1.3.1.1 Viral Vectors as Gene Carriers into Microglia 
The development of a virus-based transgene carrier specifically targeting microglia 
has been proven difficult, because most viruses display broad tropism and 
therefore require extensive modification to increase specificity [63]. Lentivirus (LV), 
a retrovirus that has the ability to infect proliferating and non-proliferating cells 
[28,320,504], has recently emerged as the viral vehicle of choice to study 
microglial function in vitro and to deliver therapeutic genes in animal models of 
neurodegeneration. 
Lentiviral vectors show a robust transfection rate of more than 70% for 
microglial cell lines and > 50% for primary microglia [209]. Studies on cultured 
microglial cells show that LV-mediated knock-down of genes via small interfering 
or short hairpin RNA or protein over-expression can be employed to investigate 
mechanisms of activated microglia in chemotaxis [137,268], phagocytosis 
[225,446] and pro-inflammatory gene expression [120,301,370]. In vivo, LV-
mediated gene over-expression successfully attenuates the microglial pro-
inflammatory response with beneficial behavioural outcomes and reduced 
neuronal cell death in animal models for neuropathic pain [257,295], PD [280] and 
multiple sclerosis [302]. 
The absence of LV-induced microglial activation appears to be a general and 
desirable feature of LV-mediated gene transfer. However, microglia-specific 
transfection has not been reported so far although LV seem to preferentially 
transfect glial cells in vivo [99,372]. Further selectivity towards microglial cells may 
be achieved by substituting the commonly used cytomegalovirus (CMV) promoter 
with a microglia-specific promoter such as CD11b, F4/80 or Iba1 that drives 
transgene expression [95,96].   
The use of other viral vehicles for microglial gene transfer is less promising. 
Vectors derived from the simian virus 40 (SV40) transfect microglial monocultures 
with high efficiency (> 90%) [270-273], but SV40 transduces mostly neurons 
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( > 95%) and only few microglia in vivo [99]. Recombinant adeno-associated virus 
(AAV) shows similar transfection efficiencies to LV in primary microglia when 
under the control of the CMV promoter [31,160,185,453]. Because neurons and 
glial cells are targets of AAV vectors [99], substitution of the CMV promotor with 
microglial-specific promoters is required, but this reduces transfection efficiency to 
less than 25% in vitro [69,420,452]. Finally, adenovirus (AV) of serotype 5 is also 
able to transfect primary microglia [108], but shows broad tropism in vivo [406]. 
Some progress in targeting microglial has been achieved recently with AV vectors 
of serotype 35 which show strong tropism towards microglia in vivo [95,453]. 
In conclusion, the choice of viral vehicles to transfect microglial cells is limited 
and lentiviruses appear to be most appropriate to achieve high transgene 
expression and some microglial selectivity. Nevertheless, LVs as well as AAVs 
and SV40-derived vectors have the ability to insert genetic material into the host 
genome [53,70,413]. This bears the risk of insertional mutagenesis potentially 
activating proto-oncogenes as observed predominantly for retroviruses [63]. In 
contrast to these vehicles, AVs do not integrate into the host cell’s genome 
[43,143,258]. However, gene transfer with AV leads to an inflammatory response 
with microglial activation in vitro and in vivo [7,491] which is absent for LVs. 
Further, gene therapy trials with AV vectors demonstrate that individuals pre-
exposed to AV during infection exhibit an immune response to AV-mediated gene 
delivery or develop it rapidly after application of the AV vector [266].  
Therefore, viruses require further development to increase safety and to 
enhance specificity for microglial gene transfer. Non-viral vectors with targeting 
ligands such as antibodies may provide an alternative to viruses to increase safety 
and specificity for microglia. 
1.3.1.2 Non-Viral Vectors for Targeted Gene Delivery into Microglia 
In recent years, the field of gene transfer and therapy has seen an enormous 
increase in the variety of vehicles for non-viral gene transfer into CNS cells [266]. 
Naked DNA [426,427], nanoparticles [42,471,509], dendrimers [215] and cationic 
polymers (polyplexes) [163,247,308,354,419,451,458,484,506] are now being 
used to transfect CNS cells in vitro and deliver therapeutic genes in vivo. However, 
Chapter 1: Investigating the Immune Functions of Microglia 
27 
 
none of these approaches targets microglia specifically and most often transgene 
expression in microglia is either not observed or not investigated. 
In order to increase the transfection rate in microglia (and macrophages), 
non-viral vehicles may be conjugated to a cell-targeting ligand. Poly-L-lysine (PLL) 
and cationic lipids (lipoplexes) conjugated to mannose which targets the mannose 
receptor transfects macrophages in vitro and in vivo [129,141,142,219]. Mannose-
conjugated linear polyethyleneimine (lPEI, jetPEI®-Macrophage) is also able to 
deliver genes into primary microglia [288] and a leptin-derived protein conjugated 
to PLL transfects a microglial cell line [267]. However, targeted gene transfer with 
non-viral vehicles into microglia has not been demonstrated in vitro or in vivo. 
Another class of targeting ligands are monoclonal antibodies. Their inherent 
property to be specific for an antigen makes them useful for targeting receptors 
that are cell-type specific. Gene transfer with antibodies can achieve higher 
transfection efficiencies compared to non-targeting vehicles and also increase 
specificity for a particular cell type [83,128,228,230]. Antibody-mediated gene 
delivery or knock-down has been achieved for neuronal sub-populations in vivo 
resulting in improved functional outcomes in animal models [29,37,395]. 
Therefore, antibody-mediated delivery of genes via a microglia-specific receptor 
could provide the specificity needed to modulate microglial function in vivo. 
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1.3.2 Strategies for Antibody-Mediated Non-Viral Gene Transfer 
by Receptor-Mediated Endocytosis 
Viruses have evolved to bypass the various extra- and intracellular barriers to 
efficiently transduce cells. Synthetic non-viral vehicles therefore have to be 
designed in a way that incorporates many of the viral functions which promote 
gene transfer. A non-viral vehicle consisting of a monoclonal antibody, the cationic 
polymer polyethyleneimine (PEI) and a stabilizing agent such as polyethylene 
glycol (PEG) could address and circumvent the barriers [395] and facilitate gene 
transfer in microglia. 
The extracellular environment represents a barrier to gene transfer because 
it facilitates rapid degradation of oligonucleotides. PEI condenses oligonucleotides 
such as plasmid DNA (pDNA) thus protecting it from degradation [299,343]. 
Modification of PEI with PEG has additional positive effects on reducing 
degradation of pDNA [309,312,451] and also minimizes aggregation of the non-
viral vehicle [46,241,362]. 
The internalization of positively charged vehicles based on PEI occurs via 
adsorptive endocytosis via negatively charged proteoglycans that can be found on 
the surface of any cell [344]. Thus, proteoglycan-mediated internalization is not 
desired for targeted gene transfer. Engrafting PEI with PEG reduces the non-
specific adsorption of PEI on off-target cells [303]. Further, a targeting monoclonal 
antibody can confer specificity for a particular cell type by binding to a cell-type 
specific surface receptor and triggering receptor-mediated endocytosis. 
Internalization via clathrin-coated pits is a classical example for receptor-mediated 
endocytosis [510]. Internalization of vehicles by receptor-specific mechanisms is 
important as pinocytosis (eg., macropinocytosis) can occur in off-target cells which 
can cause non-specific cellular uptake of the gene vehicle [165,232,403] (Figure 
1-2 A).  
As the non-viral vehicle is internalized via receptor-mediated endocytosis it 
usually enters the endosomal-lysosomal trafficking pathway which is desired for 
gene deliver by PEI. Several cellular sorting events cause the maturation of 
endosomes into late endosomes and may eventually lead to destruction of the 
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gene vehicle within the lysosomal compartment [10,57,223]. Thus, escaping the 
endosomal-lysosomal pathway is crucial for efficient gene delivery. 
Polyethyleneimine is suggested to facilitate endosomal escape by two 
mechanisms. Firstly, it acts as ‘proton sponge’ which interferes with the gradual 
acidification of early endosomes as they mature into lysosomes. The buffering 
effect of PEI leads to an influx of water which causes swelling and osmotic rupture 
of the endosome [46,235,454,519]. Secondly, evidence suggests that PEI 
physically disrupts the endosomal membrane upon direct interaction [46,376].  
It is believed that the pDNA remains at least partly complexed with PEI after 
endosomal escape, however, the exact mechanism(s) that lead to nuclear 
translocation are still under debate [493]. The diffusion of the vehicle towards the 
nucleus may be assisted by microtubules and mediated by a polyanion gradient 
towards the cell nucleus [274]. Further, the size and thus the mobility of the PEI-
pDNA complex [150] as well as the location of endosomal escape (close vs. far 
from nucleus) [474,493] may also be decisive for successful gene transfer with 
PEI-based vehicles. 
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Figure 1-2: Internalization mechanisms and intracellular trafficking of immunogenes. 
A: Internalization mechanisms for uptake of non-viral vehicles. Pinocytosis is an internalization 
mechanism exploited by all cells to take up extracellular nutrients and soluble material. Receptor 
binding triggers the concentration of ligands in clusters on the membrane and subsequent receptor-
mediated endocytosis. Clathrin-mediated endocytosis is a classical example for receptor-mediated 
endocytosis, but other internalization mechansisms has been recently discovered. Phagocytosis is 
a receptor-mediated mechanism for internalization of soluble aggregates or particles of sufficient 
size (> 0.5 μm). Phagocytosis is mainly performed by immune cells. B: Trafficking of antibody-
based non-viral gene vehicles (immunogenes). The immunogene binds (A) and triggers receptor-
mediated internalization via the antibody (red) binding to its receptor (green, B). The internalized 
immunogene preferentially enters the endosomal-lysosomal pathway (C). Intracellular sorting of 
endosomes (D-E) causes the maturation of early endosomes into late endosomes (F) 
accompanied by vesicle acidification. Polyethyleneimine (blue) facilitates endosomal escape (G) 
and prevents lysosomal degradation of the immunogene. The transgene (purple) is then 
transported towards the cell nucleus by mechanisms that are yet to be described in detail (H). The 
pDNA then enters the nucleus through nuclear pores or during mitosis (I) leading to transgene 
transcription and protein translation. Based on [520]. 
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The transgene may then enter the nucleus by either diffusion through nuclear 
pores [303] or during mitosis in proliferating cells (eg., activated microglia) when 
the nuclear membrane breaks down [256]. Nuclear uptake can be facilitated by 
cell-specific promoters that bind to transcription factors. Plasmid DNA may further 
be protected by PEI in the cytosol prior to mitosis [29,37,395]. 
Combining a monoclonal antibody with PEI and PEG into one single 
bioconjugate (‘immunoporter’) therefore addresses the barriers of non-viral gene 
delivery and provides specificity. Thus, immunoporters that bind and condense 
pDNA (‘immunogenes’) could be used for targeted gene transfer (Figure 1-2 B). 
Although antibody-mediated gene transfer into neurons can be accomplished 
[84,337,349,508], there may be additional barriers associated with microglial gene 
transfer due to their role as immune cells that need to be investigated and 
addressed.  
1.3.3 Specific Considerations for Successful Gene Delivery into 
Microglial Cells with Immunoporters 
In contrast to non-phagocytic cells, microglia express immune receptors that 
perform phagocytosis and stimulate an immune response (eg., respiratory burst) 
which can initiate or excacerbate neuroinflammation [19,489]. Thus, phagocytosis 
needs to be considered as one of the potential internalization mechanism into 
microglia. Nevertheless, delivery of transgenes may be accomplished via 
phagocytosis as demonstrated for the mannose and dectin-1 receptor. 
As discussed before, microglial activation proceeds in gradual steps and 
activated microglia can also be anti-inflammatory. Thus, a strong pro-inflammatory 
immune response has to be avoided by choosing the right antibody targeting an 
appropriate microglial receptor. Targeting a receptor that is linked to alternative 
activation or acquired deactivation of microglia would therefore be beneficial. 
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1.4 Project Aims 
The overall aim of this PhD project is to elucidate the involvement of cell surface 
receptors in neurotoxic microglial activation and use these receptors to develop of 
a novel gene delivery technology for targeted gene transfer into microglia via 
antibodies. Targeted non-viral gene transfer may be used to modulate microglial 
function and further investigate the role of chronically activated microglia in 
neuropathologies. 
In part 1 of this project, the role of integrin receptor CD11b (CR3) in 
activation of a phagocytosis-induced respiratory burst is investigated. The 
monoclonal α-CD11b antibody OX42 may be useful to discern under which 
conditions CD11b/CR3-mediated microglial activation is neuroprotective or 
contributes to neurotoxicity. In part 2, a non-viral gene delivery vehicle 
(‘immunoporter’) is developed to specifically target microglia. This will require the 
identification of a specific microglial receptor and a suitable corresponding 
antibody that undergoes receptor-mediated internalization and does not trigger an 
immune response. Microglia-specific immunoporters may then be used to over-
express the hydrogen peroxide scavenging enzyme catalase in microglia to 
manipulate microglial activation. 
In conclusion, this project will help to understand the role of microglia in 
health and disease by investigating microglial receptor function and non-viral gene 
delivery. Further, the development of non-viral vehicles for targeted gene transfer 
into microglia may also provide an alternative to viral vectors for basic research 
and gene therapy. 
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2.1 Tissue Culture and Isolation of Microglial 
Cells for in Vitro Studies 
Microglia usually exhibit ramified morphology under normal conditions and 
respond with changes in morphology and gene expression upon stimulation in vivo 
(‘microglial activation’). Microglia in culture may adopt different phenotypes under 
non-stimulated and stimulated conditions that differ from quiescent and activated 
microglial cells in vivo (reviewed in [388]). The preparation of cultured microglia is 
very likely to cause microglial activation. Nevertheless, the use of cultured 
microglial cells is warranted as it helps to support the understanding of microglial 
physiology in vivo (e.g. the role of caspases in microglial activation [62]). 
Primary microglial cells are commonly obtained from mixed glia cultures, 
because astrocytic support is needed for microglia to survive for extended times. 
Many protocols have been developed since the 1980s to prepare mixed cultures. 
Preparation of mixed glia cultures from neonatal rat or mice has proven to be most 
convenient [498]. This section describes the preparation of mixed glia cultures 
from neonatal rat brain by mechanical and enzymatic dissociation of brain tissue 
and the isolation of almost pure microglia from these mixed cultures by shaking. 
This protocol has been optimized previously in our lab based on Nakajima et al. 
[328]. 
2.1.1 Materials 
T-25 tissue culture flasks were purchased from TPP (Switzerland), coverslips (13 
mm diameter, No. 1) from ProSciTech (Australia) and black 96-well plates with 
clear bottom from Greiner (Germany). Poly-D-lysine hydrobromide (PDL), trypsin, 
deoxyribonuclease and salts were purchased from Sigma (Australia). Cell culture 
medium (high glucose DMEM, Invitrogen, Australia) was supplemented with 10% 
fetal bovine serum (FBS, Bovogen) and 2% penicillin-streptomycin (Invitrogen). 
Dulbecco’s phosphate-buffered saline (DPBS) was prepared from a 20 x stock 
solution (28.8 g Na2HPO4 anhydrous, 4.8 g KH2PO4 anhydrous, 4 g KCl, 160 g 
NaCl, dissolved in 1 L water, pH adjustment not necessary). 
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2.1.2 Coating of Cell Culture Flasks, Coverslips and 96-Well 
Plates 
Coverslips were washed and sterilized in 70% ethanol for 10 minutes and air dried 
prior to coating. Sterile PDL-solution (0.05 mg/mL) was added to cell culture 
flasks, onto coverslips in 24-well plates and to 96-well plates to cover the surface. 
Cell culture flasks were briefly swirled, coating solution removed and air dried. 
Coverslips and 96-well plates were incubated with PDL-solution for 1 hour, 
washed with water and air dried. 
2.1.3 Preparation of Mixed Glia Cultures 
Mixed glia cultures were prepared from neonatal Sprague-Dawley rat brains (day 
1-3) that were kindly donated by Prof. E. Woodcock (Baker IDI, Melbourne). Brains 
were removed from decapitated heads and mechanically dissociated by passing 
through a coarse mesh (size 40). Cells were washed by centrifugation (1500 RPM, 
5 minutes), decanting the supernatant and resuspending the cell pellet in DPBS. 
Brain tissue was enzymatically digested for 10 minutes (37ºC, 5% CO2) with 
0.16% trypsin in the presence of 0.01% deoxyribonuclease. Complete cell culture 
medium was added to stop the digestion. The suspension was then further 
mechanically dissociated by passing through a fine mesh (size 100). The cell 
pellet was then washed twice (2000-2500 RPM, 5 minutes each) and resuspended 
in complete cell culture medium (1-1.5 mL per brain). One to 1.5 mL of cell 
suspension and 4 mL of complete cell culture medium were added to each PDL-
coated tissue culture flask and incubated for 1 hour (37ºC, 5% CO2). 
Mixed glia cultures in the tissue flasks were then washed to remove debris 
and non-adherent cells and 5 mL fresh complete cell culture medium added to the 
flasks. After an overnight incubation (37ºC, 5% CO2), the supernatant was 
removed and tissue culture flasks supplemented with 5 mL of fresh complete cell 
culture medium. Mixed glia cultures were maintained by exchanging half of the cell 
culture medium twice a week. Microglial cells appeared on top of an astrocytic 
layer after a few days and were available in sufficient amounts for isolation (1-2 x 
105 cells/mL) after 8-12 days.  
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For immunofluorescence studies and transfections that involved mixed glia 
cultures, mixed cultures were prepared as above, but plated on PDL-coated 
coverslips in 24-well plates (1 brain/2 mL cell culture medium, 150 μL per 
coverslip). After 10 minutes incubation (37ºC, 5% CO2), 300 μL of complete cell 
culture medium was added and cells washed after 1 hour incubation by removing 
the supernatant and supplementing each well with 500 μL of complete cell culture 
medium. Mixed cultures were used for experiments 3-4 days thereafter. 
2.1.4 Isolation of Microglia 
Microglial cells were isolated from mixed cultures by shaking cell culture flasks at 
37ºC for 60 minutes (120 RPM). Isolated microglia (> 98% pure, determined by 
CD11b-immunoreactivity, illustrated in confocal images throughout Chapter 2-8) 
were plated at desired numbers on PDL-coated coverslips in 24-well plates or in 
PDL-coated 96-well plates. After 10 minutes incubation, the same volume of fresh 
complete cell culture medium was added to the wells and further incubated (37ºC, 
5% CO2) before the experiment. 
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2.2 Production and Purification of Monoclonal 
Antibodies 
Monoclonal antibodies are widely used as cell markers, to study cellular functions 
and as therapeutic drugs among other applications. The fusion of antibody-
secreting spleen-cells with mouse myeloma cells (‘hybridoma cells’) has provided 
a break-through for the large-scale production of monoclonal antibodies [238]. 
Milligram quantities of antibody were required for the development of an antibody-
based vehicle for non-viral gene transfer into microglia (Chapter 6). This section 
describes the maintenance of antibody-secreting hybridoma cell lines in culture 
and the purification of immunoglobulin G (IgG) antibodies. This protocol has been 
shared by Dr Mary-Louise Rogers (Flinders University, Adelaide). 
2.2.1 Materials 
The OX42 (IgG2a) hybridoma cell line was kindly provided by Prof K.A. Williams 
(Flinders University, Adelaide), SR-B1 (IgG1) antibody secreting cells were a gift 
from Dr H. Muyderman (Flinders University, Adelaide) and the X63 (IgG1) 
hybridoma cell line was obtained from Prof. RA. Rush (Flinders University, 
Adelaide). Purified MLR2 antibody (IgG2a) was provided by Dr M-L. Rogers 
(Flinders University, Adelaide).  
T-75 and T-175 flasks were obtained from Greiner. RPMI1640 with GlutaMax 
containing 10% FBS (heat-inactivated, Australian origin), penicillin-streptomycin-
glutamine (1%) and hypoxanthine-thymidine supplement (1%) were all purchased 
from Invitrogen. Hybridoma fusion and cloning supplement (HFCS) was from 
Roche (Australia). Dimethyl-sulfoxide (DMSO) and pH strips were purchased from 
Sigma. Conditioned media was tested for antibody with a mouse antibody 
isotyping kit (Thermo, Australia) and filter sterilized (0.22 µm, Corning, USA). 
Protein G agarose beads (Millipore, Australia) were packed in disposable plastic 
columns (Bio-Rad, Australia).  
Slide-A-Lyzer G2 dialysis cassettes (20 kDa) were purchased from Thermo. 
Phosphate-buffered saline, elution buffer (0.1 M glycine in DPBS, pH 2.7), 
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neutralization buffer (2 M Tris-base), column storage buffer (0.1% sodium azide in 
DPBS), conjugation buffer (20 mM HEPES, 0.25 M sodium chloride, pH 7.9) and 
transfection/antibody storage buffer (20 mM HEPES, 0.15 M sodium chloride, pH 
7.3) were prepared with chemicals purchased from Sigma. Amicon Ultra-4 
ultrafiltration spin columns of 100 kDa molecular weight cut-off (MWCO) were 
purchased from Millipore. 
2.2.2 Hybridoma Cell Culture 
Hybridoma cells were grown in RPMI1640 medium with supplements and cell 
culture was started in 24-well plates and gradually up-scaled to T-75 and T-175 
flasks. Cells were split at exponential growth and around 80% confluency. One or 
two drops of HFCS solution was added to newly split cultures, if cells grew slowly 
or did not produce antibody. For long-term storage, hybridoma cells were slowly 
frozen to -80ºC at a concentration of 1-5 x 105 cells/mL in cell culture medium 
containing 25% FBS and 15% DMSO and then transferred to liquid nitrogen. 
Antibody conditioned media appeared yellow in colour and was collected by 
removing cells by centrifugation (5 minutes at 400 G). Conditioned media was 
stored at -20ºC until purification.  
2.2.3 Antibody Purification 
Conditioned media was thawed and filter sterilized. The solution was re-circulated 
over the protein G column at 0.2 mL/min for 5 days at 2-8ºC using a peristaltic 
pump. The antibody was then eluted on ice with elution buffer. The protein amount 
was estimated measuring the absorbance at 280 nm taking into account a molar 
absorbance of A280 = 1.35 for 1 mg/mL IgG. The pH of the antibody solution was 
then quickly adjusted to neutral pH using neutralization buffer. The protein G 
column was flushed with DPBS and stored in column storage buffer at 2-8ºC until 
next usage. Antibodies were dialysed using dialysis cassettes for 2 days with 
frequent buffer exchange and then concentrated using spin columns to about 2 -
3 mg/mL in either DPBS or antibody storage buffer depending on the downstream 
application. Typically, 1 L of conditioned medium yielded around 8-10 mg OX42 
and X63 antibody and 5 mg SR-B1. Antibodies were stored at -80ºC until further 
use.  
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2.3 Generation and Purification of OX42-F(ab‘)2- 
Antibody Fragments 
The ability of monoclonal antibodies to bind to a specific antigen is likely the most 
important feature that accounts for their frequent use in research. Antigen binding 
occurs via the variable domains (V) of the antibody‘s heavy (H) and light chains 
(L). However, phagocytes such as microglial cells express Fcγ-receptors (FcR) 
and thus have the ability to bind antibodies via their constant domains (C) in the 
Fc- (fraction crystallizable) part (CH2 and CH3 domains). This may lead to non-
specific antibody binding and may also trigger FcγR-mediated cellular functions. 
Thus, to delineate the function of a certain receptor such as CD11b, it is 
advantageous to remove the Fc-portion of an antibody to avoid cross-reaction with 
FcγRs (Figure 2-1).  
Pepsin is a serine endopeptidase enzyme that is frequently utilized to 
prepare bivalent F(ab‘)2-antibody fragments. While pepsin cannot be used to 
prepare F(ab‘)2-antibody fragments from all IgG isotypes, pepsin preferentially cuts 
IgG2a antibodies (e.g. OX42) below their hinge region leaving intact F(ab‘)2-
fragments with 2 antigen binding sites behind [249]. These fragments contain the 
variable domains VH and VL and the constant domains of the light (CL) and heavy 
chain (CH1 and parts of CH2). Most of the Fc-part (CH2 and CH3) is proteolytically 
cleaved into small peptides [18].  
Aggregation of neutrophil integrin receptors with bivalent antibody fragments 
appears to be necessary to trigger internalization and other cellular functions, 
because monovalent Fab‘-fragments had no effect [139,492]. Therefore, bivalent 
OX42-F(ab‘)2-antibody fragments were prepared to investigate microglial CD11b 
integrin functions. The aim was to optimize conditions for enzymatic digest and 
purification in order to generate OX42-F(ab‘)2-fragments with minimal IgG-
impurities.  
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2.3.1 Materials  
OX42-IgG antibody was prepared as described previously. Chemicals were 
purchased from Sigma if not otherwise stated and used to prepare digestion buffer 
(100 mM sodium acetate/acetic acid buffer, pH 4.2), neutralization buffer (2 M Tris-
base), 10 x sodium-dodecylsulfate (SDS)-running buffer (250 mM Tris, 1.92 M 
glycine, 1% SDS, pH 8.3), 6 x Laemmli sample buffer (0.003% bromophenol blue, 
60% glycerol, 12% SDS, 378 mM Tris-HCl, pH 6.8), Coomassie blue staining 
solution (0.25% Coomassie brilliant blue R250, 10% acetic acid, 25% methanol), 
destaining solution (10% acetic acid, 25% methanol), elution buffer (0.1 M glycine 
in DPBS, pH 2.7) and column storage buffer (0.1% sodium azide in DPBS). 
Disposable 2 mL plastic columns, 7.5% tris-glycine TGX gels, Precision Plus 
Kaleidoscope protein standard and SDS were obtained from Bio-Rad. Pepsin 
(3200-4500 units/mg protein), pH strips and protein A agarose were from Sigma, 
protein G agarose and 50 kDa molecular MWCO ultrafiltration spin columns were 
from Millipore. 
2.3.2 Enzymatic Digest with Pepsin 
The enzymatic activity of pepsin is optimal at a low pH (< 3). However, extended 
incubation times at low pH may cause partial destruction of the antibody structure 
(fragmentation, aggregation etc.) and loss of affinity. These unwanted side-
reactions also depend on the enzyme (E) to monoclonal antibody (mAb) weight-
ratio (E/mAb-ratio). A preliminary trial was conducted digesting OX42-IgG antibody 
at pH 4.2 for up to 8 hours with E/mAb-ratios of 1:33 and 1:20 (Figure 2-2 A). 
These conditions were chosen based on available literature [18,249,432].  
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Figure 2-1: Simplified structure of intact and pepsin-digested monoclonal antibodies. 
Monoclonal antibodies consist of 2 identical heavy and light chains. Intact antibodies have two 
antigen binding sites in the variable regions of the heavy and light chains (VH and VL). Fcγ-
receptors are able to bind antibodies via their Fc-part (CH2 and CH3) in the constant region of the 
heavy chain. Pepsin digests antibodies preferentially below the hinge region which connects both 
heavy chains by disulfide bridges. This generates a bivalent F(ab‘)2-antibody fragment which lacks 
the binding sites within the Fc-portion of the antibody. Pepsin digests the Fc-part into small 
peptides. 
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One milligram of intact OX42-IgG antibody was buffer exchanged to digestion 
buffer using 50 kDa MWCO spin columns. Concentration was adjusted to about 2 
mg/mL using a molar absorbance of 1.35 for IgG at 280 nm. The filtrate was tested 
with pH strips to confirm the proper pH value. The concentration of OX42-F(ab‘)2-
antibody fragments was estimated with the same method. An accurate 
concentration determination would only be possible with the exact molar 
absorption coefficient for the antibody fragments. However, the exact amino acid 
sequence is required and no such information is currently available for the OX42 
antibody. 
Aliquots were taken from the reaction mixture and neutralized with 2 M Tris-
base to pH 8 in order to stop pepsin activity. Protein samples were denatured for 5 
minutes at 90-95ºC in the presence of 1 x sample buffer in a water bath and then 
run on a non-reducing SDS-PAGE gel (5-10 μg protein per lane) for 30 minutes at 
200 V. SDS-PAGE gels were stained with coommassie blue for 45 minutes and 
destained overnight. 
Pepsin gradually digested the intact OX42-IgG antibody over a time-course 
of 8 hours at 37ºC in a water bath (Figure 2-2 A). Non-reducing SDS-PAGE (10 μg 
per lane) revealed that undigested OX42-IgG had an apparent molecular weight of 
150-160 kDa, while OX42-F(ab‘)2-fragments migrated to about 100 kDa. Both 
values agree with published values for IgG2a antibodies [18,249]. OX42-F(ab‘)2-
fragments appeared as soon as 2 hours after digestion had started. Intact OX42-
IgG was completely digested after 6 hours at  E/mAb-ratio 1:33, and after 4 hours 
at E/mAb-ratio 1:20. An additional band appeared over time at around 40-50 kDa 
suggesting the emergence of monovalent OX42-Fab‘-fragments that may form 
through the reduction and shuffling of disulfide bridges in the hinge region. Fab‘-
fragments were produced more rapidly at the higher E/mAb-ratio. Importantly, 
antibody fragments unrelated to the digestion process were not detected 
supporting the notion that reaction conditions did not affect the overall antibody 
structure. Based on the results of this preliminary trial, intact OX42 was chosen to 
be digested under more gentle conditions to minimize potential antibody 
degradation. OX42-IgG was digested for 5 hours at an E/mAb-ratio of 1:33 in 
following experiments.  
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2.3.3 Purification of Antibody Fragments with Protein G and 
Protein A 
Purification of OX42-F(ab‘)2-fragments requires the removal of undigested OX42-
IgG antibodies. Protein G and protein A are bacterial cell wall components with 
high affinity for the Fc domain of antibodies, although protein G has also been 
reported to bind to F(ab‘)2-fragments of some antibodies via their CH2 domain 
[246]. Disposable columns were packed with protein G and protein A coated 
agarose beads for removal of intact IgG antibodies. 
The reaction mixture containing intact OX42-IgG and digested OX42-F(ab‘)2-
fragments was neutralized with neutralisation buffer and mixed 1:1 with DPBS to 
adjust the ionic strength of the solution. Digests were then re-circulated five times 
using gravity flow over DPBS-equilibrated protein G or protein A agarose. After the 
last cycle, the remaining solution was recovered from the column by centrifugation 
(1000 G for 1 minute) and pooled with the solution that went through the column. 
This fraction was expected to contain digested OX42-F(ab‘)2-fragments that do not 
bind to protein G or protein A (F(ab‘)2 Fraction). Intact OX42-IgG antibody was 
recovered from agarose beads with 1 mL of elution buffer (IgG Fraction) with a 
final centrifugation step (1000 G, 1 minute). Intact IgG was saved by adjusting the 
pH of the IgG Fraction with neutralization buffer.  
Both fractions were then concentrated and buffer exchanged to DPBS with 
50 kDa ultrafiltration spin-columns (3000 G). The protein concentrations of the 
filtrate and retentate after ultrafiltration of both F(ab‘)2 Fraction and IgG Fraction 
was determined by measuring the absorbance at 280 nm and non-reducing SDS-
PAGE (5 μg protein per lane) was performed as described above. Protein G and 
protein A columns were flushed with DPBS and kept in column storage buffer at 2-
8ºC. All steps in the purification process were done on ice. 
The presence of protein in the filtrate of the F(ab‘)2 Fraction after ultrafiltration 
confirmed that cleaved Fc-peptides were neither retained by protein A nor protein 
G. However, no protein bands were visible on SDS-PAGE (data not shown) 
suggesting that these cleaved peptides are smaller than the lowest molecular 
weight standard marker of 37 kDa that migrated on the SDS-PAGE gel. Non-
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reducing SDS-PAGE (Figure 2-2 B) revealed differences in the ability of protein G 
and protein A agarose to bind OX42-F(ab‘)2-fragments. OX42-F(ab‘)2-fragments 
bound to protein G while most of the OX42-F(ab‘)2-fragments were not retained by 
protein A. 
Thus, protein A agarose was chosen to purify OX42-F(ab‘)2-fragment 
antibodies. Although the protein A purification may require some more optimisation 
to recover all of the digested OX42-F(ab‘)2-fragments, the purified fraction was 
devoid of IgG impurities as shown by non-reducing SDS-PAGE (Figure 2-2 B, 
Lane 8). The average yield of protein A-purified OX42-F(ab‘)2-fragments was 30-
40% from two preparations using the absorbance at 280 nm to estimate protein 
concentration as described previously. The ability of OX42-F(ab‘)2-fragments to 
bind to CD11b was then tested on isolated microglial cells by direct 
immunofluorescence. 
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Figure 2-2: Generation and purification of OX42-F(ab’)2-antibody fragments. 
A: Preliminary trial to determine optimal digestion conditions for OX42-IgG with the enzyme pepsin. 
OX42-IgG antibody (lane 2) was digested for up to 8 hours (37ºC, pH 4.2) at two different 
enzyme/mAb weight-ratios (lanes 3-6: 1:33; lanes 7-10: 1:20). Sample aliquots were taken after 
indicated time points, pH neutralized and samples prepared for non-reducing SDS-PAGE (10 μg 
protein per lane). A time-dependent decrease in intact OX42-IgG (150-160 kDa) was observed, 
while the digestion with pepsin produced F(ab‘)2-fragments of about 100 kDa molecular weight. 
With increasing time, monovalent OX42-Fab‘-fragments (40-50 kDa) were formed as a side-
product. At higher enzyme/mAb-ratio (lanes 7-10), the digestion of intact IgG and the emergence of 
F(ab‘)2- and Fab‘-fragments proceeded faster. No additional degradation products other than 
expected from pepsin digestion were observed, suggesting that the conditions were suitable to 
digest OX42-IgG antibody. B: Development of purification procedure. OX42-IgG was digested with 
pepsin for 5 hours (enzyme/mAb-ratio = 1:33) and purification of OX42-F(ab‘)2-fragments tested on  
protein G- (lanes 4 and 5) and protein A-agarose (lanes 8 and 9) packed columns, respectively. 
Proteins contained within the retentate of both F(ab‘)2 Fraction and IgG Fraction after ultrafiltration 
(5 μg protein per lane) were detected with non-reducing SDS-PAGE. Protein G bound all digested 
OX42-F(ab‘)2-fragments besides intact IgG (lane 5) while protein A retained intact IgG but only 
some F(ab‘)2-fragments (lane 9). Protein A purification yielded pure OX42-F(ab‘)2-fragments with 
no IgG impurities detected (lane 8). MWM: molecular weight marker. 
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2.4 Tagging of Monoclonal Antibodies with 
Fluorescent Dyes and Confocal Imaging 
The use of primary antibodies labelled with fluorescent dyes has several 
advantages over labelled secondary antibodies especially in trafficking studies and 
fluorescent assays based on immunofluorescence. This section describes tagging 
of several antibody batches with fluorescein, Alexa 488- and Atto 594-
fluorophores. 
2.4.1 Materials  
N-hydroxy-succinimide-(NHS)-activated fluorescein (mixed isomers), Alexa 488 
sulfodichlorophenol (SDP) ester, Cell Tracker Red and Hoechst-dye were obtained 
from Invitrogen. Atto 594-NHS ester was from Fluka (Switzerland). Labelling 
buffers for fluorescein tagging (0.05 M borate buffer, pH 8.8), Alexa 488 and Atto 
594 tagging (0.1 M NaHCO3, pH 8.3) and diluent buffer KHB (Krebs-HEPES-
buffer: 140 mM NaCl, 2.8 mM KCl, 2 mM MgCl2, 10 mM HEPES, 10 mM glucose, 
2 mM CaCl2, pH 7.4) were prepared with chemicals purchased from Sigma. 
Paraformaldehyde was from Merck. Thirty kDa MWCO ultrafiltration spin columns 
were from Sartorius and PD10 desalting columns were obtained from GE 
Healthcare (Australia). PDL-coated fluorodishes were purchased from World 
Precision Instruments (USA). Fluorescence mounting medium was obtained from 
DAKO (Denmark). 
2.4.2 Fluorescein Labelling 
OX42-IgG antibody and OX42-F(ab‘)2-fragments were buffer exchanged to 
labelling buffer with spin columns to a protein concentration of > 2 mg/mL. Intact 
OX42-IgG and OX42-F(ab‘)2-fragments were tagged with fluorescein (FITC) at a 
dye/antibody-ratio of 20:1 and 15:1, respectively, based on manufacturer’s 
recommendations. The reaction mixture was incubated in the dark on a shaker for 
1 hour at room temperature. Tagged antibodies were purified on DPBS-
equilibrated PD10 desalting columns. For OX42-IgG, 10 mM sodium azide was 
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added as a preservative. The concentration and molar fluorophore/protein (F/P)-
ratio was determined using the values given in Table 2-1 for fluorescein and 
equations as stated by the manufacturer of the dye (Equation 2-1 and 2-2).  
 
cmAb / [mg/mL] = 
35.1
)( max280280 dyeACFA            (Equation 2-1) 
 Molar F/P = 
mAbfluor
dye
c
MWA



max
                      (Equation 2-2) 
with A280 = absorbance at λ = 280 nm (protein maximum) 
 CF280 = correction factor for fluorophore at 280 nm 
 Adye max = absorbance at wavelength maximum λdye max for fluorophore  
 MW = molecular weight of antibody IgG (≈ 150000 g/mol) 
 εfluor = molar extinction coefficient of fluorescent dye at λdye max 
Table 2-1: Values to determine concentrations and F/P-ratios for tagged antibodies 
Fluorophore CF280 λdye max / [nm] εfluor / [M-1cm-1] 
Fluorescein 0.35 493 70000 
Alexa 488 0.11 495 71000 
Atto 594 0.51 601 120000 
F/P-ratio: molar  to protein ratio. 
 
The F/P-ratio for OX42-IgG-FITC was approximately 9 and for OX42-F(ab‘)2-FITC 
13. The yield was 55% for OX42-IgG-FITC and 50% for OX42-F(ab‘)2-FITC. 
2.4.3 Alexa 488 and Atto 594 Labelling 
Fluorescent dyes such as Alexa and Atto exhibit fluorescence that is less pH 
dependent compared to fluorescein and thus more suitable for certain applications 
such as trafficking studies in acidic organelles. Further, Alexa- and Atto-dyes are 
more photostable and considered superior when fixation of tissue is required (e.g. 
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in vivo studies). For these purposes, OX42-IgG and X63 antibodies were tagged 
with Alexa 488-dye and another batch of purified OX42-IgG was labelled with Atto 
594-dye. 
Antibodies were buffer exchanged with spin columns to > 2 mg/mL in 
labelling buffer. OX42-IgG antibodies incubated with Alexa 488-dye at a molar 
dye/antibody-ratio of 20:1 and 10:1 for Atto 594 were found to give sufficient 
degree of labelling. Antibodies were labelled with Alexa 488 in the dark on a 
shaker for 1 hour at RT followed by an overnight incubation at 2-8ºC. For Atto 594 
labelling, incubation for 1 hour at RT was sufficient. Tagged antibodies were 
desalted and buffer exchanged to DPBS with PD10 desalting columns. Protein 
concentrations and molar F/P-ratios were determined by applying Equation 2-1 
and 2-2 with values stated in Table 2-1. F/P-ratios for OX42-IgG-Alexa 488 and 
X63-Alexa 488 were 5 and 4, respectively. The F/P-ratio for OX42-IgG-Atto 594 
was approximately 8. The protein yield after labelling was 80% for OX42-IgG-
Alexa 488, 72% for X63-Alexa 488 and 80% for OX42-IgG-Atto 594. 
2.4.4 Direct Immunofluorescence 
The ability of tagged antibodies to bind to microglia was qualitatively assessed by 
direct immunofluorescence in vitro using several different protocols ( Figure 2-3 A-
E). Isolated microglia (2 x 104 cells/coverslip) were either fixed and immunostained 
with OX42-IgG-FITC (1.6 µg/mL, Figure 2-3 A) to detect binding to the cell 
membrane or first incubated with fluorescein-labelled antibody (1.6 µg/mL) and 
then fixed (B) to test for antibody internalization. Isolated microglia (5 x 104 
cells/fluorodish) were incubated with 2 µg/mL OX42-F(ab‘)2-FITC for 60 minutes 
on ice to halt potential internalization of the antibody and then fixed (C). 
Fluorescein-tagged OX42 antibodies and antibody fragments detected CD11b in 
the membrane (Figure 2-3 A and C) while OX42-IgG-FITC accumulated in 
intracellular vesicles in non-fixed microglial cells (B). The ability of OX42-F(ab’)2-
FITC to bind to microglial CD11b receptor confirmed that pepsin digestion did not 
affect the antigen binding sites of OX42. 
Successful Alexa 488-tagging of OX42-IgG was tested on non-fixed isolated 
microglia (5 x 104 cells/fluorodish). OX42-IgG-Alexa 488 (2 μg/mL, 1 hour at 37ºC) 
detected membrane CD11b and accumulated in intracellular vesicles (Figure 2-3 
Chapter 2: General Material and Methods 
58 
 
D). Since X63 antibody does not bind to microglia in vitro (Chapter 4), tagging of 
X63-IgG with Alexa 488 could not be confirmed on cultured cells. However, X63-
Alexa 488 was used for in vivo injections (Chapter 3) resulting in a strong 
fluorescent signal confirming successful labelling. 
Atto 594-labelling of OX42-IgG was confirmed on fixed microglia (4% PFA, 
10 minutes) plated on PDL-coated coverslips (2 x 104 cells/coverslip,). CD11b 
showed immunoreactivity for OX42-IgG-Atto 594 (2 μg/mL) in the microglial 
membrane (Figure 2-3 E). However, laser power and gain needed to be set higher 
for Atto 594-dye compared to Alexa 488-dye albeit higher F/P-ratio. This was 
reflected by increased background fluorescence under control conditions (Figure 
2-3 E). The Atto 594-dye fluorescence spectrum is slightly red shifted compared to 
other more commonly used red fluorophores and this would require different filters 
on the confocal microscope for optimal performance. 
For all experiments, either cell nuclei were stained with Hoechst-dye (1:500 
in DPBS, 10 minutes) or cell bodies were visualized with Cell Tracker Red (2 μM, 
30 minutes at 37ºC). Each condition was run once on duplicate coverslips or 
fluorodishes. Control experiments omitting labelled antibodies confirmed specificity 
of the fluorescence for the fluorophores. In summary, several batches of 
antibodies were successfully tagged with fluorophores (Table 2-2) and were 
applied in several assays throughout this project. 
Table 2-2: Summary of antibodies labelled with fluorescent dyes 
Target Antibody Fragment Tag Conc. / [mg/mL] F/P-ratio 
CD11b OX42 IgG Fluorescein 0.40 9 
CD11b OX42 F(ab’)2 Fluorescein 0.16 13 
CD11b OX42 IgG Alexa 488 0.36 5 
CD11b OX42 IgG Atto 594 0.42 8 
Unknown X63 IgG Alexa 488 0.38 4 
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2.4.5 Confocal Microscopy 
Confocal images were aquired on a Nikon A1 (inverted) or C1 (upright) confocal 
microscope equipped with 405 nm, 488 nm and 561 nm diode lasers using NIS AR 
software (Nikon, Australia). In general, single optical sections were recorded 
(average of 8 images) with lenses of 10 – 60 x magnification. Cell shape was 
visualized using maximum pinhole, for all other applications the pinhole was 
reduced as much as possible to allow evaluation of fine cellular structures and to 
limit bleaching of the fluorophores. Where appropriate, optical sectioning was 
performed and 3D-images generated with pinhole size set to minimum. 
For live cell imaging, maximum pinhole was chosen and four images were 
averaged to produce the final image. Images were acquired with constant laser 
power and gain settings within an experiment to compare experimental conditions 
and to allow quantification where appropriate. Background fluorescence was 
recorded in control cells for each experiment with the same confocal settings to 
show fluorophore-specific fluorescence. 
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Figure 2-3: Immunostaining of isolated microglia with tagged OX42-IgG and OX42-antibody 
fragments. 
A: OX42-IgG antibodies tagged with fluorescein (green) detected CD11b receptor in the membrane 
of fixed microglia. B: Incubation of non-fixed microglia with OX42-IgG-FITC (green) appeared to 
trigger internalization of the antibody, because intracellular, vesicle-like immunostaining was 
observed after 60 minutes. C: Non-fixed microglia were incubated with OX42-F(ab‘)2-FITC (green) 
on ice to prevent potential internalization. OX42-F(ab‘)2-FITC bound to CD11b in the microglial cell 
membrane. D: CD11b-IR (green) was found on the membrane and intracellularly in non-fixed 
microglia loaded with Cell Tracker (red) and incubated with OX42-IgG-Alexa 488 (green). E:  Fixed 
microglia stained for CD11b in the membrane with OX42-IgG-Atto 594 antibody. For all labelled 
antibodies and antibody fragements, direct immunofluorescence confirmed integrity of tagged 
antibodies and antibody fragments. Control experiments omitting labelled antibodies verified that 
fluorescence was specific for the fluorophore. Confocal images represent single optical sections 
with maximum pinhole (40 x or 60 x lenses with optical zoom as indicated). FITC: fluorescein 
isothiocyanate. 
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2.5 Assays to Study Microglial Effector Functions 
Immune cells such as neutrophils, macrophages and microglia employ a variety of 
defence mechanisms to combat infection and to mediate inflammation. The 
respiratory burst is one of these mechanisms which results in rapid production of 
reactive oxygen species (ROS) [102]. This process is not only important for 
bactericidal activity and removal of invading pathogens, it is also crucial for 
mediating redox-sensitive intracellular signalling cascades that lead to pro- and 
anti-inflammatory gene expression [85].  
A variety of different techniques are in common use to detect ROS (reviewed 
in [80]). Luminescent and fluorescent probes are among the most frequently used 
in cell-based assays to detect ROS such as hydrogen peroxide. CM-H2DCFDA (5-
(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester) is a 
fluorescent probe based on fluorescein which responds to oxidation primarily by 
hydrogen peroxide with increase in fluorescence. Hydrogen peroxide can be 
formed by dismutation of superoxide either spontaneously or catalysed by 
superoxide dismutase (SOD) enzymes. Thus, Measurement of hydrogen peroxide 
production indirectly measures the generation of superoxide. However, only the 
de-acetylated form can be oxidized and fluoresce (Figure 2-4 A). Cells that exhibit 
esterase activity have the ability to retain the dye intracellular as the de-acetylated 
form is not able to cross the cell membrane. An increase of intracellular green 
fluorescence thus indicates an increase of ROS production, although the source of 
ROS cannot be determined due to the ability of hydrogen peroxide to cross cell 
membranes [115].  
The production of ROS is accompanied by degranulation/exocytosis of 
components of the NADPH oxidase enzyme family that are stored in intracellular 
vesicles and granules in phagocytes under resting conditions [217]. This group of 
enzymes is a major source of activation-induced ROS. However, activation of the 
respiratory burst has been also shown to induce CD11b degranulation in 
monocytes and neutrophils [55,275].  
Thus, ROS production and degranulation/exocytosis of CD11b are important 
effector functions for a proper immune response. The development of assays to 
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measure ROS production and CD11b exocytosis is essential to understand the 
physiology of immune cells including microglia. 
2.5.1 Materials 
Chemicals were purchased from Sigma unless otherwise stated. Phorbol-12,13-
dibutyrate (PDBu) was obtained from Enzo Life Sciences (USA), prepared as 10 
mg/mL stock solution in DMSO and kept in aliquots at -20ºC. The cell permeable 
ROS indicator CM-H2DCFDA was from Invitrogen and prepared as 10 mM stock 
solution in DMSO. CM-H2DCFDA dissolved in DMSO was stable for at least 4 
weeks at -20ºC if protected from moisture. Fluorescence mounting medium was 
purchased from DAKO and monoclonal OX42-IgG antibodies tagged with 
fluorescein and Atto 594, respectively, were prepared as per section 2.4.  
2.5.2 Fluorescent Assay for Reactive Oxygen Species 
CM-H2DCFDA has been frequently used to measure microglial hydrogen peroxide 
generation in variety of assays by flow cytometry [192,389,442], fluorescence 
microscopy [401,411] and 96-well microplate assays [49,187,378]. Measuring 
ROS on microplates has the advantage of higher sample-throughput. Further, the 
extended exposure of the dye to fluorescence light and laser that occurs in 
fluorescence and confocal microscopy causes photo-oxidation of CM-H2DCFDA 
and an artifactual increase in fluorescence (own observation). Therefore, an assay 
was developed on PDL-coated black 96-well plates. 
Ten thousand cells per well (4 wells per condition) were plated which resulted 
in 50-60% confluency. This gave sufficient levels of fluorescence for evaluation on 
a plate reader (FlexStation 3). Previous microplate-based assays have often used 
more than 4 x 104 cells per well [49,378]. A lower plating density was chosen here 
due to the limited availability of primary microglia and to reduce potential paracrine 
effects. 
Plated microglial cells were incubated for 2 hours (37ºC, 5% CO2) rather than 
overnight as in other assays used in this project to increase the speed of the assay 
procedure. Microscopic examination of microglial cells plated for 2 hours and 
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overnight showed no difference in their morphology (data not shown). Microglia 
spread out and stuck to coated wells sufficiently after 2 hours incubation.  
After 2 hours incubation, microglia were washed with KHB and loaded with 5 
μM CM-H2DCFDA in KHB for 30 minutes at 37ºC. Incubation conditions were 
determined in a series of experiments in which 100 μM hydrogen peroxide caused 
maximal oxidation of the fluorescent dye (data not shown). Oxidation by hydrogen 
peroxide was also used to determine the settings for the plate reader (Table 2-3) 
that gave highest sensitivity and resulted in fast readings to minimize photo-
oxidation of CM-H2DCFDA.  
Table 2-3: FlexStation 3 settings for ROS assay 
Reading Excitation / 
[nm] 
Emission / 
[nm] 
Cut-off / 
[nm] 
PMT Points/Well No. of 
readings 
Bottom 492 530 515 Auto 5 4 
PMT:photomultiplier. 
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Figure 2-4: Development of a fluorescent assay for reactive oxygen species. 
A: Structure of ROS-sensitive fluorescent dye CM-H2DCFDA. The non-fluorescent form is cell-
permeable and is retained within the cell after removal of acetyl groups by esterases. DCF 
fluoresces upon oxidation primarily by hydrogen peroxide. This reaction scheme is based on the 
instruction manual from the manufacturer. B: Evaluation of PKC-activator PDBu as positive control 
and internal standard. Increase in fluorescence was measured over 60 minutes indicating rapid 
production of ROS elicited by PDBu (10-100 ng/mL). Hydrogen peroxide (100 μM) caused maximal 
oxidation of the dye. C: After 60 minutes incubation, 50-100 ng/mL PDBu triggered more than 
150% increase in DCF-fluorescence over baseline. PDBu at low concentration (10 ng/mL) caused 
only a small increase of 50%. Results were expressed as% increase of fluorescence over baseline 
after background subtraction (n = 3 experiments, Mean ± SEM). 
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Phorbol esters such as phorbol-12-myristate-13-acetate (PMA) and phorbol-12,13-
dibutyrate (PDBu) are commonly used to activate protein kinase C (PKC) which is 
required to activate the respiratory burst in phagocytes [329]. Thus, PDBu was 
used as a positive control in further assays and the optimal concentration 
determined in comparison to 100 μM hydrogen peroxide (Figure 2-4 B). CM-
H2DCFDA-loaded cells were treated with 10-100 ng/mL PDBu (n = 3 experiments, 
4 wells per condition) for up to 60 minutes and fluorescence read on a plate 
reader. Wells with KHB only were included to determine baseline ROS production 
and to account for the increase in baseline fluorescence, because CM-H2DCFDA 
is prone to oxidation in solution and by light. Raw fluorescence values were read 
every 15 minutes, baseline fluorescence subtracted and results expressed as % 
increase in fluorescence over baseline at time-point 0 (Mean ± SEM). ROS 
production was rapid, evident as soon as 15 minutes and increased over time 
(Figure 2-4 B). After 60 minutes, more than 150% increase in fluorescence was 
observed when microglia were treated with 50-100 ng/mL PDBu (Figure 2-4 C). 
Lower concentration of PDBu (10 ng/mL) triggered only low levels of ROS. These 
values corresponded to published literature for murine peritoneal macrophages 
[211]. 
In conclusion, PDBu (100 ng/mL) was chosen as a positive control for further 
assays. While hydrogen peroxide only confirms the ability of CM-H2DCFDA to be 
oxidized, PDBu is useful to assess the responsiveness of cells, because different 
batches of primary microglia were found to respond to the same stimulus with 
varying degrees of ROS production (own observation). Therefore, PDBu was used 
as positive control and internal standard. Subsequent ROS assays (Chapter 5 and 
8) were evaluated as % of PDBu response after baseline subtraction and microglia 
without CM-H2DCFDA were treated with the maximum amount of any stimulus as 
a control to rule out false-positive results due to fluorescence of the stimulus itself. 
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2.5.3 Detection of CD11b Exocytosis by Immunofluorescence 
Flow cytometry is commonly used to measure degranulation/exocytosis of CD11b 
in monocytes and neutrophils [36,275,306,459]. It is the method of choice for cells 
in suspension and can also be used for adherent cells, but requires that they be 
detached from their substrate. This may change cellular functions especially of 
integrin receptors that are important for anchorage to substrates. Therefore, the 
detection of exocytosis in adherent cells such as cultured microglia requires a 
different approach. Exocytosis of CD11b can be detected in adherent cells using 
immunofluorescence of a labelled antibody that recognizes CD11b on the 
membrane and in intracellular stores. The monoclonal antibody OX42 tagged with 
fluorophores is suitable for this purpose because it is specific for CD11b and 
immunoreactivity can be visualized by confocal microscopy.  
Exocytosis of CD11b can be quantified by either measuring the remaining 
internal pool of CD11b that did not translocate to the cell membrane after 
stimulation or measuring the increased CD11b-IR in the cell membrane. Although 
quantification of membrane CD11b would only involve the application of a 
fluorescent-tagged OX42 antibody, this simple approach poses some challenges. 
Firstly, the antibody OX42 is suggested to bind to an epitope in or close to the 
inactivated complement 3b (iC3b)-binding site [233,393,430] located within the 
extracellular I-domain of CD11b [524]. This domain has been reported to be 
proteolytically cleaved rapidly upon strong stimulation with PMA [106]. Thus, 
stimulation of exocytosis may cause epitope loss and quantifying membrane 
CD11b with OX42 antibody may consequently cause false-negative results. 
Secondly, stimulation of CD11b exocytosis with ligands that bind to the CD11b 
receptor may reduce the available binding sites for OX42 antibody. Therefore, a 
method was developed to quantitatively measure the depletion of intracellular 
CD11b-stores by detecting the remaining intracellular CD11b-IR after cell 
stimulation. 
Isolated microglia were plated on PDL-coated coverslips (2 x 104 
cells/coverslip) and incubated overnight prior to the experiment. Cells were 
washed with pre-warmed KHB and CD11b-exocytosis triggered for 15 min at 37ºC 
with a variety of stimuli diluted in KHB (Chapters 5 and 8). Microglia were washed 
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with ice-cold KHB to stop exocytosis and incubated on ice for 5 minutes. In order 
to visualize cell shape, membrane CD11b was stained with ice-cold OX42-IgG-
FITC (10 μg/mL) and incubated for 30 minutes on ice to prevent antibody 
internalization. Cells were then fixed with ice-cold 4% PFA (10 minutes on ice) and 
were allowed to equilibrate to room temperature. Internal CD11b stores were 
made accessible for antibody binding by permeabilization with 0.1% Triton-X100 
(10 minutes at RT). Intracellular CD11b was then detected with OX42-IgG-Atto 
594 (2 μg/mL, 30 minutes at RT). Microglia were mounted on microscope slides 
with fluorescence mounting medium and exocytosis evaluated by confocal 
microscopy.  
Confocal settings were kept constant within an experiment to allow 
quantification, but different for each experiment. Every assay included the 
measurement of intracellular CD11b-IR in non-stimulated microglia at time-point 0. 
This value was interpreted as 100% intracellular CD11b. For each experiment, 
background fluorescence of the red channel was measured by incubating 
microglia with DPBS instead of OX42-Atto 594. Every condition was run on two 
coverslips in parallel and three independent experiments were performed. ImageJ 
was used to evaluate at least 15 cells per coverslip (30 cells per condition) by 
calculating the average red fluorescence per cell using membrane CD11b-IR 
(green) to determine cell area and intracellular CD11b-IR (red) to determine the 
amount of CD11b that has not translocated to the cell membrane.  
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Figure 2-5: Development of an assay to measure CD11b exocytosis in microglia. 
A: Permeabilization of microglia causes loss of membrane fluorescence. Membrane CD11b was 
detected with OX42-FITC antibody and cells permeabilized with 0.1% Triton-X100. Confocal 
images demonstrated that permeabilization reduces the fluorescence signal of membrane CD11b. 
B: Quantification of fluorescence in membrane. The average fluorescence intensity in the green 
channel was measured per cell in ImageJ (n ≥ 13 cells). Permeabilization of microglial cells caused 
a significant reduction in membrane fluorescence compared to DPBS (P < 0.0001, Student’s t-test). 
C: Second application of OX42 antibody (tagged with Atto 594) does not displace OX42-FITC 
bound to the cell membrane. OX42-FITC bound to membrane-CD11b in non-permeabilized 
microglia. After fixation, microglia were incubated with OX42-Atto 594 again without 
permeabilization. No increased red membrane fluorescence was visible in confocal images. D:   
Quantification of red fluorescence revealed that there was no significant increase in OX42-Atto 594 
binding to microglia suggesting that OX42-Atto 594 did not displace OX42-FITC (n ≥ 20 cells, 
Student’s t-test). Confocal images represent single optical sections with maximum pinhole. Laser 
power and gain were constant to compare different conditions. *** P < 0.0001; N.S. not significant. 
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Results were expressed as % of intracellular CD11b at time-point 0 (Equation 2-3) 
after subtracting background values and presented as Mean ± SEM. 
 
% Intracellular CD11bper cell, t=15 min = 
Backgroundt
Backgroundt
AvFAvF
AvFAvF




0
15
 x 100%    (Equation 2-3) 
 
with  AvFBackground = 
Backgroundcell
Background
n
AvRF
,

   and    AvFt=o = 
otcell
t
n
AvRF


,
0
 
 
AvRF = average fluorescence in red channel (intracellular CD11b) within Areacell 
Areacell = area of the cell determined by green fluorescence (membrane CD11b) 
AvF = average fluorescence 
ncell = number of evaluated cells  
 
Control experiments were conducted to verify the practicability of the developed 
assay. Permeabilization with 0.1% Triton-X100 caused a significant loss of 
membrane fluorescence compared to non-permeabilized microglia (n ≥ 13 cells, P 
< 0.0001, Student’s t-test, Figure 2-5 A and B). This was not considered as major 
drawback for this assay as confocal settings could be adjusted to visualize cell 
shape. However, because of this it is not possible to determine the total amount of 
CD11b in a cell. Another experiment with non-stimulated and non-permeabilized 
microglia demonstrated that the second application of OX42 antibody (tagged with 
Atto 594) did not displace membrane bound OX42-IgG-FITC (Figure 2-5 C) under 
the assay conditions. No significant increase in red fluorescence was observed 
when OX42-Atto 594 was added compared to DPBS alone (n ≥ 20 cells, Student’s 
t-test, Figure 2-5 D). 
Chapter 2: General Material and Methods 
80 
 
2.6 Cloning and Purification of Plasmid DNA 
Plasmid DNA was cloned and subcultured using standard procedures. An 
enhanced green fluorescent protein (EGFP)-expressing plasmid was used as a 
reporter plasmid for transfection experiments in vitro and in vivo (Chapter 7) and 
for gel retardation assays (Chapter 6). Restriction enzyme analysis was used to 
verify integrity and purity of the subcultured plasmid DNA. 
2.6.1 Materials 
Luria agar (LA) media ( 10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar per 1 
L solution), 2 x YT medium (16 g tryptone, 10 g yeast extract, 5 g NaCl per 1 L 
solution), Luria broth (LB) media (10 g tryptone, 5 g yeast extract, 10 g NaCl per 1 
L solution), 80% glycerol stock and 10 x Tris-buffered ethylene-di-amine-tetra-
acetic acid buffer, (TBE, 27 g Tris-base, 13.75 g boric acid, 2.33 g EDTA di-
sodium salt di-hydrate per 250 mL solution, pH 8.3) were prepared with chemicals 
purchased from Sigma except for yeast extract which was from BD Biosciences. A 
reporter plasmid expressing EGFP (pEGFP-N1) was a gift from W. Kruger (RMIT 
University). Competent E.coli cells (DH5α) were bought from Invitrogen. 
Kanamycin (Sigma) was prepared as 30 mg/mL stock solution in water and stored 
at -20ºC. Plasmid DNA was purified with NucleoBond® PC 2000 Kit (Macherey-
Nagel, Australia). Enzymatic digestion was performed with restriction enzymes 
(XhoI, BamHI) and chemicals (10 x NEBuffer 3, 100 x BSA stock solution) from 
New England Biolabs (Australia). Agarose was purchased from Promega 
(Australia). SYBR® Safe DNA gel stain, 10 X BlueJuice™ Gel Loading Buffer and 
TrackIt™ 1 Kb Plus DNA Ladder were obtained from Invitrogen. 
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2.6.2 Transformation and E.coli Culture 
Competent E.coli cells were incubated with pEGFP-N1 for 30 minutes on ice and 
gentle agitation. E.coli cells were transformed by heat-shock (30 seconds at 42ºC), 
cooled down on ice (2 minutes) and 2 x YT-medium added to make up 1 mL. Cells 
were incubated for another 1 hour at 37ºC on a shaker (250 RPM). Twenty to 200 
μL of the culture was spread on LA-plates containing 30 μg/mL kanamycin. Plates 
were incubated for 12-16 hours at 37ºC. 
One colony was picked from one LA-plate and plasmid DNA grown for 12-16 
hours at 37ºC on a shaker (250 RPM). Three hundred milliliter LB containing 30 
μg/mL kanamycin gave sufficient growth to obtain about 2 mg of purified DNA. 
2.6.3 Purification and Agarose Gel Electrophoresis 
Plasmid DNA was purified according to manufacturer’s instructions except that the 
precipitation of pDNA in isopropanol was extended to overnight incubation at 2-
8ºC. The DNA concentration was determined by measuring the absorbance at 260 
nm (A260 = 1 for 50 μg/mL DNA). The purity of the plasmid preparations was 
assessed by calculating the A260/280-ratio. A260/280 was ≥ 1.9 for all preparations. 
The integrity of sub-cloned pEGFP-N1 (4.7 kbp) was confirmed by digesting 1 μg 
pDNA with restriction enzymes XhoI (20 units) and BamHI (20 units).  After an 
overnight incubation (37ºC), samples were prepared for agarose gel 
electrophoresis (0.8% agarose gel, 400-500 ng DNA/lane, 80 V for 2 hours). 
Bands were visualized with DNA stain (30 minutes), the gel washed (30 minutes) 
and images acquired. Gel electrophoresis (Figure 2-6) revealed that both 
restriction sites were intact and that the purified EGFP-N1 plasmid had the correct 
size and was free of contaminants. This applied to all subcultures. For the double-
digests (Figure 2-6, Lanes 4 and 7), the expected second DNA fragment of about 
50 bp was not visible due to its small size and most likely ran off the gel during 
electrophoresis.  
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Figure 2-6: Agarose gel for subcultured, purified and enzymatic digested EGFP-N1 plasmid 
DNA. 
A reporter plasmid expressing EGFP (pEGFP-N1) was cloned and subcultured using heat-shock 
transformation and standard protocols for E.coli culture and plasmid purification. The integrity of 
purified pDNA was confirmed by restriction enzyme analysis with XhoI (lanes 2 and 5), BamHI 
(lanes 3 and 6) and a double-digest (lanes 4 and 7) comparing control (lanes 2-4) and subcultured 
pDNA (lanes 4-7). Samples (400-500 ng/lane) were run after an overnight digestion on a 0.8% 
agarose gel and bands were visualized with SYBR DNA stain. Molecular weight markers (lanes 1 
and 8) verified the correct size of purified pEGFP-N1 (4.7 kbp). Restriction sites were found to be 
intact and the absence of additional bands confirmed purity of subcultered EGFP-N1 plasmid. 
EGFP: enhanced green fluorescent protein; MWM: molecular weight marker. 
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3.1 Introduction 
Microglia are the principal immune cells in brain and spinal cord orchestrating the 
inflammatory response within the central nervous system (CNS). They are highly 
plastic cells changing their phenotype rapidly from a ‘surveillant’ or quiescent state 
to an activated and eventually phagocytic state (reviewed in [222]). Changes in 
morphology in activated microglia are accompanied by up- and down-regulation of 
cell surface receptors that mediate the inflammatory response of microglia 
[412,465]. While activated microglia in acute inflammation are considered helpful 
and support regeneration of neuronal tissue, chronic activation of microglia has 
been implicated in almost every neuropathology including Alzheimer’s Disease 
(AD), Parkinson’s Disease (PD) and neuropathic pain [50]. Microglia were 
previously shown to be activated in the cardiovascular centers of the brain 
including the PVN (paraventricular nucleus) of the hypothalamus in an animal 
model of myocardial infarction (MI) [386]. In this and many other neuropathologies 
it is unclear whether microglial activation is neuroprotective, neurotoxic or 
neuromodulatory. Thus, studying microglial function is essential to understand 
their role in neurological disorders. 
Targeted gene delivery into microglia is a promising tool to investigate the 
mechanisms of microglial activation without confounding the results by transfecting 
other cells. While at least some viral vectors such as adenovirus (AV) [258,406], 
adeno-associated virus (AAV) [31,453] and lentivirus (LV) [320,504] show tropism 
towards microglial cells, they have to be extensively modified to achieve targeted 
microglial gene delivery. Antibody-based non-viral bioconjugates may provide an 
alternative that is more cell-type specific, less immunogenic and easier to 
synthesize using chemical methods. Monoclonal antibodies raised against cell 
surface receptors have been used to deliver genes to several cell lines in vitro 
[228] and motor neurons [29] and cholinergic basal forebrain neurons [37] in vivo. 
Given the importance of microglia in various neuropathologies, it is surprising to 
see that, in vivo, only a few attempts at viral gene transfer into microglia have 
been made [99,258,272,295,301]. In contrast, targeted non-viral gene transfer into 
microglia has not been attempted.  
Chapter 3: Specificity of Integrin CD11b for Microglial Gene Transfer 
88 
 
Monoclonal antibodies may confer increased specificity compared to other 
non-viral ligands used previously such as polysaccharides [19]. The unique 
property of monoclonal antibodies to recognize a specific epitope on a single 
antigen accounts for their potential as targeting ligands in non-viral gene transfer. 
However, the specificity of a given non-viral vehicle depends also on the tissue 
and cellular distribution of the targeted receptor. Thus, selecting the right antibody 
and receptor is crucial as it defines one level of specificity for the non-viral vector. 
The administration route (e.g. peripheral or parenchymal injection) and cell-type 
selective promoters [99] may also be utilized to further increase specificity. 
Microglial cells express a variety of cell surface receptors that are associated with 
their immune function. Due to the unique immuno-modulatory role of microglia 
among CNS cells, immune receptors may provide the specificity needed for 
targeted gene transfer. Among those immune receptors, two pattern recognition 
receptors (PRRs) are the focus of this study – the integrin receptor CD11b and 
scavenger receptor BI (SR-BI).  
CD11b belongs to the integrin receptor family of heterodimeric 
transmembrane proteins that are widely expressed both on myeloid cells of the 
CNS and peripheral immune system [40,310]. CD11b belongs to the group of β2-
integrins that share a common β-subunit (CD18) and forms a non-covalent dimer 
with CD18. The CD11b integrin receptor is also known as Mac-1 (macrophage 
antigen complex 1), CD11b/CD18, αMβ2 and complement receptor 3 (CR3) [40]. 
Microglial cells constitutively express β2-integrins [11] and increase CD11b 
expression when activated [222]. Among the cells of the CNS, β2-integrins are 
specifically found on microglia and infiltrating myeloid cells under conditions where 
the blood-brain-barrier (BBB) is compromised [310]. In pathological states such as 
myocardial infarction, microglia are chronically activated and CD11b-
immunoreactivity (IR) remains elevated for several weeks [386]. This suggests an 
important function of CD11b in microglial activation.  
Integrins have been extensively studied for delivery of genes or siRNA into 
cancer cells with RGD (arginine-glycine-aspartate) peptides as targeting ligands 
[300,356]. While the RGD peptide sequence is recognized by several integrins, 
peptides with an RGD motif do not bind to CD11b [473,487]. Instead, a 
monoclonal antibody such as OX42 (Immunoglobulin G subtype 2a, IgG2a) that 
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targets rat CD11b [393] could be valuable to achieve specific microglial gene 
transfer. The OX42 antibody is suggested to bind at or close to the iC3b 
(inactivated complement fragment 3b) - binding site of CD11b, because OX42 
antibody prevents rosette formation in macrophages [393,430] and inhibits iC3b-
binding in monocytes [234]. Thus, integrin CD11b and its targeting monoclonal 
antibody OX42 could potentially be used to deliver genes into microglia.  
Scavenger receptors are also PRRs and currently divided into eight 
subgroups (A-H, reviewed in [50,325]). SR-BI is a membrane protein and 
distributed in a variety of peripheral tissues (e.g. liver, adrenal cortex, ovary) and 
peripheral cell types (e.g. vascular smooth muscle cells, endothelial cells, 
macrophages and monocytes, [196,243]). SR-BI is known to play a role in lipid 
metabolism and transfer of cholesterol to and from high-density lipoprotein (HDL, 
reviewed in [243]).  
In the CNS, scavenger receptors are expressed by astrocytes and microglia 
[194,196]. Microglia from neonatal mice express SR-BI and mediate binding and 
internalization of fibrillar Aβ peptide [195]. Further, neonate ramified and amoeboid 
microglia were reported to take up Aβ-peptide aggregates via scavenger receptors 
supporting the assumption that scavenger receptors including SR-BI are capable 
of receptor-mediated endocytosis and phagocytosis [194,355,513]. The possibility 
of using SR-BI as an entry point for drug delivery by nanoparticles into cancer cells 
has already been tested [319]. An anti-rat SR-BI monoclonal antibody (clone 
3D12, IgG1) has been generated which recognizes an extracellular peptide 
sequence of the SR-BI receptor [327,353] and may be used for gene delivery.  
Since SR-BI and CD11b receptors may be suitable entry points for targeted 
antibody-mediated delivery of genes into microglia, receptor expression on the 
membrane and intracellularly was studied by indirect immunofluorescence. The 
presence of SR-BI and CD11b was examined in non-stimulated and activated 
microglia and the specificity of these receptors for microglia was investigated in 
mixed glia culture and in vivo.  
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3.2 Materials and Methods 
3.2.1 Materials 
Bacterial lipopolysaccharide (LPS, strain O26:B6), Triton X-100, normal horse 
serum (NHSS), sucrose and salts to prepare Dulbecco’s phosphate buffered 
saline (DPBS) were purchased from Sigma (Australia). Paraformaldehyde (PFA) 
was from Merck (Australia). Hoechst nuclear stain dye (Hoechst 34580), DMEM 
cell culture medium (high glucose) and penicillin-streptomycin were obtained from 
Invitrogen (Australia). Fetal bovine serum (FBS) was from Bovogen (Australia). 
Fluorescence mounting medium was purchased from DAKO (Denmark). 
3.2.2 Antibodies 
Table 3-1 summarizes antibodies and reagents used for immunofluorescence 
studies. Tagged antibodies were prepared as described in Section 2.4. 
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Table 3-1: Antibodies and reagents used for immunofluorescence studies 
Target Antibody Tag Host Use c / DF Source 
CD11b OX42-IgG (M) - Mouse 
CD11b 
distribution and 
specificity in 
vitro 
1.25 
μg/mL 
RMIT 
CD11b OX42-IgG (M) Alexa488 Mouse 
Specificity in 
vivo 
2 μg/mL RMIT 
SR-BI α-SR-BI (M) - Mouse 
SR-BI 
distribution in 
vitro 
10 μg/mL RMIT 
Unknown X63 (M) Alexa488 Mouse 
Negative 
control antibody 
in vivo 
2 μg/mL RMIT 
Iba1 α-Iba1 (P) - Goat 
ICC 400 
Abcam 
IHC 100 
GFAP α-GFAP (P) - Rabbit 
ICC 1000 DAKO 
IHC 150 Invitrogen 
Mouse 
IgG 
α-mouse (P) Alexa488 Donkey ICC 400 Invitrogen 
Mouse 
IgG 
α-mouse (P) Biotin Horse ICC 400 Vector Labs 
Goat IgG α-goat (P) Biotin Horse ICC 400 Vector Labs 
Rabbit 
IgG 
α-rabbit (P) Alexa594 Donkey ICC/IHC 400 Invitrogen 
Biotin Extravidin Cy3 - ICC/IHC 600 Sigma 
M: monoclonal; P: polyclonal; c: concentration; DF: dilution factor; SR-BI: scavenger receptor B1; 
ICC: immunocytochemistry; IHC: immunohistochemistry; GFAP: glial fibrillary acidic protein; Iba1: 
ionized calcium binding adapter molecule 1. 
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3.2.3 Cellular Distribution and Specificity in Vitro 
SR-BI and CD11b receptor expression was assessed on either live or fixed (4% 
PFA, 10 minutes, room temperature, RT) isolated microglia (1 x 104 cells per 
coverslip) plated the day before the experiment. In order to test for receptor up-
regulation in stimulated microglia, cells were pre-treated with 1 μg/mL LPS diluted 
in complete cell culture medium (10% FBS) for up to 48 hours to allow protein 
synthesis to occur. Specificity of antibodies for microglia was investigated in mixed 
glia culture. Mixed cultures were fixed and then blocked for 30 minutes (10% 
NHSS, 0.1% Triton-X100). Astrocytes (glial fibrillary acidic protein, GFAP) and 
microglia (ionized calcium binding adapter molecule 1, Iba1) were immunostained 
in double-labelling experiments to assess specificity. 
Primary antibody binding was detected with either biotinylated or fluorescent-
labelled secondary antibodies. Extravidin-Cy3 conjugate was applied to visualize 
binding of biotinylated secondary antibody. All antibody incubations were 
performed for 1 hour at RT. Antibodies were diluted in either DPBS or 0.1% Triton-
X100 to permeabilize cells (10 minutes, RT). Cell nuclei were counter-stained with 
Hoechst-dye (1:500, 10 minutes, RT). Coverslips were mounted on microscope 
slides with fluorescence mounting medium and confocal images acquired (Section 
2.4.5). Control experiments were performed following the same immunostaining 
methods but omitting the primary antibodies and in the case of biotin-extravidin, 
omitting primary and a combination of primary plus secondary antibodies. Each 
condition was run on duplicate coverslips in each experiment and at least 2 
experiments were performed. Immunofluorescence was qualitatively assessed.  
3.2.4 CD11b Specificity in Vivo 
Male Sprague-Dawley rats (300-350 g) were used to assess the specificity of 
CD11b for microglial cells in vivo. Two hundred and fifty to 300 nL of Alexa 488-
labelled OX42 antibody or Alexa 488-labelled X63 negative control antibody 
diluted in sterile saline were stereotactically injected into the PVN (0.6 mm lateral 
from midline, 8.0 mm depth, -2.1 mm posterior from Bregma) under isoflurane 
anaesthesia. OX42 antibody was injected into the right side of the PVN and X63 
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into the left side of the same animal. Animal procedures followed the NHMRC 
guidelines and were approved by the RMIT University Ethics Committee. 
Animals were kept anaesthetized and perfused (4% PFA) 3 hours after 
injections before brains were collected and post-fixed for 4 hours. After 3-4 days of 
storage in 30% sucrose, 30 μm brain sections were cut on a cryostat. Sections 
were blocked in 10% NHSS containing 0.5% Triton-X100 (1 hour, RT). Cells that 
had taken up OX42 or X63 were examined by IHC to distinguish between 
microglia (Iba1) and astrocytes (GFAP). Primary antibodies α-Iba1 and α-GFAP 
were diluted in 2% NHSS and incubated for 3 days at 2-8ºC in a humidifying 
chamber. Secondary antibodies in 2% NHSS were incubated for 2 hours at RT 
followed by 1 hour incubation at RT with extravidin-Cy3 conjugate. Cell nuclei 
were labelled with Hoechst-dye (1:500, 25 minutes at RT) and sections mounted. 
Two animals were injected and localization of OX42 antibody was assessed 
qualitatively.
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3.3 Results 
3.3.1 Cellular Distribution of CD11b and SR-BI Receptor 
Immunostaining of live microglial cells revealed strong CD11b-IR on the cell 
membrane while staining for SR-BI was not different to control conditions at the 
confocal settings used (Figure 3-1 A). Control experiments confirmed specific 
staining of OX42 antibody. 
OX42 but not α-SR-BI antibody was localized on the cell membrane and 
intracellularly after incubating live microglia with primary antibodies and 
subsequent permeabilization (Figure 3-1 B). Cytosolic localization of OX42 
antibody indicated that some of the antibody was internalized after binding to 
membrane CD11b. The availability of CD11b in the membrane and continued 
binding of OX42 even after 1 hour incubation with primary antibody also suggested 
that some internalized CD11b receptor was recycled to the cell membrane.  
Confocal images showed that CD11b in fixed and permeabilized microglia 
existed in an intracellular pool and on the cell membrane (Figure 3-1 C). The α-
SR-BI antibody neither detected intracellular stores of SR-BI receptor nor SR-BI 
on the membrane in non-stimulated microglia in vitro.  
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Figure 3-1: Non-stimulated microglia in vitro express CD11b on the membrane and 
intracellularly, but do not bind α-SR-BI antibody.  
A: Live microglial cells show strong CD11b-IR (OX42, red) in the cell membrane while SR-BI-IR is 
not different to control conditions. B: OX42 antibody is localized on the membrane and 
intracellularly in non-fixed microglia, but SR-BI-IR is not increased compared to control. C: Fixed 
and permeabilized microglia show strong CD11b-IR but not SR-BI-IR on the membrane and 
intracellularly. Cell nuclei were stained with Hoechst-dye (blue). Confocal settings were higher for 
α-SR-BI antibody causing higher background fluorescence, but settings were constant between 
each antibody and its respective control. 
 
 
Chapter 3: Specificity of Integrin CD11b for Microglial Gene Transfer 
97 
 
 
A 
B 
 
Chapter 3: Specificity of Integrin CD11b for Microglial Gene Transfer 
99 
 
 
C 
  
 
 
Chapter 3: Specificity of Integrin CD11b for Microglial Gene Transfer 
101 
 
3.3.2 LPS-Stimulated Microglia Show No Increased SR-BI-
Immunoreactivity 
The absence of SR-BI-IR in non-stimulated microglia raised the question whether 
SR-BI receptor expression is up-regulated in stimulated microglia. However, SR-
BI-IR was not observed in activated microglia (Figure 3-2). In contrast, CD11b-IR 
was present on the membrane of LPS-stimulated microglia. Under these 
conditions, microglia acquired a round, phagocytic phenotype demonstrating 
activation of microglia with LPS. 
Thus, α-SR-BI antibody was excluded as a potential candidate for antibody-
mediated gene delivery. Microglia expressed CD11b under all conditions tested 
and OX42 antibody was therefore used in further studies to assess specificity of 
integrin receptor CD11b for microglia in vitro and in vivo. 
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Figure 3-2: Neonatal rat microglia do not up-regulate SR-BI receptor upon stimulation. 
A: Microglia display strong CD11b-IR (red) in the membrane while SR-BI-IR is similiar to control 
cells in LPS-stimulated microglia. B: Non-stimulated microglia exhibit processes (white arrow 
heads). Stimulated microglia acquire a round shape  with few or no processes, demonstrating 
activation of microglia with LPS. Confocal settings were different for each antibody, but consistent 
between primary antibody-labelled and control cells. 
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3.3.3 Integrin CD11b is Expressed in Microglia but Not in 
Astrocytes in Vitro 
CD11b-immunreactive cells in mixed culture stained positive for Iba1 protein 
(Figure 3-3 A) which is a selective marker for microglia [204,347]. However, cells 
that expressed GFAP protein were not positive for CD11b (Figure 3-3 B). This 
confirmed that CD11b expression is specific for microglia in vitro and that OX42 
antibody binds to microglial cells only. 
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Figure 3-3: CD11b receptor is specific for microglial cells in vitro. 
A: CD11b-positive cells (green) in mixed glia culture stain for the selective microglia marker Iba1 
(red). Many cell nuclei are negative for CD11b and Iba1 (white arrow heads). B: GFAP-positive 
cells (red) do not immunostain for CD11b (green).  
 
 
 
 
 
 
 
 
 
 
Chapter 3: Specificity of Integrin CD11b for Microglial Gene Transfer 
107 
 
 
A 
B 
 
Chapter 3: Specificity of Integrin CD11b for Microglial Gene Transfer 
109 
 
3.3.4 Microglia in Vivo Specifically Express Integrin CD11b 
When Alexa 488-tagged OX42 and X63 antibodies where injected into rat brain, 
the needle tracks displayed strong green fluorescence presumably originating from 
non-specific attachment of both antibodies to damaged cells (Figure 3-4 A). X63 
binding and fluorescence was confined to the needle track, but OX42-Alexa 488 
antibody also immunostained cells further away from the needle track. 
OX42-Alexa 488 at the injection site labelled cells and showed strong green 
fluorescence while no fluorescence was visible from X63-Alexa 488 binding 
(Figure 3-4 B). Antibody injections successfully targeted the PVN as revealed by 
the typical shape of this brain region and increased staining for cell nuclei in this 
area [386]. 
Immunohistochemistry for microglia and astrocytes showed that the injected 
OX42 antibody specifically bound to microglial cells. CD11b-positive cells also 
immunostained for Iba1 (Figure 3-5 A). However, CD11b-IR did not co-localize 
with GFAP-positive astrocytes (Figure 3-5 B). Thus, the in vivo data confirmed the 
specificity of CD11b for microglia, consistent with results obtained from 
immunofluorescence studies in cultured cells. 
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Figure 3-4: Injection of fluorescent tagged OX42 and X63 antibodies targets the PVN. 
A: Needle tracks of injected OX42-Alexa 488 and X63-Alexa 488 antibodies show strong green 
fluorescence presumably originating from non-specific attachment of antibodies to damaged cells. 
X63-fluorescence is confined around the needle track while some of the OX42 antibody is taken up 
by cells away from the needle track (white arrow heads). B: Binding of OX42 antibody but not X63 
results in strong green fluorescence at the injection site. Nuclei stained with Hoechst-dye (blue) 
display enhanced fluorescence within the PVN around the 3rd ventricle (3V). Confocal images 
represent maximum intensity projections (A, three sections) or single optical sections (B). Confocal 
settings for X63 and OX42 were the same. 
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Figure 3-5: CD11b receptor is specific for microglia in vivo. 
A: Immunohistochemistry of rat brains injected with OX42-Alexa 488 (green) demonstrate co-
labelling with microglial marker Iba1 (red). B: GFAP-IR (red) and CD11b-IR (green) do not co-
localizate demonstrating that astrocytes do not express CD11b or take up OX42 antibody. Confocal 
images are single optical sections. 
Chapter 3: Specificity of Integrin CD11b for Microglial Gene Transfer 
113 
 
 
A 
B 
  
Chapter 3: Specificity of Integrin CD11b for Microglial Gene Transfer 
115 
 
3.4 Discussion 
This study investigated the cellular distribution and specificity of SR-BI and CD11b 
receptor in microglia with monoclonal α-SR-BI and OX42 antibodies. Isolated 
microglia displayed strong CD11b-IR in non-stimulated and LPS-activated 
microglia. In contrast, SR-BI-IR was absent under all conditions tested suggesting 
that α-SR-BI antibody did not bind to microglia. Double-labelling experiments 
confirmed that OX42 antibody was specifically taken up by microglia in vitro and in 
vivo, thus making this antibody suitable for targeting microglial cells for gene 
transfer. 
3.4.1 Microglia Show CD11b-IR but not SR-BI-IR 
The first step in characterising and comparing both antibodies involved their 
potential to bind to extracellular domains of CD11b and SR-BI on the cell 
membrane of live microglia in vitro. Results obtained showed that OX42 is taken 
up by isolated microglia. The availability of CD11b in the membrane and binding of 
OX42 even after 1 hour incubation suggested that some internalized CD11b 
receptor was recycled to the cell membrane. 
In contrast, SR-BI staining was clearly absent despite higher antibody 
concentrations used. The absence of SR-BI-IR was unexpected. SR-BI-IR was 
neither found on the cell membrane nor intracellularly. The possibility that SR-BI 
receptor was degraded rapidly after internalization of α-SR-BI antibody in live 
microglial cells was excluded by investigating the cellular distribution of SR-BI 
receptor in microglia fixed prior to antibody application. However, there was no 
evidence that non-stimulated and fixed microglia show SR-BI-IR on the cell 
membrane or intracellularly. 
These data are in contrast to other studies that investigated SR-BI 
expression in a variety of cell types. Microglia and astrocytes from neonatal 
human, mice and rat brains express SR-BI protein in vitro [13,195,196]. SR-BI was 
present in homogenates of adult mouse, rat and human brain, but microglia did not 
express SR-BI [194,196]. Thus, the expression of SR-BI on microglia seems to be 
developmentally regulated. However, microglia undergo changes in gene 
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expression when activated and thus, SR-BI protein expression was investigated in 
LPS-stimulated microglia.  
3.4.2 SR-BI-IR is Absent from LPS-Activated Microglia 
Non-stimulated microglia in vitro do not represent truly quiescent cells in vivo 
[388], but microglia in vitro can be stimulated to become further activated. LPS is a 
stimulus commonly used to mimic bacterial infection and trigger an inflammatory 
response in microglia [363]. In this study, SR-BI-IR was not detected in stimulated 
microglia while CD11b-IR was present. Changes in microglial morphology upon 
LPS-treatment confirmed microglial activation. 
While there are many studies that describe the expression profile of integrin 
receptor CD11b in quiescent microglial cells in vivo and under inflammatory 
conditions such as AD [11], the regulation of SR-BI expression is less clear. The 
expression pattern of scavenger receptors changes in pathological conditions 
[507]. Scavenger receptor class A was reported to be up-regulated in brain 
microglia in AD. In addition, LPS was demonstrated to trigger up-regulation of the 
macrophage scavenger receptor (MSR, now termed SR-A, [34,88]). SR-BI protein 
expression was induced in glioma cells [119] and scavenger receptor mRNA 
expression was triggered in microglia with LPS in vitro and kainic acid or cytokines 
in vivo [166]. In contrast, the pro-inflammatory cytokines TNF-α and IFN-γ down-
regulated SR-BI expression in blood monocytes and monocyte-derived 
macrophages [194].  
3.4.3 Low Affinity of SR-BI Antibody May Limit its Use for Non-
Viral Gene Transfer 
Taken together, the literature suggests that neonatal microglia express SR-BI and 
expression can be either up-regulated or induced with microglial activators. 
However, this study demonstrated the absence of SR-BI-IR on microglial cells 
from neonatal rats. While it would have been useful to test the SR-BI antibody on 
positive control tissue in order to rule out any technical issues with the antibody, 
the low affinity of the α-SR-BI antibody could explain this discrepancy. The 
antibody was first used to detect SR-BI on sertoli cells in vitro at a concentration of 
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120 μg/mL [327]. This is about 12 times higher than the concentration used in this 
study. Even if this high concentration detected SR-BI protein in microglia, it would 
be far too high to be suitable for non-viral gene transfer into microglia. Thus, α-SR-
BI antibody was excluded as potential candidate antibody for this purpose.  
3.4.4 CD11b is Specific for Microglia and May be Useful for 
Microglial Gene Transfer 
Double-labelling experiments in mixed cultures were performed with OX42 
antibody and  markers for the two most abundant cell types in mixed glia culture – 
GFAP for astrocytes and Iba1 for microglia. The experiments clearly demonstrated 
the specificity of CD11b for microglia. This is consistent with previous reports [11] 
and accounts for the use of OX42 antibody as a selective microglial marker for 
immunocytochemistry and immunohistochemistry.  
The lack of SR-BI-IR in vitro and the absence of X63-binding in vivo strongly 
suggests receptor-mediated attachment of OX42 to microglia via the CD11b 
receptor. Microglia and other cells within the CNS express Fcγ-receptors 
[349,469,477] that can bind antibodies. Microglia and other cells also ingest 
extracellular material by pinocytosis [54,488]. The absence of these alternative 
internalization mechanisms is essential for specific gene transfer into microglia via 
CD11b.  
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3.5 Conclusion 
The α-SR-BI antibody used in this study is not suitable for antibody-mediated gene 
transfer into microglia. In contrast, OX42 antibody binds to the microglial cell 
membrane and the integrin receptor CD11b is specific for microglia. The results 
presented here confirm the selectivity of OX42 antibody for microglia and indicate 
that CD11b may be a suitable receptor for non-viral gene delivery into microglia. 
Antibodies can be injected into rat brain to target the PVN. Since microglia in 
the PVN are activated in an animal model of MI [386], this model can be used as 
an example to manipulate microglia by antibody-mediated gene delivery in order to 
investigate the role of microglia in cardiovascular complications associated with 
MI. 
However, the OX42 antibody will require further characterisation before it can 
be used for antibody-mediated gene transfer. Firstly, stimulation of internalization 
is an important prerequisite to deliver genes into the cell. Receptor-mediated 
internalization of OX42 will be investigated in more detail in Chapter 4. Secondly, 
activation of an inflammatory response in microglia with gene delivery vectors as 
observed for adenoviruses, for example, is unwanted [43,143,237,258]. Whether 
OX42 antibody can activate an immune response in microglia remains to be 
elucidated. Therefore, potential side-effects of OX42-mediated gene delivery will 
be addressed in Chapter 5. 
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4.1 Introduction 
The immune system represents an interrelated network of a variety of cell types 
that monitor their extracellular environment for danger signals, combat 
inflammation and initiate regeneration of damaged tissue via cell-cell and cell-
matrix interactions. Leukocytes (e.g. monocytes, neutrophils and macrophages) 
are among these immune cells that orchestrate the immune response in peripheral 
tissues. Microglial cells represent the corresponding first-line immune defence 
within the central nervous system (CNS). Among the many cell surface receptors 
expressed by microglia are integrin receptors which are known to be involved in 
the cellular response to inflammation. 
The internalization and trafficking of integrin receptors and their ligands is 
intimately linked to the generation of intracellular signals that control the 
inflammatory response. These receptors can initiate cell migration, proliferation 
and apoptosis and also modulate trafficking and signalling of other receptors, 
particularly those activated by growth factors [75,293,440]. While there is 
extensive evidence for these roles of integrins in peripheral immune cells, the 
properties of microglial integrin receptors have been inadequately studied. 
In order to initiate receptor internalization, trafficking and signalling, 
aggregation of integrin receptors has been identified as a crucial initial step in 
peripheral leukocytes in vitro [183,315,450]. Monoclonal antibodies were used to 
show that bivalent or multivalent ligands are required to initiate receptor 
aggregation and stimulate internalization of the receptor-ligand complex 
[139,186,213,424]. Monovalent ligands such as F(ab’) fragments of antibodies 
were not able to exert these effects. Bivalent immunoglobulin G (IgG) antibodies 
may therefore mimic the interaction of integrin receptors with extracellular matrix 
proteins or other agonists. However, temperature-induced integrin receptor 
clustering in the absence of clustering antibodies has also been observed 
[139,369]. Thus, temperature effects that may influence receptor distribution on 
the cell membrane and subsequent internalization need to be considered when 
working in vitro. 
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CD11b is an integrin receptor implicated in modulating the above mentioned 
cellular functions. Although antibody-mediated stimulation of CD11b has been 
reported to trigger receptor-mediated endocytosis in macrophages [24] and in cell 
lines [382] and also to modulate apoptosis in neutrophils [492], studies within the 
CNS have largely neglected a possible role of microglial CD11b in these 
mechanisms. Some evidence suggests that stimulation of CD11b with an α-CD11b 
antibody (OX42) results in nitric oxide production in microglia in vitro [161] and 
mitosis and apoptosis in microglia in vivo [390]. This indicates that OX42 antibody 
has some signalling properties in microglia, but the mechanisms that govern 
integrin-mediated signalling, i.e. receptor clustering, internalization and trafficking, 
have not been described. A thorough investigation of the interaction between the 
microglial CD11b receptor and its ligands is important, because there are more 
than 20 ligands known for CD11b on peripheral immune cells [450] and stimulation 
of different CD11b binding sites on these cells can elicit differential cellular 
responses [68,103,396]. 
The investigation of CD11b interaction with ligands such as OX42 is crucial 
to understand the role of CD11b in microglial function. However, internalization of 
OX42 via CD11b and trafficking is also important for the development of OX42 
antibody-based, non-viral gene vehicles for targeted gene transfer into microglia. 
While OX42 antibody was found to bind specifically to microglial cells (Chapter 3), 
the antibody must also stimulate internalization to deliver the payload into the cell. 
Endosomal trafficking of internalized OX42 is desired for non-viral gene transfer 
with polyethyleneimine (PEI) in order for PEI to exert its buffering effect in acidic 
endosomes which eventually leads to endosomal escape [10]. 
To establish that the OX42 antibody can be used as a targeting agent for 
microglia, the internalization mechanism of OX42 antibody needs to be 
established. This is because microglial cells are also capable of internalizing 
extracellular material via non-specific mechanisms such as pinocytosis [54] and 
this property is shared by other cells as well. Further, the presence of Fcγ-
receptors (FcγR) on microglial cells [364,381,468,477] requires examination of 
their potential involvement in uptake of the OX42 antibody, because other CNS 
cells express FcγRs [349] and stimulation of FcγR on microglia may initiate the 
respiratory burst and strong immune response observed in monocytes [155]. 
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Importantly, this observation is based on the ability of CD11b to interact with 
FcγRs in uptake of extracellular ligands [212,284,285]. 
Therefore, direct immunofluorescence studies and internalization assays 
were performed in order to investigate the role of CD11b in microglial function by 
examining the ability of OX42 antibody to induce receptor aggregation on the cell 
membrane, to trigger CD11b-mediated internalization in absence of other 
internalization mechanisms and to undergo lysosomal trafficking. The effect of 
temperature on the distribution of membrane CD11b was examined to rule out 
artifactual receptor internalization. This study also investigated whether the 
monoclonal antibody OX42 is useful for non-viral gene delivery into microglia by 
triggering receptor-mediated endocytosis. 
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4.2 Materials and Methods 
4.2.1 Materials 
Chemicals to prepare Krebs-HEPES-buffer (KHB), Dulbecco’s phosphate buffered 
saline (DPBS), fixing (4% paraformaldehyde, PFA) and permeabilization reagents 
(0.1% Triton-X100) were from Sigma (Australia). Cell Tracker Red, Hoechst 34580 
and Lysotracker Red were obtained from Invitrogen (Australia). Fluorescence 
mounting medium was from DAKO (Denmark) and poly-D-lysine (PDL)-coated 
fluorodishes from World Precision Instruments (USA). 
4.2.2 Antibodies 
Antibodies OX42 and X63 (negative control) were labelled with fluorophores (see 
Section 2.4). Trafficking studies were conducted with Alexa 488-tagged OX42 
(Table 4-1), because fluorescein isothiocyanate (FITC)-fluorescence is pH-
dependent. 
Table 4-1: Antibodies used to study CD11b distribution, internalization and trafficking. 
Target Antibody Fragment Tag Application Conc. / 
[mg/mL] 
CD11b OX42 IgG Fluorescein 
CD11b distribution 
2 μg/mL 
Internalization assay 
      
CD11b OX42 F(ab’)2 Fluorescein Internalization assay 2 μg/mL 
CD11b OX42 IgG Alexa 488 Trafficking 2 μg/mL 
Unknown X63 IgG Alexa 488 Internalization assay 2 μg/mL 
IgG: immunoglobulin G; F(ab’)2: bivalent antibody fragment containing both antigen binding sites, 
but lacking the Fc-part of the heavy chain that binds to Fcγ-receptors. 
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4.2.3 CD11b Distribution in the Cell Membrane 
Isolated microglia (2 x 104 cells) were incubated overnight and loaded with Cell 
Tracker Red (2 μM in KHB, 30 minutes at 37ºC). The effect of temperature on 
CD11b receptor distribution in the membrane was investigated by either cooling 
the cells from 37ºC with ice-cold KHB (shock-cooling) or incubating microglia with 
pre-warmed KHB on ice for 15 minutes (slow-cooling). Microglial cells were then 
fixed on ice (10 minutes). Control cells were fixed at 37ºC without cooling. 
Membrane CD11b was then visualized with OX42-IgG-FITC (1 hour at room 
temperature, RT), cells mounted and confocal images acquired. Two experiments 
were performed with each condition run on two coverslips in parallel and CD11b 
distribution was qualitatively assessed. 
Live cell imaging was performed on isolated microglia (5 x 104 cells per 
fluorodish) to investigate the mobility of CD11b in the membrane in the presence 
of antibody. Cells were loaded with Cell Tracker Red and incubated on ice for 30 
minutes with OX42-IgG-FITC to saturate membrane CD11b. Microglia were 
washed with ice-cold buffer and then imaged over 1 hour at 37ºC.  
4.2.4 Internalization Assay 
Isolated microglial cells were incubated with OX42-IgG-FITC at 37°C, fixed after 5, 
10, 20 and 60 minutes and nuclei stained with Hoechst-dye (1:500, 10 minutes). 
Control cells were incubated for 30 minutes on ice. Non-specific internalization of 
antibody was examined by incubating microglia with X63-Alexa 488 (60 minutes, 
37ºC). 
The effect of antibody diluent DPBS with sodium azide (40 μM NaN3 final 
concentration) on CD11b/OX42 internalization was examined, because OX42-IgG-
FITC storage buffer contained sodium azide as preservative. Microglial cells were 
incubated with and without sodium azide for 1 hour at 37º, fixed and permeabilized 
(10 minutes). Intracellular stores of CD11b were then detected with OX42-IgG-
FITC (30 minutes). Two coverslips were analysed in parallel per condition and 
results qualitatively assessed. 
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4.2.5 Involvement of FcγRs in CD11b Internalization 
Isolated microglia were loaded with Cell Tracker Red and incubated with either 
OX42-IgG-FITC or OX42-F(ab’)2-FITC (60 minutes, 37ºC). After incubation, cells 
were shock-cooled with ice-cold KHB, incubated on ice (5 minutes) and 
membrane-bound OX42 antibody stripped off with ice-cold DPBS (pH 2.0, 10 
minutes). Microglia were then fixed and cell nuclei stained. Three independent 
experiments were conducted with each condition run on two coverslips in parallel. 
At least 15 cells per coverslip were imaged. 
4.2.6 Intracellular Trafficking of OX42 Antibody 
Microglial cells on fluorodishes were incubated with OX42-IgG-Alexa 488 for 30 
minutes on ice to saturate membrane CD11b. Cells were washed to remove 
unbound antibody and internalized antibody chased for 60 minutes at 37ºC. Cell 
nuclei (Hoechst) and acidic vesicles (Lysotracker Red, 50 nM) were stained for 5 
minutes at 37ºC and cells imaged. Extracellular fluorescence was quenched with 
0.2% trypan blue before imaging. Two fluorodishes were evaluated and results 
assessed qualitatively. 
4.2.7 Quantification and Statistical Analysis 
Confocal images were aquired (Section 2.4.5) and antibody internalization 
quantified (ImageJ) as the increase in intracellular fluorescence. The quantified 
area was defined either by accumulated OX42 antibody in the perinuclear region 
or by Cell Tracker Red. One-way ANOVA and posthoc one-sample t-tests with 
Bonferroni correction (GraphPad) were used to assess significant internalization. 
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4.3 Results 
4.3.1 Low Temperature Induces CD11b Patching in the 
Membrane 
OX42-immunoreactivity (IR) showed that membrane CD11b was diffusely 
distributed on the cell membrane at 37ºC. At low temperatures when the rigid cell 
membrane restricts lateral movement of receptors, CD11b was organized in 
patches as demonstrated by punctuate fluorescence in non-permeabilized cells 
(Figure 4-1 A and B). The formation of puncta was independent of the cooling 
methodology applied (slow- vs. shock-cooling of cells). This suggested that these 
puncta formed very quickly. Punctuate CD11b-IR was predominantly found on the 
cell body away from the cell-substrate interface (Figure 4-1 C) while CD11b in the 
lamella region of the membrane was distributed evenly.  
4.3.2 Membrane CD11b is Mobile and Re-distributes in the 
Presence of OX42 Antibody 
In presence of OX42 antibody, membrane CD11b appeared concentrated in 
puncta at 0ºC similar to the pattern observed in the absence of antibody (Figure 
4-2). With increasing temperature, however, the distribution pattern of membrane 
CD11b did not change to the diffuse distribution observed before at 37ºC. Time-
lapse imaging showed that existing CD11b patches dissipated while new puncta 
formed (Figure 4-2, see also supplementary video). After 60 minutes, microglial 
cells had an increased appearance of green fluorescent vesicle-like puncta close 
to the perinuclear region. However, it was unclear whether this concentrated 
fluorescence represented CD11b puncta in the perinuclear membrane or 
internalized CD11b/OX42 in the perinuclear cytoplasm. 
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Figure 4-1: Low temperature induces rapid CD11b patching in the microglial cell membrane. 
A and B: Direct immunofluorescence for CD11b distribution in the membrane. Integrin CD11b in 
the cell membrane (OX42-FITC, green) is diffusely distributed (white arrowheads) in cells fixed at 
37ºC, but forms patches when cells are fixed at low temperatures as demonstrated by punctuate 
green fluorescence (yellow arrowheads). C: 3D confocal imaging shows that puncta predominantly 
form on the elevated part of the cell body (blue arrowheads) away from the substrate surface. The 
lamella region of the cell membrane (brown arrowheads) displays a mostly diffuse distribution of 
CD11b. Confocal settings (laser power and gain) were adjusted for each experimental condition 
due to higher fluorescence intensity of CD11b puncta. 
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Figure 4-2: Membrane CD11b receptor re-distribution in presence of OX42 antibody. 
Membrane CD11b appears in patches when incubated with OX42 antibody at low temperature. 
With increasing temperature, membrane CD11b diffuses within the cell membrane causing existing 
puncta to dissipate and new patches to form (white arrowheads). Time-lapse imaging shows an 
increased appearance of small vesicle-like puncta that move towards the center of the cell. 
Supplementary video sequence is available on DVD. 
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4.3.3 OX42 Antibody Triggers Receptor-Mediated Internalization 
in Microglia 
In order to ensure that OX42 internalization is not promoted by temperature-
induced receptor patching, internalization of OX42 was conducted at 37ºC without 
prior cooling and washing off unbound antibody. After 60 minutes incubation with 
OX42-IgG-FITC at 37ºC, strong vesicle-like fluorescence accumulated in the 
perinuclear region (Figure 4-3 A). 3D-confocal imaging confirmed that this 
fluorescence was mostly intracellular (Figure 4-3 B). Microglia incubated with 
OX42-IgG-FITC on ice exhibited CD11b-IR only in the cell membrane (Figure 4-3 
A).  
Internalization of OX42-IgG antibody was further investigated in a time-lapse 
experiment. After 5 minutes incubation some cells started to internalize OX42 
antibody while some only showed immunoreactivity for CD11b receptor in the 
membrane (Figure 4-3 C). OX42-IgG-FITC fluorescence in the perinuclear region 
increased significantly at later time-points (10 minutes: 163 ± 18 AU; 20 minutes: 
232 ± 26 AU; 60 minutes: 448 ± 50 AU; P < 0.0001, Figure 4-3 D) with an 
accumulation of OX42 antibody-containing vesicles close to the cell nucleus. Alexa 
488-tagged X63 antibody (negative control) did not bind or internalize into 
microglia after 60 minutes. 
Antibody diluents DPBS and DPBS with sodium azide had no effect on 
CD11b/OX42 internalization. Low concentrations of sodium azide did not inhibit 
cell metabolism and internalization but did not stimulate CD11b internalization 
either (Figure 4-3 E). Microglia treated with DPBS or DPBS/sodium azide did not 
exhibit characteristic punctuate fluorescence of internalized antibody. Instead, 
permeabilized microglia showed intracellular CD11b-IR scattered throughout the 
cytoplasm demonstrating the presence of intracellular CD11b stores.  
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Figure 4-3: OX42 antibody triggers receptor-mediated internalization in microglia. 
A: Microglial cells incubated on ice with OX42-IgG-FITC (green) immunostain for CD11b in the 
membrane only. Microglia incubated with OX42-IgG-FITC at 37ºC exhibit green fluorescent 
vesicles close to the cell nucleus (Hoechst-dye, blue). B: 3D-confocal imaging reveals that this 
punctuate fluorescence is intracellular. C: Time-lapse of CD11b receptor internalization. Microglia 
internalize OX42 antibody and show increase in perinuclear fluorescence over time. X63 negative 
control antibody does not bind and internalize in microglia (n = 15 cells). Confocal images shown 
are single optical sections. D: Quantification of OX42 internalization. The average green 
fluorescence was measured in the perinuclear region of each cell after background subtraction 
(Mean ± SEM of 3 experiments, n ≥ 77 cells per condition). E: Low concentrations of sodium azide 
neither inhibit nor trigger OX42 internalization. Microglia treated with diluents do not show the 
characteristic vesicle-like fluorescence in the perinuclear region seen in cells that internalize OX42. 
Instead, cytosolic pools of CD11b are detected that are scattered througout the cytoplasm. * P < 
0.0001 vs. control, N.S. not significant, AU: arbitrary units. 
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4.3.4 CD11b Internalization is Independent of FcγR Stimulation 
In order to rule out an involvement of FcγRs in antibody internalization, another 
internalization assay was performed comparing fluorescein-tagged OX42-IgG and 
OX42-(Fab’)2. OX42-IgG-FITC (Figure 4-4 A) and OX42-(Fab’)2-FITC (Figure 4-4 
B) triggered internalization of CD11b in microglia and vesicle-like green 
fluorescence was detected in the perinuclear region after 60 minutes. 
Quantification of internal fluorescence after membrane stripping revealed a 
significant increase (P < 0.0001) of intracellular green fluorescence per cell for 
OX42-IgG (4-fold) and for OX42-(Fab’)2 (2-fold, Figure 4-4 C). Stripping conditions 
were optimized in preliminary experiments (data not shown) to ensure that 
membrane-bound antibody was removed and only internalized antibody was 
quantified. The results of this internalization assay confirmed the previous data 
and showed that OX42 antibody undergoes receptor-mediated internalization via 
the CD11b receptor. 
4.3.5 Internalized OX42 Antibody is Trafficked to Acidic 
Organelles 
The intracellular fate of internalized OX42 antibody was investigated by co-
labelling with Lysotracker Red dye. OX42-IgG-Alexa 488 antibody accumulated in 
perinuclear vesicles after 60 minutes (Figure 4-5) as observed in previous 
internalization assays. Antibody-containing vesicles were essentially all positive for 
Lysotracker Red staining demonstrating that internalized OX42 antibody is 
trafficked to acidic organelles where it is likely to be degraded. Quenching the 
extracellular fluorescence further confirmed that OX42 accumulated intracellularly 
(Figure 4-5 B). However, CD11b-IR was also found concentrated in membrane 
ruffles in microglia where extracellular fluorescence was not quenched (Figure 4-5 
A). 
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Figure 4-4: OX42 antibody is internalized via CD11b. 
A and B: IgG and antibody fragments of OX42 trigger internalization of CD11b and accumulate in 
intracellular vesicles close to the cell nucleus. C: Quantification of internalized CD11b (Mean ± 
SEM, 3 experiments, n ≥ 90 cells per condition) shows a significant increase of intracellular 
fluorescence per cell  for OX42-IgG and OX42-F(ab‘)2 after 60 minutes over control. The intensity 
of intracellular green fluorescence due to OX42-F(ab‘)2-internalization is about half that observed 
after OX42-IgG internalization. This is likely due to differences in the degree of labelling for OX42-
IgG-FITC and OX42-F(ab‘)2-FITC (Section 2.4). *P < 0.0001 vs. control, AU: arbitrary units. 
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Figure 4-5: OX42 antibody accumulates in acidic vesicles in microglial cells. 
A: After 60 minutes incubation with OX42-IgG-FITC, microglial cells show membrane CD11b-IR 
and green vesicle-like staining close to the cell nucleus. Lysotracker-dye stains these intracellular 
vesicles demonstrating that the internalized OX42 antibody is trafficked to acidic organelles. 
CD11b-IR is also visible on the cell membrane and concentrated in membrane ruffles. B: 
Quenching the extracellular fluorescence confirms that the perinuclear vesicles containing OX42 
antibody are intracellular and again co-localize with Lysotracker Red. Confocal images represent 
single optical sections. 
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4.4 Discussion 
This study demonstrated that CD11b is internalized in microglia independent of 
stimulation of other receptors such as FcγRs. Membrane CD11b internalized upon 
ligation with OX42 antibody and the internalized antibody accumulated in vesicles. 
Direct immunofluorescence studies showed that the internalized antibody was 
trafficked to acidic organelles in the perinuclear cytoplasm. Thus, the microglial 
CD11b integrin receptor may trigger intracellular signals important for microglial 
function.  
4.4.1 OX42 Antibody Initiates Aggregation of CD11b Receptor 
Clustering of cell membrane receptors is an early event in cell signalling and 
aggregation of integrin receptors in the cell membrane is necessary in other cells 
to trigger intracellular signalling. This can lead to initiation of intracellular signalling 
cascades through tyrosine phosphorylation and accumulation of cytoskeletal 
proteins including talin and F-actin [315]. The appearance of punctuate CD11b-IR 
on the cell membrane in this study is similiar to other studies that showed receptor 
aggregation and cell signalling induced by bivalent ligands such as monoclonal 
antibodies [139,186,213,492]. Thus, CD11b receptor aggregation may also be 
important for signalling in microglia. 
CD11b aggregates on the microglial membrane were mobile and re-
distribution of membrane CD11b was observed at 37ºC. The lateral re-distribution 
of clustered integrin receptors has been shown before in cell lines [470] but is not 
yet reported in microglia. Punctuate CD11b receptor aggregates formed on the 
membrane and vesicles containing fluorescent labelled OX42 antibody emerged 
that moved towards the perinuclear region of the cell. Thus, clustering of microglial 
CD11b receptor was a first indication that OX42 can trigger receptor-mediated 
endocytosis in microglia and might initiate cell signalling. 
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4.4.2 OX42 Antibody Triggers Internalization of CD11b and does 
not Require FcγR-Stimulation 
The ability of OX42 antibody to trigger receptor-mediated internalization via CD11b 
was then demonstrated in two assays by quantifying the increase in intracellular 
fluorescence of fluorescein-labelled OX42 antibody and antibody fragments. There 
was no linear increase in intracellular fluorescence within the first 10 minutes of 
stimulation. Instead, the time-course of antibody internalization revealed a delay at 
the start and then a sigmoidal increase in perinuclear fluorescence. At later time-
points, the increase in intracellular fluorescence appeared to be linear. Taken 
together, these observations suggest that endocytosis of CD11b was stimulated 
by OX42 antibody. These data also imply that the OX42 antibody stimulated 
CD11b internalization rather than taking advantage of continuous CD11b 
internalization and recycling. 
In contrast, a study conducted by Bretscher [59] demonstrated that CD11b is 
internalized continously in thioglycollate-elicited mouse macrophages. However, 
thioglycollate as well as other macrophage/microglia stimulants (PMA, phorbol-12-
myristate-13-acetate and LPS, lipopolysaccharide) can activate macrophages and 
stimulate CD11b receptor clustering through ‘inside-out‘-signalling [360]. This 
leads to changes in the receptor affinity state from low (inactive integrin) to high 
(active integrin) accompanied by conformational changes in integrin structure 
(reviewed in [450]). In the current study, integrin activation by extracellular ligands 
(e.g. OX42) activates CD11b through ‘outside-in‘-signalling. This highlights that in 
microglia CD11b requires stimulation to be internalized and that CD11b like other 
integrins can signal bi-directionally across the cell membrane [197].  
Internalization of OX42-(Fab‘)2-antibody fragments that lack FcγR binding 
sites further showed that OX42 stimulates receptor-mediated internalization via 
CD11b binding and that CD11b internalization occured in the absence of FcγR 
stimulation. This is an important finding, because co-ligation of other cell surface 
receptors can change the outcome of cell signalling and stimulate immune 
functions such as production of ROS, for instance in monocytes [155]. 
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4.4.3 Receptor-Mediated Endocytosis may Occur via CD11b and 
FcγRs 
While there was significant internalization of OX42-IgG and OX42-F(ab‘)2 seen in 
microglia, the fluorescence levels of internalized OX42-IgG was about twice as 
high. This raises the question of whether some intact OX42-IgG antibody was also 
endocytosed via FcγRs. Further experiments could verify exclusive internalization 
of OX42 via CD11b by quantifiying OX42-IgG endocytosis while blocking FcγR-
binding sites.  
It is very likely, however, that overlabelling of OX42-F(ab‘)2 with fluorescein 
caused lower levels of OX42-F(ab‘)2 endocytosis. The molar fluorophore/protein-
ratio for OX42-F(ab‘)2-FITC was 13. Overlabelling of OX42-F(ab‘)2 may have 
interfered with antigen binding. Although direct immunofluorescence of microglial 
CD11b demonstrated successful binding to CD11b (Section 2.4), tagging of OX42-
F(ab‘)2 with fluorescein possibly interfered with one antigen binding site on some 
OX42-F(ab‘)2 fragments. This would not cause reduced fluorescence for qualitative 
detection of microglial CD11b. However, it may have reduced levels of 
internalization, because two intact binding sites on antibodies are required to 
aggregate receptors and trigger internalization [139,186,213,424]. 
4.4.4 Implications of Temperature-Induced Receptor Clustering 
for Receptor Internalization  
Control experiments aimed to investigate the effect of temperature changes on the 
distribution of membrane CD11b, because studies in other cells reported 
temperature-induced CD11b receptor clustering [139,369,449]. This could 
potentially interfere with aggregation-induced CD11b receptor internalization. In 
line with these studies, CD11b aggregates in the microglial cell membrane formed 
rapidly when the temperature was decreased and these clusters were found on 
the cell body away from cell-surface contact site.  
The mechanisms leading to temperature-dependent or ligand-stimulated 
receptor aggregation seem to be different based on the rate of cluster formation. 
Low temperature induced almost immediate CD11b clustering, while OX42-
mediated CD11b aggregation was delayed as observed in the internalization 
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assay. This artifactual temperature-dependent receptor clustering is most likely not 
related to cell signalling. However, low temperatures are often used in 
internalization assays to saturate cell membrane receptors [24,382,470]. In order 
to exclude an effect of temperature on aggregation-induced receptor 
internalization, assays should also be conducted at physiological temperature 
without temperature changes as carried out in the present study. Here, a 
temperature effect on internalization was excluded and it was demonstrated that 
CD11b internalization was triggered by stimulation with OX42 antibody. 
4.4.5 Microglia Traffic OX42 Antibody to Lysosomes 
The fate of internalized OX42 antibody was then examined in trafficking studies. 
Internalized OX42 antibody was trafficked to acidic organelles as shown by co-
labelling with Lysotracker Red dye. Lysotracker Red accumulates in acidic 
organelles and is commonly used as a marker of lysosomes. Although endosomes 
acidify gradually with maturation and Lysotracker may therefore accumulate in 
other endosomal vesicles as well, the known perinuclear localization of lysosomes 
and late endosomes [193] agreed with the localization of OX42-fluorescence seen 
here confirming lysosomal trafficking of OX42 antibody in microglia. 
4.4.6 Trafficking Pathways for Microglial CD11b Receptor  
While internalized OX42 antibody was trafficked to lysosomes, internalized CD11b 
receptor did not necessarily co-traffick with its ligand. The sorting of internalized 
cell surface receptors and their ligands occurs at the early endosome. The lower 
pH of early endosomes facilitates the dissociation of the receptor-ligand complex 
and this can lead to the trafficking of ligands to lysosomes for degradation while 
the receptor is recycled, for example [292]. Appropriate control of intracellular 
sorting events is crucial, because they regulate cell migration via integrin-matrix 
interactions [394], maintenance of cell membrane composition [165] and down-
regulation of cellular responses to integrin ligands [292]. 
In the present study, CD11b-IR was detected in the membrane after 1 hour 
incubation with OX42-IgG-Alexa 488 and internalization of antibody (Figure 4-5 A). 
Unbound antibody was washed away before internalization was started, thus, this 
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suggests that some of internalized CD11b/OX42 receptor-antibody complexes 
were co-trafficked and re-expressed on the cell surface. This agrees with studies 
conducted in macrophages and neutrophils where CD11b receptor recycled to the 
cell surface after internalization [59,77,131].  
It is interesting to note that the recycling pathway of integrins can be 
influenced by their active or inactive conformation which defines the receptor 
affinity state. Recycling of integrins can occur at early endosomes within a few 
minutes (short-loop) or via the endocytic recycling compartment (long loop) which 
causes a delay in the re-appearance of internalized integrin on the cell membrane 
[74,165]. In cancer cells, integrin β1 in its inactive form was rapidly recycled (short-
loop) and its active form was recycled through the endocytic recycling 
compartment which resulted in different recycling kinetics [22]. A role of microglial 
CD11b receptor affinity in intracellular trafficking has not been established yet, but 
could form a basis to study why some CD11b-IR was visible in the microglial 
membrane after 1 hour. Further research in this area may have major implications 
for our understanding of the regulation of immune functions in the CNS and the 
role of CD11b in microglial function. 
4.4.7 Microglia are Activated via CD11b ‘Outside-In’-Signalling 
Further evidence suggested that CD11b can mediate microglial activation. Besides 
inducing receptor aggregation, internalization and intracellular trafficking, 
microglial cells treated with OX42 antibody spread out and exhibited membrane 
ruffles as shown by concentrated CD11b-IR. Cell spreading and membrane ruffle 
formation are characteristic of activated microglia in vitro [184,222,347]. 
Activation of integrins usually signals cell spreading [286] which requires the 
reorganization of the actin cytoskeleton. Rac is a Rho GTPase involved in actin 
cytoskeleton reorganization among other functions (reviewed in [206]) and is 
activated when microglia form membrane ruffles [347]. A general feature of 
internalized CD11b receptor appears to be CD11b recycling and concentration of 
CD11b in membrane ruffles [60]. The present study supports this notion, because 
internalized CD11b was re-expressed on the cell surface in microglia as observed 
by concentrated CD11b-IR. 
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The physiological significance of CD11b trafficking to membrane ruffles in 
microglia is yet to be elucidated. However, membrane ruffling and the 
concentration of the activated CD11b receptor in membrane ruffles has been 
reported to be important for uptake of complement-coated particles via CD11b in 
activated macrophages [265,360]. Macrophages in these experiments were 
primed with PMA and LPS via an inside-out signalling mechanism and this caused 
CD11b internalization and trafficking. In relation to the present study conducted in 
microglia this indicates that OX42 antibody primed microglia via ligation of CD11b 
(outside-in) which then caused internalization and trafficking of CD11b in microglia 
to membrane ruffles and that some OX42 antibody was co-trafficked with CD11b.  
Since CD11b acts as a phagocytic receptor within the CNS [154] similar to 
macrophages in the periphery, a detailed understanding of CD11b internalization 
and trafficking pathways will shed light on the mechanisms of phagocytosis which 
is not only part of the immuno-surveillant function of microglial cells but also 
important for normal CNS function in synaptic plasticity and learning [47,463]. It 
may further provide insight into the progression of chronic diseases where 
phagocytic functions of CD11b play a crucial role, for instance multiple sclerosis 
[170,385,399]. 
4.4.8 Implications of OX42 Internalization and Trafficking for 
Non-Viral Gene Transfer 
This study has not only identified a role of CD11b in microglial activation, it also 
extended the characterisation of CD11b as target and OX42 as targeting antibody 
for non-viral gene transfer into microglia.  
The results from direct immunofluorescence studies and internalization 
assays clearly demonstrated the ability of OX42 antibody to trigger receptor-
mediated internalization via CD11b. This is crucial, because microglia like other 
mammalian cells are able to ingest extracellular fluid non-specifically in a process 
called pinocytosis [54,488] and this may affect specificity of antibody-mediated 
gene delivery into microglia. Control experiments with X63-IgG antibody confirmed 
that microglia undergo receptor-mediated internalization of OX42 antibody. 
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Microglia did not take up X63 antibody and hence no intracelluar fluorescence was 
detected. 
Lysosomal trafficking of internalized OX42 further reinforced the potential use 
of this antibody for gene transfer. Lysosomal trafficking is desirable for non-viral 
vehicles that utilize polyethylene-imine (PEI) as DNA condensation agent (Chapter 
6), because the gradual acidification of endosomes facilitates the endosomal 
escape of the gene vehicle (reviewed in [475]). The proximity of lysosomes to the 
cell nucleus also improves transfection efficiency by reducing the spatial distance 
from endosome exit to nucleus entry [150]. Taken together, CD11b may be an 
useful entry point for OX42-mediated gene transfer into microglial cells.  
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4.5 Conclusion 
The microglial CD11b integrin receptor plays a role in stimulating microglial 
functions elicited by soluble ligands such as monoclonal antibodies. The specific 
interaction of OX42 antibody with CD11b displays features characteristic for 
initiating intracellular signalling via integrin receptors, i.e. ligand-mediated receptor 
clustering, receptor-mediated internalization and intracellular trafficking.  
This study demonstrates that OX42 antibody is a valuable tool to investigate 
microglial function. Although OX42 activates microglia causing cell spreading and 
membrane ruffle formation, further studies need to define the consequences of 
OX42-stimulated microglial activation downstream of receptor activation. 
OX42 is suitable for antibody-mediated non-viral gene transfer into microglia. 
However, the integrin CD11b receptor is involved in the immune response of 
microglia and linked to activation of the respiratory burst [363] which may be 
undesirable. Whether OX42 antibody can activate an immune response through 
CD11b signalling and microglial activation remains to be investigated. 
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5.1 Introduction 
Microglia are the principal immune cells of the central nervous system (CNS) and 
as such are crucial for maintaining integrity of the neuronal network. In 
pathological situations microglia undergo changes in morphology and gene 
expression commonly referred to as microglial activation (reviewed in [222]). 
Activated microglia initiate and resolve inflammation, however, multiple activation 
states exist and activated microglia have been associated with facilitating disease 
progression and neuronal cell death [366]. Although the exact mechanisms of 
microglial activation are yet to be determined, a tightly controlled immune 
response is crucial to avoid neurotoxicity. Excessive microglia-mediated 
production of reactive oxygen species (ROS) is known to facilitate 
neurodegeneration [50] and thus, mechanisms that govern microglial activation 
and ROS production need to be defined.    
Microglial cells express various membrane receptors that mediate cellular 
activation during neuroinflammation. For example, microglia express purinergic 
P2X4, P2X7 and P2Y12 receptors that are crucial for modulating neuropathic pain 
states in vivo [207,236,460,465]. Adenosine-triphosphate (ATP) acts on purinergic 
receptors and increased concentrations of ATP, eg. released from damaged cells 
[94,434], can trigger an increase in intracellular calcium and microglial activation 
[200,316]. Further, low micromolar concentrations of ATP stimulate macropore 
formation via P2X4 stimulation [38].  
Microglial activation proceeds in gradual steps from partially activated cells to 
fully immunocompetent cells that display cytotoxic effector functions to fight 
pathogens [174]. Activated microglial cells express a variety of pattern recognition 
receptors (PRRs) that are involved in mediating the inflammatory response, for 
instance stimulation of the respiratory burst by phagocytosis [494]. Complement 
receptor 3 (CR3) is a PRR that has been subject to intensive study particularly in 
macrophages, monocytes and neutrophils which are peripheral immune cells with 
functions related to CNS microglia. CR3 consists of the two subunits CD11b and 
CD18 that form a non-covalent dimer and has multiple roles in cell-cell and cell-
matrix interactions, cell signalling and activation of immune effector functions 
(reviewed in [126]). 
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The respiratory burst is characteristic of a strong immune response and is 
accompanied by degranulation/exocytosis of intracellular granules and 
translocation of intracellular CD11b stores to the membrane in peripheral immune 
cells [55,459]. Microglia express CR3 receptor and its activation and excessive 
production of ROS has been associated with neurotoxicity in vitro and in vivo 
[50,188,363,525].  However, studies on tissue macrophages have determined that 
the ability of CR3 to mediate phagocytosis-induced cytotoxic ROS production 
depends on stimulation of the lectin-binding site of CR3 by cross-linking the 
receptor [455,508] and/or co-ligation with Fcγ-receptors (FcγRs) [189,527]. The 
consequences of cross-linking individual CR3-binding sites, i.e. respiratory burst 
and CR3 exocytosis, have yet to be described in detail for microglial cells despite 
the fact that the microglial CR3 receptor is known to be important for phagocytosis 
and removal of fibrillar β-amyloid peptide [86,154] and α-synuclein aggregates 
[525]. 
Particulate material (e.g. bacteria) or complement-coated immune complexes 
can be taken up by immune cells in events termed non-opsonic or opsonic 
phagocytosis, respectively [253,254,524]. Complement is part of the innate 
immune defence that facilitates clearance of foreign material. The complement 
system represents an array of proteins that bind to target particles in a process 
known as opsonisation and direct complement-coated particles to complement 
receptors such as CR3. Although the intact blood-brain-barrier restricts influx of 
complement factors from the periphery, the CNS expresses a fully operational 
complement system and complement factors can be locally produced by neurons 
and glial cells [478,482]. Increased complement levels are detected under 
pathological situations [500]. Opsonisation with certain proteins of the complement 
system (inactivated complement 3b fragment, iC3b) directs iC3b-coated particles 
to receptors with high affinity for iC3b including CR3 [126]. 
Complement receptor 3 is specific for microglial cells in the CNS (Chapter 2) 
and functions that are elicited by iC3b-CR3 interaction may therefore be specific 
for the microglial immune response. The need for a detailed understanding of the 
downstream effects of CR3-mediated phagocytosis in microglia is emphasized by 
the fact that dysregulation of complement activation has been linked to a wide 
variety of neurodegenarative diseases [98,392,472]. Interaction of microglial CR3 
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with iC3b complement has been suggested to be a factor for microglial priming in 
multiple sclerosis (MS) and linked to the release of pro-inflammatory mediators 
that exacerbate disease progression [385].  
This study therefore investigated the role of the microglial CR3 receptor in 
microglial activation utilizing the monoclonal α-CD11b antibody OX42. This 
antibody is suggested to bind, or close to, the iC3b-binding site [234,393,430] thus 
mimicking iC3b-CR3 interaction. The relationship of phagocytosis and activation of 
cytotoxic effector functions based on stimulation of different CR3 binding sites and 
FcγRs was also examined. Oxidative stress due to persistent activation of 
microglia facilitates neurodegeneration for example in Alzheimer’s (AD) and 
Parkinson’s disease (PD, [91,526]) and the underlying mechanism(s) involve 
complement- and FcγR-mediated phagocytosis in microglia [98,220,239]. 
Delineating the role of the microglial CR3 in phagocytosis-induced ROS production 
and exocytosis will therefore shed light on conditions under which CR3 can 
contribute to cytotoxicity and will also determine whether CR3 could serve as an 
entry point for antibody-mediated gene delivery in absence of an immune 
response. 
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5.2 Materials and Methods 
5.2.1 Materials 
Adenosine-triphospate (ATP), zymosan A (average particle diameter: 3 μm) and 
chemicals to prepare Krebs-HEPES-buffer (KHB), Dulbecco’s phosphate buffered 
saline (DPBS), fixing reagent (4% paraformaldehyde, PFA) and permeabilization 
solution (0.1% Triton-X100 in DPBS) were purchased from Sigma (Australia). Yo-
Pro®-1 Iodide, ROS-indicator CM-H2DCFDA (5-(and-6)-chloromethyl-2',7'-dichloro-
dihydro-fluorescein diacetate, acetyl ester), protein G-coated Dynabeads (2.8 μm 
diameter), Cell Tracker Red and Hoechst 34580 were obtained from Invitrogen 
(Australia). Phorbol 12,13-dibutyrate (PDBu) was purchased from Enzo Life 
Sciences (Switzerland). Fluorescence mounting medium was from DAKO 
(Denmark) and poly-D-lysine (PDL)-coated fluorodishes from World Precision 
Instruments (USA). 
5.2.2 Antibodies 
Intact OX42-IgG antibody was used as a soluble ligand to stimulate microglial 
activation via CD11b/CR3 (see also Chapter 4). Immunglobulin G (IgG)- and 
F(ab‘)2-fragments of OX42 antibody bound to protein G-coated beads were used 
to promote receptor cross-linking and phagocytosis (Table 5-1). OX42-F(ab‘)2-
antibody fragments were prepared as described in Section 2.3. OX42-F(ab‘)2-
fragments bound to the beads, because OX42 antibody was previously found to 
exhibit protein G-binding sites within both the Fc- and F(ab‘)2-part of the antibody 
(Section 2.3.3). 
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Table 5-1: Summary of antibodies and antibody fragments used. 
Target Antibody Fragment Application Concentration 
CD11b OX42 IgG 
Yo-Pro Assay 10 μg/mL 
Bead Coating 440 μg/mL 
     
CD11b/FcγR OX42 IgG (beads) 
Phagocytosis 
30 μg/mL (beads) 
ROS Assay 
     
CD11b OX42 F(ab’)2 Bead Coating 690 μg/mL 
     
CD11b OX42 F(ab’)2 (beads) 
Phagocytosis 
30 μg/mL (beads) 
ROS Assay 
IgG: immunoglobulin G; F(ab’)2: bivalent antibody fragment containing both antigen binding sites, 
but lacking the Fc-part of the heavy chain that binds to Fcγ-receptors; FcγR: Fcγ-receptor;  ROS: 
reactive oxygen species. 
5.2.3 Macropore Formation in Microglia 
Isolated microglia were plated on fluorodishes (5 x 104 cells/dish) and incubated 
overnight before the experiment. Cells were loaded with Cell Tracker Red (2 M in 
KHB, 30 minutes at 37ºC) and then incubated with 1 M Yo-Pro-1 dye for 30 
minutes (37ºC) before imaging. Only microglial cells that were initially 
impermeable to Yo-Pro-1 were selected for analysis. Images were recorded every 
100 seconds for 30 minutes by confocal microscopy (Section 2.4.5). Three 
individual experiments were performed. 
5.2.4 Coating of Protein G-Beads with Antibodies 
Three milligram of protein G-coated dynabeads (‘protein G beads‘) were washed 
with DPBS using magnetic separation of the beads from the solution. Beads were 
resuspended in an excess of either OX42-IgG antibody (OX42-IgG-beads) or 
OX42-F(ab‘)2-fragments (OX42-F(ab‘)2-beads) and incubated for 10 minutes at 
room temperature (RT) on a shaker. Antibody-coated beads were separated from 
supernatant and resuspended in DPBS (30 mg beads/mL). Control beads were 
prepared the same way without antibodies. 
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The amount of protein bound by the beads was calculated by determining the 
protein concentrations (A280 = 1.35 for 1 mg/mL IgG) in the supernatant before and 
after binding to the beads. Protein G-beads bound 10 μg OX42-IgG and 16 μg 
OX42-(Fab‘)2 per mg beads.  
5.2.5 Phagocytosis of Antibody-Coated Beads and Live Cell 
Imaging 
Microglial cells plated on fluorodishes (5 x 104 cells/dish) were loaded with Cell 
Tracker Red. Antibody-coated and control beads were then added to the dish and 
imaged by confocal microscopy over 1 hour at 37ºC taking 1 image every 2 
minutes. The ability of microglia to internalize beads was qualitatively assessed. 
5.2.6 Phagocytosis-Induced Reactive Oxygen Species 
Production 
The production of ROS was measured as described previously (Section 2.5.2). 
Briefly, CM-H2DCFDA-loaded microglia (1 x 104 cells per well) were stimulated to 
produce ROS at 37ºC and fluorescence was read on a plate reader (FlexStation 3) 
after 60 minutes. Each condition was measured in quadruplicate wells and at least 
5 individual assays were performed. Baseline fluorescence (KHB only) was 
subtracted from fluorescence values and results expressed as the percentage of 
the PDBu response (100 ng/mL).  
5.2.7 Exocytosis of Intracellular CD11b 
Exocytosis and translocation of internal CD11b stores was detected by direct 
immunofluorescence as described in Section 2.5.3. Briefly, isolated microglial cells 
(2 x 104 cells per coverslip) were treated for 15 minutes with various stimuli and 
exocytosis stopped by cooling the cells on ice. Membrane CD11b was detected 
with OX42-IgG-FITC after cell fixation. Internal CD11b was then detected with 
OX42-IgG-Atto 594 after permeabilization of microglia. 
Three experiments were performed (2 coverslips per condition per 
experiment). At least 15 cells per coverslip were evaluated for translocation of 
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internal CD11b (ImageJ). Results were expressed as the percentage of 
intracellular CD11b per cell that had not translocated to the cell membrane. 
Internal CD11b-immunoreactivity (IR) in non-stimulated microglia was interpreted 
as 100% internal CD11b.  
5.2.8 Statistics 
Results were expressed as Mean ± SEM and statistical analysis was performed in 
GraphPad Prism 6. Macropore formation was assessed using two-way ANOVA 
with Holms-Sidak’s multiple comparisons posthoc test. Significant ROS production 
and CD11b exocytosis were determined with one-way ANOVAs with posthoc one-
sample t-tests with Bonferroni correction and posthoc t-tests with Bonferroni 
correction, respectively. 
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5.3 Results 
5.3.1 CD11b and P2X4 Receptor Agonists Activate Microglia by 
Inducing Macropore Formation 
The ability of microglial integrin receptor CD11b to signal microglial activation was 
first examined with the soluble ligand OX42 antibody. Stimulation of purinergic 
receptors on microglia with ATP was used as control. After excluding pre-activated 
microglia for analysis, microglial cells activated with 50-100 μM ATP demonstrated 
macropore formation and increase in Yo-Pro-1 fluorescence (Figure 5-1 A). The 
average fluorescence intensity per cell increased continuously over time and was 
significantly higher than control levels (P < 0.05 after 900 seconds, Figure 5-1 B). 
The fluorescence intensity for 100 μM ATP compared to 50 μM ATP was 
significantly different from 1200 seconds onwards (P < 0.05). After 30 minutes, 
100 μM ATP caused a two-fold increase in Yo-Pro-1 fluorescence compared to 50 
μM ATP (2336 ± 175 AU vs. 1152 ± 242 AU) which correlated with the percentage 
of activated microglia (88% for 100 μM ATP, 50% for 50 μM ATP, Figure 5-1 C). 
This confirmed that macropore formation in microglia at micromolar concentrations 
of ATP is dose-dependently.  
OX42 antibody induced macropore formation in microglial cells as well. There 
was a strong increase in Yo-Pro-1 fluorescence after 30 minutes incubation with 
OX42 (Figure 5-1 A). The average fluorescence intensity per cell increased 
continuously over time and became significant compared to control after 900 
seconds (P < 0.05, Figure 5-1 B). Microglia exposed to OX42 showed macropore 
formation in 66% of cells (Figure 5-1 C) demonstrating that CD11b can mediate 
microglial activation by receptor stimulation. 
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Figure 5-1: Activation of microglia by purinergic and CD11b receptor ligation induces 
macropore formation in microglia.  
A: Confocal images showing increase of Yo-Pro-1 fluorescence (green) over 30 minutes in 
presence of either 50 - 100 μM ATP or OX42-IgG antibody. Stimulation of microglia with ATP or 
CD11b agonist OX42 antibody causes macropore formation and microglial activation. B: Average 
fluorescence intensity of Yo-Pro-1 uptake in microglia after application of 50 μM ATP, 100 μM ATP 
and OX42 antibody. The formation of macropores is rapid and increases over 30 minutes. The 
increase in Yo-Pro-1 fluorescence appears to be concentration-dependent for micromolar 
concentrations of ATP. C: Percentage of activated microglia after 30 minutes in single optical fields 
which show Yo-Pro-1 uptake. ATP and OX42 antibody both induce macropore formation in ≥ 50% 
microglia. Pre-activated microglia were excluded from analysis. n = 23 for control, n = 56 for 50 μM 
ATP, n = 52 for 100 μM ATP, n = 35 for OX42. * Significant difference (P < 0.05) in average 
fluorescence intensity per cell to control from 900 seconds onwards after ATP- or OX42-
application. # Significant difference (P < 0.05) in average fluorescence intensity per cell of 100 μM 
ATP compared to 50 μM ATP from 1200 seconds onwards. AU: arbitrary units. Experiments were 
performed by J. Watson (RMIT University). 
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5.3.2 Microglia Phagocytose via CR3 without FcγR Stimulation 
Stimulation of CD11b with the soluble ligand OX42 antibody caused activation of 
microglia. However, CR3 is also known to ingest particulate material by 
phagocytosis, but phagocytosis via CR3 has been reported to depend on co-
stimulation of FcγRs [189].  
After 1 hour incubation, microglia accumulated OX42-IgG-beads that exhibit 
binding sites for CR3 and FcγR. The same was observed for OX42-F(ab‘)2-beads 
that exhibit binding sites for CR3 only. In contrast, uncoated control beads were 
mostly scattered within the well and only a few were associated with microglia. 
This suggested that microglia can at least bind antibody-coated beads via CR3. 
Phagocytosis of antibody-coated beads after binding to microglia was 
demonstrated by live cell imaging over 1 hour. Microglial processes coalesced as 
cells flattened and became larger upon stimulation with antibody-coated beads 
(Figure 5-2 B and C, see also supplementary video). Microglial cells also acquired 
a round shape which is characteristic of the initial stages of activation in microglia 
in vitro [222].  
The number of intracellular vesicles that contained beads and were devoid of 
Cell Tracker dye increased over time, strongly suggesting phagocytosis of OX42-
F(ab‘)2-beads (Figure 5-2 B) and OX42-IgG-beads (Figure 5-2 C). Some cells 
moved towards the antibody-coated beads clearing the extracellular environment 
of particles. Interestingly, phagocytosis of OX42-IgG-beads and OX42-F(ab‘)2-
beads appeared to involve different internalization mechanisms (Figure 5-2 B and 
C, see also supplementary video). OX42-F(ab‘)2-beads sank into the cell while 
OX42-IgG-beads seemed to stimulate pseudopod formation. 
These results showed that CR3 is capable of phagocytosis in the absence of 
FcγR-stimulation in microglia when CR3-receptors are cross-linked on the cell 
surface by an anti-CR3 antibody. However, whether CR3 is able to trigger the 
respiratory burst upon phagocytosis remained to be investigated. 
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Figure 5-2: Microglial CR3 receptor is capable of phagocytosis in absence of FcγR 
stimulation. 
A: Microglia bind and internalize antibody-coated beads but not uncoated control beads. Beads 
concentrate around microglial cells after 60 minutes incubation while control beads are mostly 
scattered throughout the well. B: OX42-F(ab‘)2-beads stimulate phagocytosis via CR3 and 
microglia accumulate them intracellular. The co-localization of beads with vesicles that lack Cell 
Tracker Red staining strongly suggests uptake of OX42-F(ab‘)2-beads into the cell (white arrows). 
Microglia become activated upon application of OX42-F(ab‘)2-beads. Activated microglia flatten and 
aquire a typical round shape with less processes (yellow arrows). OX42-F(ab‘)2-beads seem to sink 
into the cell during phagocytosis (green arrows). C: OX42-IgG-beads stimulate phagocytosis via 
FcγR and/or FcγR-CR3 interaction. Microglia accumulate OX42-IgG-coated beads intracellular 
(white arrows). Phagocytosis is accompanied by microglial activation demonstrated by changes in 
microglial morphology (yellow arrows). Phagocytosis of OX42-IgG-beads seems to involve a 
different internalization mechanism compared to OX42-F(ab‘)2-beads. Phagocytosis of OX42-IgG-
beads involves pseudopod formation (green arrows). Supplementary video sequences are 
available on DVD. 
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5.3.3 Phagocytosis-Induced Respiratory Burst via CR3 Depends 
on CD11b Binding Site 
Phagocytosis of OX42-F(ab‘)2-beads caused only a small increase in DCF-
fluorescence (7.61% ± 2.07%, P < 0.05) compared to baseline demonstrating 
absence of the respiratory burst (Figure 5-3). In contrast, cross-linking microglial 
PRRs with OX42-IgG-beads caused a 7-fold higher DCF-fluorescence (53.52% ± 
3.77%, P < 0.0001) and the respiratory burst in microglia. Both solube agonists, 
OX42-IgG antibody (2.57% ± 1.68%) and 50 μM ATP (-3.14% ± 4.16%) did not 
stimulate the respiratory burst demonstrating that receptor cross-linking with 
particular material is required to trigger strong ROS production. Uncoated protein 
G-beads (-2.99% ± 0.75%, P < 0.05) did not stimulate significant ROS production 
either confirming that phagocytosis-induced ROS production was a receptor-
mediated event (Figure 5-3 B). 
Particulate zymosan, a polysaccharide known to stimulate the respiratory 
burst in immune cells through interaction with the lectin-binding site within the 
CD11b-subunit of CR3 [254,396,397], triggered a robust increase in ROS levels 
(45.77% ± 4.70%, P < 0.01,Figure 5-3) demonstrating that the microglial CR3 is 
able to activate the respiratory burst. These data showed that the microglial CR3 
receptor is able to internalize particles via phagocytosis, but this does not 
necessarily activate the respiratory burst. 
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Figure 5-3: Phagocytosis-induced ROS production depends on CD11b binding site. 
A: Confocal images demonstrating differences in DCF-fluorescence after 60 minutes treatment 
with receptor-specific agonists. B: Quantification of DCF-fluorescence after 60 minutes as an 
indicator of ROS production in microglial cells. Activation of microglia with soluble CD11b- and 
P2X4- agonists OX42-IgG and 50 μM ATP does not cause ROS production. Uncoated beads 
reduce ROS levels slightly but significantly. Cross-linking of CR3 alone with OX42-F(ab‘)2-beads 
produces a small but significant increase in ROS. Stimulation of microglia with OX42-IgG-beads 
and zymosan triggers the respiratory burst and significantly increases ROS levels to about 6-7 
times higher than stimulation with OX42-F(ab‘)2-beads. Results are expressed as% of internal 
standard PDBu after baseline subtraction. Values are plotted as Mean ± SEM. * P < 0.05 vs. 
control; ** P < 0.01 vs. control; *** P < 0.0001 vs. control; N.S.: not significant. 
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5.3.4 Cross-linking of Microglial CR3 can Trigger Exocytosis of 
Intracellular CD11b 
Peripheral immune cells undergo degranulation/exocytosis of intracellular CD11b 
stores upon activation of the respiratory burst [102]. Whether microglia exhibit 
intracellular CD11b stores and whether these can be depleted upon appropriate 
stimulation was examined here. 
Direct immunofluorescence with labelled OX42-antibodies demonstrated that 
microglia express CD11b on the cell membrane and intracellularly (Figure 5-4 A). 
Intracellular CD11b was concentrated within vesicles scattered throughout the 
cytoplasm. However, stimulation of microglia with 50 μM ATP did not cause 
depletion of intracellular CD11b stores (Figure 5-4 B). Quantification of intracellular 
CD11b-IR demonstrated that ATP-stimulated microglia contained 98.0% ± 3.6% 
intracellular CD11b in relation to non-stimulated microglia at t=0 (Figure 5-4 C). 
Cross-linking of CR3 with zymosan or stimulation of protein kinase C (PKC) with 
PDBu caused translocation of intracellular CD11b (white arrows, Figure 5-4 B) and 
significant exocytosis (61.7% ± 2.7% for zymosan, 27.0% ± 3.0% for PDBu, P < 
0.0001, Figure 5-4 C). This response was specific for the agonists and not affected 
by buffer alone (104.7% ± 5.4% remaining intracellular CD11b, Figure 5-4 C). 
Thus, CR3 can initiate an immune response in microglia which requires stimulation 
of specific receptor binding sites within CD11b leading to exocytosis of CD11b and 
phagocytosis-induced respiratory burst activity. 
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Figure 5-4: Cross-linking of CR3 triggers exocytosis of internal CD11b stores. 
A: 3D-confocal imaging showing the cellular distribution of CD11b in non-stimulated microglia in 
vitro. Direct immunofluorescence with tagged OX42-antibodies demonstrates that CD11b receptor 
is found on microglial cell membrane (green) and in vesicles scattered throughout the cytoplasm 
(red). CD11b on the membrane appears in patches which was previously shown to be an artifact of 
incubating microglia on ice (Chapter 4). Cell nuclei were stained with Hoechst-dye (blue). B: 
Intracellular CD11b-immunoreactivity (IR) before stimulation of exocytosis. C: Application of 50 μM 
ATP does not cause translocation of intracellular CD11b to the cell membrane. D: Cross-linking of 
CR3 with zymosan triggers translocation of intracellular CD11b stores to the cell membrane (white 
arrows). E: After 15 minutes treatment with PDBu, most intracellular CD11b has translocated to the 
cell membrane and hardly any CD11b-IR remains inside the cell (white arrows). F: Direct 
comparison of intracellular CD11b-IR before and after stimulation with various stimuli. G: 
Quantification of CD11b exocytosis. Treatment of microglia with KHB (104.7% ± 5.4%) and 50 μM 
ATP (98.0% ± 3.6%) does not cause depletion of intracellular CD11b stores. Stimulation with 
particulate zymosan (61.7% ± 2.7%, P < 0.0001) and PDBu (27.0% ± 3.0%, P < 0.0001) triggers 
exocytosis of intracellular CD11b. *** P < 0.0001 vs. KHB; N.S.: not significant. 
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5.4 Discussion 
This study highlighted a central role of CR3 in mediating microglial activation. The 
ability of CR3 to initiate a strong inflammatory response (respiratory burst and 
CD11b exocytosis) was dependent on the type of ligand and the CD11b binding 
site involved. Although the soluble CR3 agonist OX42 (α-CD11b) activated 
microglia and caused macropore formation, it did not stimulate the respiratory 
burst. This was also observed for micromolar concentrations of ATP.  
Microglial CR3 was also able to independently internalize antibody-coated 
immune complexes by phagocytosis. Phagocytosis via CR3 triggered the 
respiratory burst only when the lectin binding site of CD11b was stimulated or Fcγ-
receptors were co-stimulated. Non-stimulated microglia were shown to possess an 
intracellular pool of CD11b. Agonists that stimulated the respiratory burst also 
stimulated CD11b exocytosis whereas partial activation of microglia with ATP did 
not. Thus, the activation of a strong immune response and the production of ROS 
via CD11b requires specific conditions suggesting that the activation of immune 
effector functions via CD11b is tightly controlled. 
5.4.1 Downstream Effects of Integrin CD11b Receptor Signalling 
in Microglia 
Previous studies on aggregation, internalization and trafficking of microglial CD11b 
receptor (Chapter 4) demonstrated that CD11b can be stimulated with a soluble 
agonist (OX42 antibody) to signal intracellularly independent of FcγR stimulation. 
Here, this finding was extended to show the ability of OX42 to stimulate microglial 
activation via CD11b/CR3 interaction, demonstrated by macropore formation.  
Microglial activation is associated with an increase of intracellular calcium 
[182,316] which is a second messenger for regulating intracellular signalling 
cascades. The formation of macropores most likely leads to an influx of 
extracellular calcium providing a link between macropore formation and elevated 
calcium levels. This was further substantiated in this study by activating microglial 
cells with 50-100 μM ATP. Low micromolar concentrations of ATP are known to 
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trigger sustained calcium increase in microglia in vitro [434] and stimulate 
macropore formation predominantly via P2X4 receptor [38]. 
The functional consquences downstream of CD11b-mediated activation are 
still not fully understood in microglia. The effects on microglia elicited by OX42 
antibody can be best explained by the ability of antibodies to mimic cell-
extracellular matrix (ECM) interactions. Signalling via integrin receptors is initiated 
by receptor clustering with bi- or multivalent ligands that cause cytoskeletal 
rearrangements and subsequent recruitment of intracellular kinases [126]. 
Stimulation of microglia with OX42 antibody was shown to cause nitric oxide 
production in vitro [161] as well as apoptosis and mitosis in vivo [390]. The present 
study emphasizes that these effects are directly initiated by CD11b receptor 
stimulation and microglial activation. 
5.4.2 Microglial CR3 Mediates Phagocytosis Independent of 
FcγR-Stimulation 
Internalization of antibody-coated immune complexes further confirmed that the 
microglial CR3 is also able to perform phagocytosis and activate microglia. Beads 
coated with OX42-antibody preparations were used to elucidate the role of the 
complement binding site of CD11b (the proposed binding site of OX42) in 
phagocytosis. 
Phagocytosis of OX42-F(ab‘)2-beads via CR3 occurred independently and 
did not require other receptors such as FcγRs. However, this study also strongly 
suggests that CR3 can cooperate with FcγR in phagocytosis, because OX42-IgG-
beads which exhibit binding sites for CD11b (antigen binding site) and FcγRs (Fc-
part of OX42) were internalized into microglia apparently in different mechanisms 
and with different cellular consequences to CR3 alone.  
The ability of microglial CR3 to phagocytose independently agrees partially 
with studies on peripheral immune cells that have investigated the relationship of 
CR3 and FcγRs in phagocytosis and also their interaction. Monocyte and 
macrophage FcγRs constitutively perform phagocytosis of IgG-opsonized particles 
[332]. However, iC3b-complement-mediated phagocytosis appears to be regulated 
based on maturation stage, cell priming and culture conditions. Human monocytes 
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freshly isolated from humans do not ingest iC3b-coated immune complexes, but 
acquire this ability during maturation to macrophages in culture [332,333]. 
Adherence to substrates in vitro renders human monocytes capable of 
phagocytosis via CR3 [189,216,333,334], but non-adherent monocytes require 
priming [501,502]. Murine macrophages only bind but do not perform phagocytosis 
via CR3, but primed thioglycollate-elicited macrophages [44] and macrophages co-
stimulated with aggregated IgG [189] ingest immune complexes in a CR3-
mediated manner. Thus, in order to be able to ingest particles via CR3 the cell has 
to be primed and the receptor has to be in its active conformation [398]. 
Stimulation of certain FcγR subtypes represents one potential priming mechanism, 
because it causes activation of CR3, mobilization and accumulation of CR3 at the 
site of phagocytosis [212] and augmentation of the overall rate of phagocytosis 
[284]. The ability of FcγRI to exert inhibitory effects on CR3-mediated 
phagocytosis [189] further corroborates the importance of CR3 and FcγR 
interactions. 
Microglia are commonly referred to as ‘brain macrophages‘ suggesting 
similiar functions to tissue macrophages. Microglia in this study internalized OX42-
F(ab‘)2-beads via CR3 alone. This suggests that either microglia are capable to 
perform phagocytosis via CR3 independently in contrast to macrophages or that 
cell priming may have occured, for instance through depriving isolated microglia of 
astrocytic support and/or plating them on an artificial substrate.  
Microglia may have also been primed directly via CR3 through binding of 
OX42 antibody to CD11b before phagocytosis of OX42-F(ab‘)2-beads occurred. 
This hypothesis is supported by the observation that the OX42 antibody partly 
activated microglia to a primed state based on the ability of OX42 to induce 
macropore formation. The ability of CR3 to mediate phagocytosis independently is 
relevant to neuroinflammation in vivo, because in an inflammatory environment 
microglia are activated/primed and CR3 would be expected to be in its active form, 
e.g. to phagocytose iC3b-coated apoptotic neurons [167]. 
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5.4.3 Microglial CR3 has a Dual Role in Mediating Inflammation 
Interestingly, microglia ingested OX42-F(ab’)2-beads via CR3 in absence of a 
respiratory burst. However, the absence of a phagocytosis-induced respiratory 
burst was not due to the inability of CR3 to trigger ROS production, because 
particulate zymosan which is known to stimulate the lectin-binding site of CR3 
[397] triggered the respiratory burst in microglia. This confirms studies in 
neutrophils and macrophages that showed absence of ROS production under 
conditions where cells promoted iC3b-complement-mediated phagocytosis via 
CR3 in absence of FcγR-stimulation [39,503,527]. 
In contrast to OX42-F(ab’)2-beads, phagocytosis of OX42-IgG-beads 
triggered the respiratory burst suggesting an involvement of FcγRs in this cellular 
response. Cross-linking of FcγRs is associated with respiratory burst activity in 
immune cells other than microglia and CR3 and FcγRs can interact in order to 
ingest immune complexes [189,467,503,514]. This is exemplified by a study where 
zymosan opsonized with rat serum (containing complement factors and IgG) 
stimulated ROS production in cultured microglia [92].  
The interaction of CR3 with FcγRs in other immune cells involves a 
mechanism by which FcγR binds to the lectin domain of CD11b priming CR3 for 
phagocytosis and cytotoxicity [397,528]. The involvement of FγRs in phagocytosis 
and respiratory burst activity is relevant for microglial function in vivo, because in 
inflammation not only complement expression is up-regulated within the CNS, but 
expression of FcγRs on microglia and brain IgG-levels are increased as well 
[277,364,381,469]. The production of ROS by microglia may therefore depend on 
an adaptive immune response and the integrity state of the blood-brain-barrier. 
Thus, phagocytosis of immune complexes via the microglial CR3 does not 
necessarily trigger the respiratory burst and the stimulation of a cytotoxic response 
depends on the CR3 binding site and ligation of other receptors (e.g. FcγR). The 
results presented here provide an explanation for the apparent contradictory role 
of the microglial CR3 in mediating neurotoxic ROS production [50,188,363,525] 
and the absence of respiratory burst activity and down-regulation of inflammatory 
cytokine expression when microglia ingest iC3b-opsonized apoptotic neurons via 
CR3 [331,392]. 
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5.4.4 Mechanisms of Particle Uptake in Microglia 
The activation of immune effector functions by phagocytosis in peripheral immune 
cells is directly linked to the type of phagocytosis executed. The phagocytosis of 
OX42-IgG-beads in microglia observed here involved pseudopod formation while 
OX42-F(ab‘)2-beads sank into the cell. The type of phagocytosis executed is 
commonly referred to as type I (pseudopod formation) and type II phagocytosis 
(sinking of particles into the cell) [72], but this has not been described in microglia 
before. 
Differences in the type of phagocytosis are attributed to the recruitment of 
Cdc42 and Rac kinases for type I and Rho kinase for type II phagocytosis [72]. 
Rac kinase is involved in the activation of NADPH (nicotinamide adenine 
dinucleotide phosphate) oxidase 2 (NOX2), the major inducible form of 
superoxide-producing enzymes in the respiratory burst in phagocytes [61]. FcγRs 
are known to perform type I phagocytosis [72] whereas complement-mediated 
phagocytosis via CR3 in neutrophils is linked to type II phagocytosis [253]. The 
recruitment of different intracellular kinases upon phagocytosis provides a basis 
for the dissociation of the respiratory burst from particle ingestion. This further 
emphasizes the involvement of FcγRs in phagocytosis-induced ROS production 
triggered by OX42-IgG-beads and the absence of the respiratory burst when CR3 
performs phagocytosis of OX42-F(ab’)2-beads in microglia. 
5.4.5 Activation of Respiratory Burst Requires Cross-Linking of 
Cell Surface Receptors 
The role of CR3 in transmitting signals to activate ROS production is not only 
dependent on the binding site, but also on the valency of binding sites present on 
ligands that bind to the receptor. OX42 antibody, a soluble (bivalent) CD11b 
agonist, exhibits 2 identical binding sites which causes receptor aggregation 
(Chapter 4) which is typical for initiating intracellular signalling by complement 
receptors in immune cells [450]. Although OX42 antibody (and ATP) triggered 
macropore formation and microglial activation, this was not sufficient for activating 
the respiratory burst. This agrees with the finding that a rise in intracellular calcium 
is not sufficient for superoxide production in rat macrophages [171]. 
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In contrast, beads coated with OX42 antibody exhibit a multitude of binding 
sites (multivalent) for CR3 and/or FcγR dependent on whether F(ab’)2 fragments or 
intact IgG is used. In both cases, large particles coated with a high number of 
ligands initiate cross-linking of phagocytosis receptors which is required to signal 
particle ingestion [337]. Stimulation of ROS production via CR3 with zymosan 
represents another example. Microglial cells (in this study) and other immune cells 
[175,254,496] activate the respiratory burst upon incubation with unopsonized, 
particulate zymosan which cross-links the lectin binding site of CR3. Particulate 
zymosan is constituted of polysaccharides that mediate the cytotoxic response 
through receptor cross-linking. However, soluble polysaccharides that are unable 
to cross-link CR3 prime CR3 for cytotoxic activation, but do not activate the 
respiratory burst in peripheral immune cells [480,508]. The present study therefore 
illustrates that stimulation of the respiratory burst also requires receptor cross-
linking in microglia and that microglial activation alone is not sufficient.  
The requirement for appropriate PRR ligands to trigger ROS production is 
further highlighted by the fact that very few uncoated beads were taken up by 
microglial cells after 1 hour incubation in absence of respiratory burst activity. 
However, the internalization of some uncoated beads points at the existence of 
other internalization mechanisms besides phagocytosis such as macropinocytosis 
[283]. Macropinocytosis is not associated with activation of the respiratory burst in 
neutrophils [250] and the data presented here demonstrated that ROS production 
was absent in microglia treated with uncoated beads.  
Thus, the respiratory burst in microglia represents a specific receptor-
mediated event and not a generalized response to rise in intracellular calcium. 
This supports the idea that microglial activation proceeds in distinct stages and the 
step to a fully immunocompetent microglial cell requires a strong trigger. 
5.4.6 Exocytosis of CD11b in Activated Microglia is Part of the 
Immune Response 
The respiratory burst is accompanied by the assembly of the superoxide-
producing NOX2 enzyme [433]. Subunits of NOX2 (gp91phox and p22phox) are 
stored in intracellular granules and vesicles that also contain CD11b receptor and 
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are mobilized upon receptor-mediated stimulation in peripheral immune cells 
[55,248]. Whether microglia exhibit intracellular CD11b and under what conditions 
CD11b exocytosis can be stimulated in microglia has not been defined yet.  
Direct immunofluorescence here demonstrated that non-stimulated microglia 
in vitro express CD11b on the cell membrane and store CD11b intracellularly 
concentrated within vesicles and scattered throughout the cytoplasm. While 
cellular activation accompanied by a rise in intracellular calcium is usually 
sufficient for neutrophils [459] and monocytes [275] to initiate CD11b exocytosis, 
microglia did not respond to ATP with depletion of intracellular CD11b stores. 
Microglial cells required receptor cross-linking with particulate zymosan to initiate 
signals that cause CD11b exocytosis. 
Interestingly, the existence of an intracellular pool of CD11b in non-
stimulated microglia reflects a property of monocytes and neutrophils rather than 
macrophages [275,306], because non-stimulated human alveolar macrophages as 
well as resting and thioglycollate-elicited murine peritoneal macrophages were 
reported to lack intracellular pools of CD11b and therefore were not able to 
respond to phorbol ester stimulation (phorbol-12-myristate-13-acetate, PMA) with 
an increase in CD11b expression on the cell membrane.  
5.4.7 Microglia are Specialized Tissue Macrophages of the CNS 
Microglial cells share the myeloid lineage with peripheral immune cells including 
neutrophils, monocytes and macrophages [387]. Microglia are often regarded as 
resident brain macrophages which suggests similiar functions to peripheral 
immune cells. The present study, however, identified subtle differences between 
microglia and macrophages that could affect their cytotoxic immune response. 
The data reported here point at a higher ‘activation threshold’ of microglial 
cells to become fully immunocompetent. As discussed above, a rise in intracellular 
calcium is sufficient to activate a cytotoxic response in monocytes and neutrophils 
whereas microglial cells require stronger signals such as immune complexes. 
Although this property is shared by microglia and tissue macrophages, non-
stimulated microglial cells in vitro were shown to have a substantial intracellular 
pool of CD11b which macrophages do not have. The loss of intracellular CD11b 
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pools during extravasation of monocytes into tissue and maturation to 
macrophages could explain the non-existence of intracellular CD11b in tissue 
macrophages [198]. However, the significance of the observed differences in 
intracellular CD11b stores in microglia and macrophages remains to be 
investigated in vivo. 
The storage of CD11b in intracellular pools and lower membrane CD11b 
expression may render microglia less sensible to cytotoxic activation. Exocytosis 
of CD11b and respiratory burst activity may therefore represent the final stage of 
the inflammatory response in microglia. This is supported by the fact that secretory 
vesicles in peripheral immune cells are released in response to strong stimuli and 
are not reformed by endocytosis once their content is released [55]. It is important 
to mention in this context, that an increase of CD11b expression is not necessarily 
associated with a (cytotoxic) phagocytic state of microglia [164]. This supports the 
finding of this study that CR3 can mediate non-cytotoxic functions under certain 
circumstances, but requires additional priming to trigger a strong inflammatory 
immune response. 
5.4.8 Implications for OX42-Mediated Gene Transfer into 
Microglia 
Previous studies (Chapters 3 and 4) have established that the monoclonal 
antibody OX42 specifically binds to microglia via CD11b/CR3 and triggers 
receptor-mediated endocytosis. The suitability of CD11b as targeting receptor is 
further reinforced by the absence of an immmune response when stimulated with 
OX42 antibody. Although OX42 antibody triggers partial microglial activation, it 
does not activate the respiratory burst. The consequences of OX42-mediated 
macropore formation are not clear as yet, but the absence of a strong immune 
response is crucial to avoid potential degradation of the gene delivery vehicle and 
to avoid initiation or exacerbation of inflammation. These results suggest that 
OX42 antibody does not bind to CD11b binding sites associated with activation of 
cytotoxic funtions. Thus, a non-viral gene vehicle based on OX42 antibody may be 
suitable for non-viral gene transfer into microglia, but cross-linking of FcγRs will 
need to be avoided. 
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5.5 Conclusion 
This study defines a central role of CD11b/CR3 in mediating microglial activation. 
Stimulation of CD11b with either soluble or particulate ligands elicits differential 
intracellular signals leading to partial activation and macropore formation in 
absence of a cytotoxic immune response (respiratory burst and CD11b exocytosis) 
or to a strong immune response with production of reactive oxygen species (ROS). 
Phagocytosis via microglial CR3 is not always associated with the respiratory 
burst. Stimulation of a strong immune response in microglia requires specific 
‘danger signals’ such as immune complexes that trigger receptor cross-linking and 
phagocytosis. Cross-linking of CR3 alone only stimulates ROS production if the 
lectin-binding site is involved. Microglial CR3 can also interact with Fcγ-receptors 
to perform type I phagocytosis and to activate the respiratory burst. 
The data reported here strengthen the dual role of microglial CR3 in 
mediating non-cytotoxic and cytotoxic cell activation known from peripheral 
immune cells. Dysregulation of CR3 function or inappropriate CR3 stimulation 
could be significant for the progress of neuropathologies where inflammation and 
oxidative stress prevails.  
In terms of antibody-mediated gene transfer into microglia, the absence of an 
immune response in OX42-stimulated microglia suggests that OX42 antibody is 
useful for targeted non-viral gene transfer into microglia by receptor-mediated 
endocytosis.
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6.1 Introduction 
The manipulation of gene expression is a tool to study cell physiology and to 
transfer oligonucleotides into cells for therapeutical purposes. The medical need 
for gene delivery vehicles is particularly pronounced in neuropathologies, because 
there are still no effective treatments for the majority of neurological disorders. 
Ongoing gene therapy trials mostly use viral vehicles for gene delivery, for 
example to treat motoneuron disease [140,296,428].  
The use of viruses has been justified by their inherent properties that make 
them efficient carriers causing high levels of stable gene expression [384]. Viruses 
have evolved to bypass the various barriers that exist to protect the host organism 
including degradation in the circulation and within the cell. The structure of viruses 
can thus serve as a template to design non-viral vehicles. Non-viral vectors 
possess several advantages over viruses, for instance the ease of production, 
flexible combination of single biochemical entities using chemical synthesis and 
lower immunotoxicity [278,384]. Immunoporters are synthetic, non-viral vehicles 
(‘polyplexes’) that can be used for targeted gene transfer via receptor-mediated 
endocytosis with monoclonal antibodies [395].  
The delivery of oligonucleotides such as plasmid DNA with immunoporters 
requires a DNA binding agent. The cationic polymer polyethyleneimine (PEI) has 
drawn enormous interest [276,330], because PEI binds exogenous DNA, protects 
it from degradation and facilitates endosomal escape [10,519]. Polyethyleneimine 
comes in various molecular weights and in either linear (lPEI) or branched (bPEI) 
forms. Branched PEI shows higher affinity to DNA compared to lPEI [41,203] and 
low molecular weight bPEI (25 kDa) gives higher transfection efficiencies in brain 
compared to 50 kDa and 800 kDa bPEI [2]. Low molecular weight bPEI is also less 
toxic [229,278]. Thus, bPEI may be appropriate for non-viral gene delivery into the 
central nervous system (CNS).  
PEI can be modified with cell-targeting ligands and stabilizing polymers to 
improve cell-type specificity, transfection efficiency and vehicle stability in vivo. 
The attachment of monoclonal antibodies allows targeting cell type specific 
receptors which reduces the off-target gene delivery seen with PEI alone 
Chapter 6: Development of Immunoporters for Microglial Gene Transfer 
216 
 
[228,344,481]. Engrafting PEI with polyethyleneglycol (PEG), for example, 
stabilizes polyplexes by decreasing aggregation [309,312,451] and reducing 
toxicity [278,367] as well as diminishing opsonization and activation of immune 
responses [15]. Therefore, PEGylated bPEI (‘PEI-PEG‘) bound to monoclonal 
antibodies (immunoporter, Figure 6-1) is a promising non-viral vehicle to achieve 
targeted gene delivery into microglia [395]. 
Microglial cells play an important role in the immune defence of the CNS. 
However, the role of activated microglia in neuropathologies is controversial. Non-
viral gene transfer with immunogenes could help to investigate microglial function 
and also be used in clincal settings. Part 1 of this PhD project identified the 
integrin CD11b receptor as a suitable target for gene delivery into microglia. The 
monoclonal antibody OX42 specifically bound to CD11b (Chapter 3) and triggered 
receptor-mediated internalization (Chapter 4). Further, OX42 antibody did not 
stimulate an immune response in microglia (Chapter 5) as demonstrated by the 
absence of the respiratory burst. Thus, an immunoporter based on OX42 antibody 
(OX42-immunoporter) may be useful to deliver genes into microglia.    
This chapter describes the procedure to synthesize OX42-immunoporters. 
The basic protocols to conjugate antibody-based vehicles used here have been 
developed by the research group of R. A. Rush (Flinders University, Adelaide). 
Experiments presented here were undertaken to optimize immunoporter 
conjugations with OX42 antibody and to develop an assay to monitor PEI content 
throughout the synthesis. The ability of OX42-immunoporters to bind plasmid DNA 
was tested in gel retardation assays. 
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6.2 Immunoporter Synthesis Procedure 
6.2.1 Materials  
Solvents, salts for buffers and chemicals for conjugations were from Sigma-Aldrich 
(Australia) unless otherwise stated. 3-(2-pyridyldithio) propionic acid N-
hydroxysuccinimide ester (SPDP) and N-hydroxy-succinimide (NHS)-activated 
TMS(PEG)12 were purchased from Thermo (Australia). Conjugation buffer 
consisted of 20 mM HEPES, 0.25 M sodium chloride (pH 7.9). Transfection and 
storage buffer consisted of 20 mM HEPES, 0.15 M sodium chloride (pH 7.3).  
Ultrafiltration spin columns (100 kDa molecular weight cut off, MWCO) were 
purchased from Millipore (Australia), PD-10 desalting columns and HiTrap SP/HP 
cation exchange columns were from GE Healthcare (Australia). The presence of 
protein or PEI was qualitatively determined with a DC (detergent-compatible)-
assay kit (Bio-Rad, Australia) in 96-well plates (Corning, USA). Immunoporter 
conjugates were purified on an FPLC (e.g. BioLogic DuoFlow, Bio-Rad) equipped 
with a gel filtration column (HiLoad 16/60 Superdex 200 prep grade, GE 
Healthcare).  
6.2.2 Antibody 
The monoclonal mouse antibody OX42 (IgG2a) recognizes an epitope on the 
external domain of the integrin receptor CD11b that is specific for microglia and 
macrophages within the CNS. The OX42 hybridoma cell line to produce antibody 
was developed by Robinson et al. [393]. 
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Figure 6-1: Components of an immunoporter. 
Immunoporters are synthetic bioconjugates for targeted non-viral gene transfer. A monoclonal 
antibody confers cell type specificity and bPEI condenses DNA to be delivered into the cells. The 
antibody is covalently linked to bPEI via a hetero-bi-functional linker (SPDP). Branched PEI (bPEI) 
is engrafted with PEG to provide enhanced stability and shielding of the bPEI-DNA complex 
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6.2.3 Modification of Antibodies with SPDP-Linker 
6.2.3.1 Introduction 
The conjugation of immunoporters requires the covalent attachment of the DNA 
binding agent PEI to the cell targeting monoclonal antibody. SPDP is a hetero-bi-
functional linker that can be used for this purpose. SPDP binds to the antibody via 
primary amine groups on the protein, thereby releasing NHS as a leaving group 
and forming a stable amide bond between antibody and SPDP (Figure 6-2 A).  
6.2.3.2 Optimization Experiments 
It is crucial to achieve one SPDP-linker per antibody molecule (molar ratio 
nSPDP/Antibody = 1) in order to avoid oligomer formation. Therefore, the molar ratio of 
SPDP linker to OX42 antibody was determined in preliminary trials. 
Antibodies were buffer exchanged to conjugation buffer using 100 kDa 
ultrafiltration spin columns and protein concentration was determined (A280 = 1.35 
for 1 mg/mL IgG antibody). Different volumes of 10 mM SPDP dissolved in ethanol 
were incubated with 1 mg of antibody (2-3 mg/mL) on a shaker (2 hours at room 
temperature, RT). The mixture was purified on a PD-10 desalting column, 1 mL 
fractions collected and the antibody containing fractions qualitatively identified on a 
96-well plate using a 2 µL aliquot of each fraction and following the manufacturer’s 
protocol for the DC-protein assay kit.  
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Antibody containing fractions were pooled and the absorbance measured for 
protein concentration (280 nm) and the leaving group of SPDP, pyridine-2-thione 
(343 nm, Figure 6-2 B). To determine the molar ratio of SPDP to OX42 antibody, 
10 μL of 15 mg/mL dithiothreitol (DTT, in conjugation buffer) were added to an 
aliquot of SPDP-modified antibody and incubated at room temperature for 15 
minutes in the dark. The absorbance at 343 nm was read again after the 
incubation. The molar ratio of SPDP to antibody was calculated according to 
following formula: 
 
nSPDP/Antibody = 
thionepyridine 

2
343 A

 x 
]/[
 WAntibody
mLmgc
M
Antibody
      (Equation 6-1) 
 
with ε = extinction coefficient (M-1cm-1) = 8080 M-1cm-1 for pyridine-2-thione 
 ∆A343 = A343, t=15 min - A343, t=0 min 
 MWAntibody = 150000 g/mol 
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Figure 6-2: Modification of monoclonal antibody with SPDP and determination of molar 
ratio. 
A: Modification of monoclonal antibodies with hetero-bi-functional linker SPDP releases NHS as a 
leaving group. B: Reduction of the SPDP-disulfide bridge with DTT yields a reactive free sulfhydryl-
group and pyridine-2-thione. The latter can be quantified by photometry at 343 nm. mAb: 
monoclonal antibody; SPDP: 3-(2-pyridyldithio) propionic acid N-hydroxysuccinimide ester; NHS: 
N-hydroxy-succinimide ester; DTT: dithiothreitol. 
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Preliminary experiments indicated that on average 2 SPDP linkers bound to 1 
OX42 antibody (nSPDP/OX42 = 2) at a ratio of 2.6 μL SPDP per milligram OX42 
antibody. Thus, 1.3 μL of SPDP per milligram OX42-antibody was required to 
obtain an average molar ratio of nSPDP/OX42 = 1. 
6.2.3.3  Protocol for Immunoporter Conjugations 
OX42 antibody (6-8 mg in conjugation buffer, 2-3 mg/mL) was modified with 10 
mM SPDP at a ratio of 1.3 μL SPDP/mg OX42 for 2 hours on a shaker at RT. 
SPDP-modified antibodies were then desalted on PD-10 columns, protein positive 
fractions (DC-assay) pooled and antibody concentration estimated on a 
spectrophotometer (280 nm). Pyridine-2-thione positive fractions (343 nm) were 
pooled and the absorbance measured to calculate conjugation efficiency at the 
end of the immunoporter synthesis. 
6.2.4 Development of an Assay to Measure PEI Content 
6.2.4.1 Introduction 
Monitoring the PEI-content throughout the immunoporter synthesis allows 
assessment of batch-to-batch consistency. PEI is cationic polymer with a high 
density of primary amine groups. This can be analytically exploited by using amine 
reactive probes such as picrylsulfonic acid (2,4,6-trinitrobenzene sulfonic acid, 
TNBS). TNBS is a compound that reacts with primary amines to form a 
chromogenic product which can be measured on a spectrophotometer (Figure 
6-3). Previous TNBS-assays have used large volumes to allow photometric 
measurement in cuvettes [429]. Here, a 96-well plate assay was developed to 
reduce the sample volume and allow higher sample through-put.  
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Figure 6-3: The reaction of TNBS with primary amines of proteins or PEI. 
Modification of PEI with TNBS yields a chromogenic product that exhibits absorbance at 405 nm 
and thus can be used to measure PEI-concentration photometrically. PEI: polyethyleneimine; 
TNBS: 2,4,6-trinitrobenzene sulfonic acid. 
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6.2.4.2 Assay Development and Optimization 
The correct absorbance wavelength to measure TNBS-modified PEI was 
confirmed on a spectrophotometer by scanning wavelengths from 300 – 500 nm 
(Figure 6-4 A). Incubation of PEI with TNBS increased absorption at the 
absorption maximum (405 nm) compared to PEI and TNBS alone. 
The TNBS-assay was then optimized for use on 96-well plates taking into 
account the concentration range, incubation time, sample and TNBS-reagent 
volume. A stock solution was prepared with PEI diluted to 100 mg/mL (stock 
solution) in water and the pH adjusted to pH 7.0 with concentrated hydrochloric 
acid (HCl).  The stock solution was diluted in 0.1 M sodium borate buffer, pH 9.3 to 
generate standard curves. The TNBS-labelling reagent (5% in H2O) was freshly 
prepared as a 1/500 dilution in water. 
A linear relationship of absorbance at 405 nm to PEI-concentration was 
found in the range of 0.5 – 4 µg/mL PEI (R2 = 0.9984, Figure 6-4 B). The optimal 
incubation time of TNBS with PEI was determined by incubating both compounds 
for 25 - 75 minutes at 37ºC. Regression analysis (Table 6-1) showed that 
increasing the incubation time for more than 25 minutes decreased sensitivity. 
Extended incubation times also resulted in higher background values indicating 
that an incubation of 25 minutes at 37ºC is sufficient. 
Table 6-1: Linear regression analysis of standard curves obtained at different incubation 
times. 
Incubation / [min] Slope / [AU x µL x µg-1]  Background (405 nm) R2 
25 0.0099 0.101 0.9981 
35 0.0097 0.105 0.9946 
75 0.0086 0.107 0.9872 
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Figure 6-4: Optimization of TNBS-assay to monitor PEI-concentration for immunoporter 
conjugations. 
A: Wavelength scans between 300-500 nm demonstrate that TNBS-modified PEI exhibits an 
absorption maximum at 405 nm that can be used for measuring TNBS-modified PEI 
photometrically. B: A dilution series of 0.5-10 µg/mL PEI on a 96-well plate indicates that 
absorbance of TNBS-modified PEI at 405 nm is linear up to a PEI-concentration of 4 µg/mL. PEI: 
polyethyleneimine; TNBS: 2,4,6-trinitrobenzene sulfonic acid. 
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Different ratios of PEI and TNBS labelling reagent were tested to investigate their 
effect on sensitivity and background of the assay (Table 6-2). The slope increased 
with increased volumes of PEI and TNBS with acceptable background readings 
(Table 6-2). Linear regression analysis indicated that at this PEI/TNBS-volume 
ratio the amount of TNBS is not limiting. 
Table 6-2: Linear regression analysis of standard curves obtained at different ratios of PEI 
and TNBS. 
PEI/TNBS-ratio Slope / [AU x µL x µg-1] Background (405 nm) R2 
10/1 (100 µL + 10 µL) 0.0099 0.101 0.9981 
7.5/1 (150 µL + 20 µL) 0.0137 0.104 0.9992 
5/1 (100 µL + 20 µL) 0.0108 0.109 0.9997 
 
6.2.4.3 Assay Protocol for Immunoporter Conjugation 
TNBS-assays were performed with a PEI standard diluted to 0.5–4 µg/mL with 0.1 
M sodium borate buffer, pH 9.3. The same diluent was used to prepare 3 different 
dilutions of samples containing unknown concentrations of PEI. One hundred fifty 
μL of standard and sample solution was incubated with 20 µL TNBS reagent 
(1/500 dilution in water, prepared fresh) for 25 min at 37ºC and the plate 
immediately read at 405 nm. Standards and samples were measured in 
quadruplicate wells. The concentration of PEI was estimated using linear 
regression and the results of all three sample dilutions were averaged. 
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6.2.5 Preparation of PEI for Conjugation 
6.2.5.1 Introduction 
PEI dissolved in water exhibits a high pH value (10-11). The pKa value of PEI 
polymers lies in a range of 8-9 and thus, PEI exists in a mainly deprotonated form 
at basic pH [330].  At physiological pH (< pKa), the equilibrium of protonated to 
deprotonated PEI is shifted to a more protonated form of PEI and therefore 
exhibits a slightly postive charge [330]. Protonated amine groups are necessary to 
bind negatively charged DNA. Therefore, PEI solutions need to be protonated 
before use for transfection [2] which is usually performed at physiological pH.  
6.2.5.2 Protocol for Immunoporter Conjugations 
Approximately 2 g of PEI were weighed in and dissolved in 20 mL water. The pH 
value was adjusted to 7.0 with concentrated HCl. Neutralized PEI was desalted on 
PD-10 columns (3 x 2.5 mL for each batch) and exchanged to conjugation buffer, 
PEI-containing fractions identified using the DC-assay and PEI-positive fractions 
pooled. The concentration of PEI was estimated with the TNBS-assay. Two 
batches of PEI were prepared (Table 6-3). 
Table 6-3: Batches of PEI prepared for optimization experiments and immunoporter 
conjugations. 
Batch m / [g] VFraction / [mL] c / [mg/mL] 
PEI (1) 2.001 14 52.0 
PEI (2) 2.010 14 54.0 
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6.2.6 Engrafting of PEI with PEG 
6.2.6.1 Introduction 
The reaction conditions to bind PEG to PEI were previously optimized (R. Rush, 
Flinders University) in order to engraft PEI with PEG at a molar ratio of 1:12 (12 
PEG molecules per PEI). This ratio was found to give best transfection results 
(personal communication). 
6.2.6.2 Protocol for Immunoporter Conjugations 
Thirty mg of PEI (20 mg/mL) in conjugation buffer were incubated with a 7.5 molar 
excess of 125 mM PEG-NHS ester (dissolved in DMF) for 1 hour at room 
temperature on a shaker in the dark under nitrogen (Figure 6-5 A). After 
incubation, PEI-PEG was purified on a PD-10 desalting column, PEI containing 
fractions identified (DC-assay) and concentration of PEI-PEG estimated with a 
TNBS-assay. Two PEI-PEG batches were prepared (Table 6-4). 
Table 6-4: Summary of PEI-PEG batches prepared for optimization experiments and 
immunoporter conjugations. 
Batch mPEI / [mg] VFraction / [mL] c / [mg/mL] 
PEI-PEG (1) 30 2 10.0 
PEI-PEG (2) 30 2 10.6 
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Figure 6-5: PEGylation of PEI, modification of PEI-PEG with SPDP and activation. 
A: PEG binds to PEI via primary amine groups. N-hydroxy-succinimide (NHS) is released during 
that reaction. PEGylation of PEI has been optimized by the research group of R. A. Rush (Flinders 
University, Adelaide) to result in an average ratio of 12 PEG to 1 PEI. B: The hetero-bi-functional 
linker SPDP reacts with primary amines of PEI releasing NHS. C: Treatment of SPDP-modified 
PEI-PEG with the reducing agent dithiothreitol (DTT) yields activated PEI-PEG with a reactive free 
sulfhydryl group (-SH). Pyridine-2-thione is released in this reaction. PEI: Polyethyleneimine; PEG: 
polyethylene glycol; SPDP: 3-(2-pyridyldithio) propionic acid N-hydroxy-succinimide ester. 
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6.2.7 Modification of PEI-PEG with SPDP-Linker 
6.2.7.1 Introduction 
Conjugation of PEI-PEG to monoclonal antibodies requires the modification of 
PEI-PEG with a linker (e.g. SPDP) and this can be achieved via its primary amine 
groups (Figure 6-5 B). As with SPDP-antibody linkage, it is crucial that one SPDP-
linker per PEI-PEG is introduced to avoid oligomer formation. Thus, different 
volumes of SPDP were tested in preliminary experiments to achieve an average 
molar ratio of 1 between SPDP and PEI (nSPDP/PEI = 1).  
6.2.7.2 Optimization Experiments 
Three aliquots of 1 mg PEI-PEG in conjugation buffer were prepared and mixed 
with 3.5 μL, 4.0 μL and 7.0 μL SPDP (10 mM in ethanol) per milligram PEI-PEG (1 
hour on a shaker, RT). The molar ratio of SPDP to PEI (nSPDP/PEI) was determined 
according to the manufacturer’s protocol. The concentration of PEI (PEI-PEG) 
after desalting on a PD-10 column was estimated with a TNBS-assay. 
The molar ratio of SPDP to PEI was calculated according to following 
formula: 
 
nSPDP/PEI = 
thionepyridine 

2
343 A

x 
]/[
 WPEI
mLmgc
M
PEI
   (Equation 6-2) 
with  ε = extinction coefficient (M-1cm-1) = 8080 M-1cm-1 for pyridine-2-thione 
 ∆A343 = A343, t=15 min - A343, t=0 min 
 MWPEI = 25000 g/mol 
 
Approximately 5 μL of 10 mM SPDP per milligram PEI-PEG was needed in order 
to obtain an average molar ratio of nSPDP/PEI = 1 (Table 6-5). 
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Table 6-5: Relationship of SPDP volume to molar ratio of SPDP/PEI. 
VSPDP / [µL] 3.5 4.0 7.0 
nSPDP/PEI 0.7 0.8 1.4 
 
6.2.7.3 Protocol for Immunoporter Conjugations 
PEI-PEG was modified by incubating PEI-PEG in conjugation buffer with 5 μL of 
10 mM SPDP per milligram PEI-PEG for 1 hour at RT on a shaker in the dark. 
SPDP-modified PEI-PEG was desalted on PD-10 column, PEI positive fractions 
identified (DC-assay) and pooled.  
6.2.8 Activation of SPDP-Modified PEI-PEG 
6.2.8.1 Introduction 
SPDP-modified antibodies and PEI-PEG are non-reactive with each other unless 
one component is activated. The cleavage of pyridine-2-thione from SPDP results 
in formation of a reactive free sulfhydryl-group (-SH). Activation can be achieved 
by using DTT as shown previously (Figure 6-2 B). Treatment of PEI-PEG-SPDP 
(Figure 6-5 C) rather than mAb-SPDP is favourable, because reduction of disulfide 
bonds with DTT could lead to disulfide-bond breakage in the antibody structure.  
6.2.8.2 Protocol for Immunoporter Conjugation 
An excess of 150 μL of 25 mg/mL DTT in conjugation buffer was added to 
desalted PEG-PEI-SPDP and incubated for 1 h at RT under nitrogen atmosphere. 
After reaction, the mixture was desalted on a PD-10 column to remove cleaved 
pyridine 2-thione and DTT. PEI-positive fractions (DC-assay) were pooled and the 
PEI-concentration estimated (TNBS-assay). Batches of activated PEI-PEG-SPDP-
SH (Table 6-6) in conjugation buffer were prepared immediately before 
conjugation to avoid extended exposure to air and oxidization of the sulfhydryl-
group. 
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Table 6-6: Batches of activated PEI-PEG-SPDP used for optimization experiments and 
immunoporter conjugations. 
Batch mPEI / [mg] VFraction / [mL] c / [mg/mL] 
PEI-PEG-SPDP-SH (1) 8.0 3 2.1 
PEI-PEG-SPDP-SH (2) 8.0 3 2.2 
 
6.2.9 Conjugation of Antibody with Activated PEI-PEG and 
Purification of Immunoporters 
6.2.9.1 Introduction 
The final step in the synthesis of the immunoporter is to link the monoclonal 
antibody with PEI-PEG. The free sulfhydryl-group of activated PEI-PEG-SPDP-SH 
can react with the disulfide-bond (-S-S-) of mAb-SPDP at basic pH causing 
disulfide bond shuffling (exchange of disulfide bonds) and the release of pyridine-
2-thione (Figure 6-6 A).  
6.2.9.2 Protocol for Immunoporter Conjugations and Purification 
SPDP-modified OX42 antibody and activated PEI-PEG were incubated overnight 
at a molar ratio of OX42 to PEI-PEG (nOX42/nPEI) =1:3 which was chosen based on 
previous work. The reactants were incubated at room temperature under nitrogen 
on a shaker in the dark in presence of 1 µL of 100 mM ethylene-diamine-
tetraacetic acid (EDTA) per milliliter reaction volume. After overnight incubation, 
the reaction mixture was desalted on a PD-10 column equilibrated with 
conjugation buffer. One mL fractions were collected and measured for protein (280 
nm) and pyridine-2-thione (343 nm). Protein positive fractions were pooled and 
purified on a syringe-driven cation exchange column using increasing molarities of 
NaCl (0.5 M, 1 M, 2 M and 3 M) in 20 mM HEPES, pH 7.3. Four 1 mL fractions for 
each salt concentration were collected and measured for protein. The conjugate 
eluted in fractions 1-3 at 2 M NaCl concentration. The immunoporter was then 
purified with a gel filtration column connected to an FPLC and equilibrated with 
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transfection buffer (flow: 0.5 mL/min). Five mL fractions were collected. A typical 
chromatogram is presented in Figure 6-6 B. 
The FPLC fractions containing the immunoporter were pooled and 
concentrated using 100 kDa MWCO ultrafiltration spin columns to a concentration 
of about 2-3 mg/mL in transfection buffer. The concentration of the immunoporter 
was determined photometrically based on the antibody concentration using a 
formula according to Warburg: 
 
cAntibody / [mg/mL] = 1.55 x (A280 – A320) – 0.76 x (A260 – A320)        (Equation 6-3) 
 
The yield of the conjugation reaction was calculated with: 
 
Yield / [%] = 
 [mg/mL] 
 [mg/mL] 
nconjugatio  beforeAntibody 
nconjugatioafter  Antibody 
c
c
 x 100%      (Equation 6-4) 
 
The molar ratio of conjugated PEI-PEG to monoclonal antibody (nPEI/Antibody) was 
estimated by measuring the absorbance at 343 nm of the pooled pyridine-2-thione 
fractions.  
 
nPEI/mAb = 
thionepyridine 

2
343 A

x 
]/[
 WAntibody
mLmgc
M
Antibody
      (Equation 6-5) 
with ε = extinction coefficient (M-1cm-1) = 8080 M-1cm-1 for pyridine-2-thione 
 ∆A343 = [A343, after conjugation x V / [mL]] – [A343, before conjugation x V / [mL]] 
 MWAntibody = 150000 g/mol 
 
Table 6-7 summarizes the results for conjugations of OX42-immunoporters. The 
molar ratio of PEI-PEG was close to 1 in both cases and the yield ranged from 
25% (batch 1) to 40% (batch 2). 
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Table 6-7: Result summary for conjugations of OX42 antibody with PEI-PEG. 
Batch nPEI/mAb cOX42 / [mg/mL] Yield / [%] 
OX42-immunoporter (1) 0.7 2.1 25 
OX42-immunoporter (2) 1.1 2.5 40 
 
The ability of OX42-immunoporters to bind plasmid DNA was then tested in gel 
retardation assays. 
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Figure 6-6: Conjugation of antibody to activated PEI-PEG and FPLC purification. 
A: SPDP-modified antibody is linked to SPDP-modified, activated PEI-PEG via disulfide bond 
shuffling at basic pH. Pyridine-2-thione is released and can be measured at 343 nm to determine 
the molar ratio of conjugated PEI-PEG to antibody. B: The absorbance at three wavelengths (280 
nm, 214 nm and 320 nm) was monitored. FPLC fractions (5 mL) in the shaded area were pooled 
and immunoporter concentrated on spin columns. mAb: monoclonal antibody; SPDP: 3-(2-
pyridyldithio) propionic acid N-hydroxysuccinimide ester; PEI: polyethyleneimine; PEG: 
polyethylene glycol. 
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6.3 Assay to Demonstrate Binding of DNA 
6.3.1 Introduction 
Gel retardation assays determine the ability of polyplexes (e.g. PEI-PEG or 
immunoporters) to bind DNA. Immunoporters are positively charged due to the 
cationic polymer PEI. If immunoporters are mixed with negatively charged DNA, 
immunoporters bind the DNA and form an immunogene (Figure 6-7 A). Increasing 
the ratio of immunoporter to DNA facilitates binding and condensation of DNA 
leading to decreased migration of DNA on agarose gels and exclusion of DNA 
detection agents such as SYBR® Safe Stain. The ratio of immunoporter to DNA 
can be expressed as the nitrogen/phosphate (N/P)-ratio.  
The N/P-ratio is calculated by taking into account the molar concentration of 
nitrogen residues (23.2 mmol/L) of 25 kDa bPEI and the phosphate content of 3 
nmol per 1 µg nucleic acid. The N/P-ratio for bPEI (25 kDa) is calculated according 
to following formula: 
 
N/P = 
phosphate) nmol (3  DNA) (µg
 nitrogen) mM (23.2  PEI) (µL


x cPEI / [mg/mL]       (Equation 6-6) 
 
Retardation of DNA with increasing N/P-ratios demonstrates ability of the 
immunoporter to bind DNA and provides a qualitative measure of the success of 
an immunoporter conjugation. With higher N/P-ratios, the immunoporter/DNA 
complex will become more positive due to excess of PEI. 
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Figure 6-7: OX42-immunoporters retard and condense plasmid DNA.  
A: Negative charged oligonucleotides such as plasmid DNA bind to positively charged PEI of 
immunoporters due to electrostatic interactions. This causes spontaneous complexation forming 
immunogenes. B: Both OX42-immunoporter preparations show retardation of pDNA with 
increasing N/P-ratio.  PEI: polyethyleneimine; PEG: polyethylene glycol; IP: immunoporter; bp: 
base pairs. pDNA: plasmid DNA. 
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6.3.2 Materials 
Salts to prepare Tris-buffered EDTA (TBE) running buffer were from Sigma-
Aldrich. Agarose was purchased from Promega (Australia). Gel loading buffer (e.g. 
10X BlueJuiceTM), DNA ladder (e.g. TrackItTM 1 Kb Plus) and DNA stains (e.g. 
SYBR® Safe DNA) were obtained from Invitrogen (Australia). A plasmid 
expressing enhanced green fluorescent protein (EGFP, pEGFP-N1, 4.7 kbp, RMIT 
University) was used. 
6.3.3 Assay Protocol and Results 
The ability of PEI, PEI-PEG and OX42-immunoporters to bind non-linearized 
plasmid DNA (pDNA, 400 ng/well) was tested for N/P-ratios between 2-10 (Figure 
6-7 B). PEI-conjugates and pDNA (0.1 mg/mL in transfection buffer) were mixed to 
form PEI-DNA complexes and incubated at room temperature for 30 minutes. Gel 
loading buffer was added and samples run on a 0.8% agarose gel for 40-60 min 
(100 V). Images were acquired on a fluorometer after DNA staining. 
The gel retardation assays demonstrated that OX42-immunoporters as well 
as PEI and PEI-PEG were able to bind plasmid DNA with increasing N/P-ratio 
(Figure 6-7 B). Based on this qualitative indicator, OX42-immunoporter 
conjugations were considered to be successful.  
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6.4 Conclusion 
A 96-well assay for PEI was developed that allows monitoring PEI content 
throughout the immunoporter synthesis. OX42-immunoporters for microglial gene 
transfer were conjugated with optimized conditions and their DNA-binding ability 
demonstrated in gel retardation assays. Transfections of mixed glia culture and in 
vivo will be conducted with OX42-immunoporter batch 2 to assess the specificity 
and transfection efficiency of OX42-immunoporters for microglia (Chapters 7 and 
8).
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7.1 Introduction 
The central role of microglia in mediating the immune response of the central 
nervous system (CNS) requires a detailed understanding of the mechanisms that 
govern microglial function. Manipulation of gene expression is a powerful 
approach to studying microglia. Viruses have been the major vehicles employed to 
achieve gene transfer into microglia [120,270,406,529]. However, microglia-
specific transduction with viruses has not been accomplished and the application 
of viral vectors in vivo bears risk of insertional mutagenesis especially with 
lentiviral vectors [53] that are often used to transfect microglia and other glial cells 
[28,295,301,302,504]. Targeted gene delivery with non-viral vehicles based on 
antibodies (‘immunoporter‘) could bypass these issues [395].  
Immunoporters consist of the cationic polymer polyethyleneimine (PEI) which 
is engrafted with polythyleneglycol (PEG) and conjugated to a targeting 
monoclonal antibody. Immunoporters bind and condense oligonucleotides, for 
instance plasmid DNA, forming immunogenes. Antibody-mediated delivery of 
oligonucleotides has been described for neuronal sub-populations in vivo 
[29,37,395], however, targeted non-viral gene transfer into microglia has not been 
reported thus far.  
In addition, there are only few examples were targeting non-viral vehicles 
based on cationic polymers (polyplexes) and cell targeting ligands were used to 
transfect primary microglia or microglial cell lines in vitro, e.g. mannose-conjugated 
linear polyethyleneimine (PEI) [225,288] and leptin-conjugated poly-L-lysine [267]. 
However, the specificity of these non-viral vehicles for microglia has not been 
tested in either a mixed culture system or in vivo. The current lack of availability of 
non-viral vehicles for targeted microglial gene transfer therefore requires the 
development of novel techniques to deliver transgenes into microglia in order to 
gain a thorough understanding of microglial function in vivo. 
Thus, immunogenes are a promising tool to investigate basic microglial 
physiology and they also may provide a safer alternative to viral gene therapy. In 
previous work, immunoporters for targeted gene transfer into microglia were 
successfully synthesized and shown to bind plasmid DNA (Chapter 6). An 
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antibody targeting the microglial CD11b receptor (OX42 antibody) was conjugated 
to the cationic polymer PEI. OX42 was demonstrated to specifically bind to 
microglia via CD11b (Chapter 3), to trigger receptor-mediated endocytosis 
(Chapter 4) and to circumvent activation of an immune response in microglia 
(Chapter 5).  
The aim of this study therefore was to investigate whether antibody-mediated 
delivery of genes could be achieved for microglial cells. The transfection efficiency 
and specificity of targeting OX42-immunogenes in comparison to non-targeting 
PEI-PEG polyplexes was determined using an enhanced green fluorescent protein 
(EGFP)-expressing reporter plasmid. Since auto-fluorescence has been observed 
in cultured microglia before [259,313,439], auto-fluorescence of primary microglia 
was investigated prior to transfections. Mixed primary glia cultures were utilized as 
an in vitro test system for PEI-PEG and the OX42-immunogene. Both non-viral 
vehicles were also injected into rat brain. Transfected cells were identified with 
cell-type specific markers by immunofluorescence.  
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7.2 Materials and Methods 
7.2.1 Materials 
Triton X-100, normal horse serum (NHSS), sucrose and salts to prepare 
Dulbecco’s phosphate buffered saline (DPBS) and transfection buffer (20 mM 
HEPES, 150 mM NaCl, pH 7.3) were purchased from Sigma (Australia). 
Paraformaldehyde (PFA) was from Merck (Australia). Hoechst nuclear stain dye 
(Hoechst 34580) was obtained from Invitrogen (Australia). Cell culture medium 
(high glucose DMEM, Invitrogen) was supplemented with 10% fetal bovine serum 
(FBS, Bovogen) and 2% penicillin-streptomycin (Invitrogen). Fluorescence 
mounting medium was purchased from DAKO (Denmark). Enhanced green 
fluorescent reporter plasmid pEGFP-N1 was a gift from W. Kruger (RMIT 
University) and subcultured as outined in Section 2.6. Empty control vector 
pcDNA3.1/Zeo(+) was a gift from H. Cuny (RMIT University). 
7.2.2 Antibodies 
Immunocytochemistry (ICC) and immunohistochemistry (IHC) was performed with 
antibodies and detection reagents according to Table 7-1. 
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Table 7-1: Antibodies and reagents used for ICC and IHC. 
Target Antibody Tag Host Use c / DF Source 
CD11b OX42 (M) Atto594 Mouse 
ICC 4 μg/mL 
RMIT 
IHC 8 μg/mL 
       
Iba1 α-Iba1 (P) - Goat 
ICC 400 
Abcam 
IHC 100 
       
GFAP α-GFAP (P) - Rabbit ICC/IHC 150 Invitrogen 
       
EGFP α-GFP (M) - Mouse 
ICC 400 
Roche 
IHC 200 
       
Mouse IgG α-mouse (P) Alexa594 Donkey ICC/IHC 400 Invitrogen 
       
Goat IgG α-goat (P) Biotin Horse ICC/IHC 400 Vector Labs 
       
Rabbit IgG α-rabbit (P) Alexa594 Donkey ICC/IHC 400 Invitrogen 
       
Biotin Extravidin Cy3 - ICC/IHC 600 Sigma 
M: monoclonal; P: polyclonal; c: concentration; DF: dilution factor; ICC: immunocytochemistry; IHC: 
immunohistochemistry; GFAP: glial fibrillary acidic protein; Iba1: ionized calcium binding adapter 
molecule 1; EGFP: enhanced green fluorescent protein. 
7.2.3 Polyplex Preparation  
PEI-PEG and OX42-immunoporter were synthesized as decribed before (Chapter 
6). Ice-cold transfectants (PEI-PEG or OX42-immunoporter) and plasmid DNA 
(pDNA) were diluted in transfection buffer and polyplexes prepared at N/P-ratio of 
4. Plasmid DNA was completely retarded at this ratio as demonstrated by gel 
retardation assays (Section 6.3). Transfectants were added slowly to pDNA and 
incubated for 15 minutes on ice without vortexing. For in vitro assays, ice-cold 
complete cell culture medium was then added to a total volume of 0.5 mL and the 
solution mixed by pipetting up and down. 
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7.2.4 Transfections 
Fresh and aged mixed glia cultures in tissue culture flasks were examined for 
auto-fluorescence before transfections. Mixed glia cultures for transfections were 
prepared as outlined in Section 2.1 and transfected after 3 days (concentration of 
transfectants: 0.5 mg/mL, 20 μg pEGFP-N1 plasmid per well). Astrocyte-
conditioned medium was removed and saved for later use. Mixed cultures were 
incubated with transfectants for 16-24 hours, transfection medium removed and a 
1:1 mixture of fresh complete medium and astrocyte conditioned medium added. 
Cells were fixed (4% PFA, 10 minutes) after a total of 72 hours and 
immunocytochemistry (ICC) performed. 
Male Sprague-Dawley rats (300-350 g) were used to assess transfection 
efficiency and specificity in vivo. Polyplexes were brought to room temperature 
(RT) before injecting PEI-PEG into the left and OX42-immunogene into the right 
side of the brain of the same animal (Table 7-2). Rats were perfused after 72 
hours, brains collected and post-fixed for 4 hours. After 3-4 days of storage in 30% 
sucrose, 30 μm brain sections were cut on a cryostat and immunohistochemistry 
(IHC) performed. Animal procedures followed the NHMRC guidelines and were 
approved by the RMIT University Ethics Committee. 
Table 7-2: Brain areas targeted and details of polyplex preparation. 
Target Coordinates / [mm] c / [mg/mL] V / [μL] m / [ng] 
PVN 
6.9 (AP) 0.4 (L) 8.0 (D) -
2.1 (B) 
1.0 0.3 200 
Right Lateral Ventricle 
(OX42-immunogene only) 
-0.8 (AP) 1.4 (L) 3.6 (D) 
-0.8 (B) 
0.5 10 3000 
Dorsal Striatum (CPu) 
9.5 (AP) 3.4 (L) 5.0 (D) 
0.48 (B) 
0.1 5 300 
PVN: paraventricular nucleus of the hypothalamus; CPu: caudate putamen; AP: anterior posterior; 
L: lateral; D: dorsal; B: Bregma; c: concentration of transfectants and plasmid DNA; V: injection 
volume; m: amount of DNA injected. 
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7.2.5 Immunostaining 
Mixed cultures were blocked in 10% NHSS containing 0.1% Triton-X100 (30 
minutes, RT) and brain sections were blocked in 10% NHSS containing 0.5% 
Triton-X100 (1 hour, RT). Microglial cells were detected either by CD11b-
immunoreactivity (IR) or Iba1-IR (ionized calcium binding adapter molecule 1). 
Astrocytes were stained for glial fibrillary acidic protein (GFAP) and EGFP 
expression was confirmed with an α-EGFP antibody. The α-EGFP antibody was 
only used on PEI-PEG transfected cells to avoid cross-reaction of the secondary 
α-mouse antibody with the mouse antibody of the OX42-immunogene.  
Primary antibody binding was detected with either biotinylated or fluorophore-
labelled secondary antibodies. All antibodies were diluted in 2% NHSS. For ICC, 
antibodies were incubated for 1 hour at RT. Extravidin-Cy3 conjugate (in DPBS) 
was applied to visualize binding of biotinylated secondary antibody (30 minutes, 
RT). For IHC, primary antibodies were incubated for 3 days at 2-8ºC in a 
humidifying chamber. Secondary antibodies were incubated for 2 hours at RT 
followed by 1 hour incubation at RT with extravidin-Cy3 conjugate (in DPBS).  
Coverslips and sections were mounted on microscope slides with 
fluorescence mounting medium and confocal images taken (Section 2.4.5). Each 
condition was run on duplicate coverslips in vitro and at least 2 experiments were 
performed. Transfection efficiency and specificity of PEI-PEG and OX42-
immunogene in vitro was assessed by cell counting and was based on cell-type 
specific markers. Values were expressed as Mean ± SEM and significance 
assessed with a Student’s t-test. 
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7.3 Results 
7.3.1 Aged Cultures Display Non-Specific Fluorescence 
Transfections in this study were conducted on mixed glia cultures with a reporter 
plasmid expressing EGFP. Therefore, the first experiment aimed at characterising 
mixed glia cultures regarding their auto-fluorescence properties.  
Confocal images of young (1 week) and aged (4 weeks) untreated mixed 
cultures displayed different levels of auto-fluorescence (Figure 7-1). In aged 
cultures, background fluorescence was observed over a broad wavelength 
spectrum in blue, green and red filters which was absent in young cultures. This 
non-specific auto-fluorescence was most evident in the green filter and appeared 
to localize with microglial cells that typically acquire a round shape in mixed culture 
and reside on top of an astrocytic layer. Aged microglial cells that displayed strong 
non-specific fluorescence increased in cell size compared to the cell size of 
microglia in young cultures. The existence of non-specific fluorescence in aged 
cultures therefore made it necessary to use fresh mixed glia cultures for 
transfections with an EGFP expressing plasmid. 
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Figure 7-1: Aged mixed glia cultures display non-specific fluorescence.  
Non-specific auto-fluorescence is visible over a broad wavelenght spectrum in aged cultures. 
Fluorescence co-localizes with microglial cells that increase in cell size (yellow arrow heads) 
compared to 1 week old phase-bright microglia with small cell size. 
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7.3.2 OX42-immunogene Does not Transfect Microglia in Vitro 
Mixed cultures were freshly prepared for transfection experiments and then used 
to compare transfection efficiency and specificity of the targeting OX42-
immunogene compared to non-targeting PEI-PEG.  
PEI-PEG transfected microglia (Iba1) and astrocytes (GFAP) as shown by 
EGFP-specific fluorescence (Figure 7-2 A). The OX42-immunogene transfected 
few cells and only some of them were potentially microglia, others were astrocytes 
(Figure 7-2 B). Quantification revealed that PEI-PEG transfected significantly more 
cells per coverslip than the OX42-immunogene (214 ± 37 vs. 5 ± 2, P < 0.005). 
However, 80-90% of PEI-PEG-transfected cells were GFAP-IR astrocytes and not 
microglia. The OX42-immunogene decreased the number of transfected cells, but 
4 out of 5 transfected cells were GFAP-IR astrocytes. Thus, the OX42-
immunogene reduced off-target gene delivery into astrocytes, but did not cause 
substantial gene expression in microglia.  
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Figure 7-2: Representative confocal images and quantification of EGFP-transfected cells. 
A: Non-targeting PEI-PEG transfects microglial cells (yellow arrow heads) with EGFP (green) that 
are either Iba1-immunoreactive (IR, red) or lack GFAP expression (red). PEI-PEG also transfects 
GFAP-IR astrocytes (white arrow heads). B: The targeting OX42-immunogene transfects few 
GFAP-negative cells that potentially are microglial cells (yellow arrow heads), but it also delivers 
the reporter gene into GFAP-IR astrocytes (white arrow heads). C: Quantification of transfected 
cells per coverslip. PEI-PEG (214 ± 37 cells) transfects significantly more cells than the OX42-
immunogene (5 ± 2 cells). However, 80-90% of transfected cells were not microglia. **P < 0.005. n 
= 6 coverslips for PEI-PEG and n = 4 coverslips for OX42-immunogene. EGFP: green fluorescent 
protein; GFAP: glial fibrillary acidic protein. 
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7.3.3 Transfected Microglia Exhibit Vesicle-Like Non-Specific 
Fluorescence 
The low number of cells that were transfected with the OX42-immunogene 
prompted an investigation of the cause of the lack of EGFP expression in 
microglia. Confocal images at lower magnification demonstrated that PEI-PEG 
caused green fluorescence of different intensities (Figure 7-3 A). In OX42-
immunogene treated cells, mainly green fluorescence of low intensity was 
observed (Figure 7-3 A) and this fluorescence was seen in GFAP-negative 
microglia (Figure 7-3 A). The fluorescence pattern appeared to be similar to the 
non-specific fluorescence seen in aged, untreated mixed glia cultures (Figure 7-1). 
At higher magnification, cells that exhibited high intensity of green 
fluorescence also stained positive for EGFP (Figure 7-3 B). EGFP-specific 
fluorescence was distributed within the cytoplasm and cell nucleus. In contrast, the 
green fluorescence of low intensity was vesicle-like, concentrated around the cell 
nucleus and EGFP-IR was absent (Figure 7-3 B).  This indicated that the non-
specific fluorescence is unrelated to EGFP expression. CD11b-immunoreactive 
microglia were the predominant cell type that displayed non-specific fluorescence 
upon treatment of mixed cultures with PEI-PEG or the OX42-immunogene (Figure 
7-3 C). 
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Figure 7-3: Low intensity green fluorescence is non-specific and localized in microglia. 
A: PEI-PEG transfects few GFAP-negative (red) cells that potentially are microglia. Green 
fluorescence of high (yellow arrow heads) and low intensity is visible (blue arrow heads). The green 
fluorescence of low intensity almost exclusively co-localizes with GFAP-negative cells (blue arrow 
heads) with a pattern similar to the non-specific fluorescence observed in untreated. aged mixed 
glia cultures. B: The green fluorescence of high intensity is EGFP-specific (green) and visible in the 
cytoplasm and in the cell nucleus. Expression of EGFP is confirmed with an α-EGFP antibody 
(red). However, the green fluorescence of low intensity is not non-specific as it does not co-localize 
with EGFP-IR. Non-specific fluorescence appears vesicle-like and accumulates in the perinuclear 
region. C: Non-specific fluorescence (green) is mainly localized in CD11b-IR microglia (red). When 
imaging non-specific fluorescence, laser power and gain were increased compared to imaging 
EGFP-specific fluorescence. 
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7.3.4 Transfection with Control Vector Causes Increase in Non-
Specific Fluorescence 
In order to firmly establish that the non-specific fluorescence was unrelated to 
EGFP-expression, mixed cultures were transfected as previously but delivering an 
empty control vector that lacked the EGFP reporter gene. 
After 3 days, PEI-PEG and OX42-immunogene treated cultures exhibited the 
same pattern of non-specific fluorescence (Figure 7-4) as observed in untreated, 
aged mixed glia cultures (Figure 7-1). This non-specific fluorescence was localized 
in GFAP-negative microglia (Figure 7-4). Untreated control cells had only a very 
low level of non-specific background fluorescence.  
Thus, the increase in intracellular, non-specific fluorescence was due to 
treatment of mixed cultures with PEI-PEG and the OX42-immunogene and it 
indicated that PEI-PEG and the OX42-immunogene were internalized but did not 
cause gene expression.  These data supported the finding that the OX42-
immunogene and PEI-PEG in many cells were unable to cause EGFP expression 
in microglia. 
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Figure 7-4: Transfection with control vector causes increase in non-specific fluorescence. 
Untreated control cells display very low levels of non-specific green background fluorescence. 
GFAP-negative (red) microglia exhibit increased non-specific fluorescence after treatment with PEI-
PEG and the OX42-immunogene that carry an empty vector which lacks the EGFP reporter gene. 
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7.3.5 PEI-PEG and OX42-immunogene do not Transfect 
Microglia in Vivo 
Whether the inability of the OX42-immunogene and PEI-PEG to cause EGFP 
expression in microglia was an artefact of the in vitro test system or reflected the 
actual inability of the OX42-immunogene to transfect microglia was investigated in 
vivo by injecting PEI-PEG and the OX42-immunogene into different brain areas. 
PEI-PEG and the OX42-immunogene injected into the PVN caused an 
increase in green fluorescence and accumulation of Iba-IR microglia around the 
injection site (Figure 7-5 A). In order to allow injection of greater volumes, the right 
lateral ventricle and the dorsal striatum were then used. 
After injecting the OX42-immunogene into the right lateral ventricle, Iba1-IR 
microglia also showed green fluorescence (Figure 7-5 B). The majority of cells 
displaying green fluorescence were Iba1-IR microglial cells that aquired a round 
amoeboid or phagocytic shape. Astrocytes did not exhibit green fluorescence 
(Figure 7-5 B). The fluorescence appeared to be non-specific as judged by the 
vesicle-like structure and absence of fluorescence in the nucleus (Figure 7-5 A) as 
observed in EGFP-transfected cells in vitro (Figure 7-3 B). 
The OX42-immunogene was then injected into the dorsal striatum. In order to 
demonstrate absence of EGFP-expression in vivo, brain sections were either 
imaged directly without performing  immunohistochemistry (IHC) or IHC was 
performed for brain sections with an α-EGFP antibody (Figure 7-5 C). In absence 
of cell-type specific markers, the fluorescence observed was non-specific and also 
seen in the red filter. An increase in red fluorescence due to application of an α-
EGFP antibody was not apparent demonstrating that EGFP was not expressed in 
vivo. The absence of an increased red fluorescence due to the secondary α-
mouse antibody also suggested that the OX42-immunogene was degraded, 
because the secondary antibody did not cross-react with the OX42 antibody 
component of the immunogene. Thus, the absence of EGFP-expression in 
microglia in vivo was consistent with the lack of EGFP-expression in vitro. 
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Figure 7-5: PEI-PEG and OX42-immunogene do not transfect microglia in vivo. 
A: Representative confocal images show that PEI-PEG injected into the paraventricular nucleus 
(PVN) of the hypothalamus causes green vesicle-like fluorescence mainly in Iba1-IR (red) microglia 
(yellow arrow heads) that accumulate around the injection site. B: OX42-immunogene injected into 
the right lateral ventricle causes an increase in green fluorescence that co-localizes in Iba1-IR 
microglia which exhibit an amoeboid  shape (yellow arrow heads). GFAP-IR astrocytes (red) do not 
display green fluorescence; C: Confocal imaging of brain sections (dorsal striatum) reveals that the 
green fluorescence observed is non-specific, because non-specific fluorescence is also seen in the 
red filter in absence of red fluorophore-labelled cell markers. Further, an α-EGFP antibody does not 
detect EGFP-expression. 
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7.4 Discussion 
This study demonstrated that non-viral gene delivery into microglia is difficult to 
achieve. While non-targeting PEI-PEG transfected mainly astrocytes in vitro, the 
targeting OX42-immunogene significantly reduced the number of transfected cells, 
but did not increase specificity for microglia. Around 80-90% of transfected cells 
were not microglia. PEI-PEG- and OX42-immunogene-treated mixed cultures 
exhibited non-specific fluorescence mainly localized in microglial cells which was 
unrelated to EGFP expression. The pattern of non-specific fluorescence in 
transfected cells after 3 days was similar to the non-specific fluorescence seen in 
untreated, aged mixed glia cultures.  
PEI-PEG and the OX42-immunogene caused an increase in non-specific 
fluorescence in vivo which was almost exclusively localized in microglial cells that 
acquired an amoeboid or phagocytic phenotype. In contrast to transfections in 
vitro, PEI-PEG did not cause gene expression in astrocytes in vivo. The OX42-
immunogene did not cause EGFP expression in microglia in vivo consistent with in 
vitro observations. 
7.4.1 PEI-PEG and OX42-immunogene are Degraded in Microglia 
Expression of EGFP was mostly absent in microglia regardless of whether PEI-
PEG or the OX42-immunogene was used for transfection of mixed cultures. This 
was demonstrated by the absence of EGFP-IR with an α-EGFP antibody and by 
the observed pattern for green fluorescence of high intensity (EGFP, cytoplasmic 
and nuclear) and low intensity (non-specific, vesicle-like and perinuclear). Treating 
mixed glia cultures with PEI-PEG or the OX42-immunogene carrying a control 
vector that lacked the EGFP reporter gene then confirmed that the polyplexes 
were taken up by microglia and that the intracellular non-specific fluorescence is 
unrelated to EGFP expression. Thus, the non-specific fluorescence was thought to 
be related to an intracellular event downstream of internalization. 
There are obvious parallels between the non-specific fluorescence observed 
in transfected microglia and the auto-fluorescence observed in untreated, aged 
cultures in terms of its vesicle-like appearance and perinuclear localization. The 
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source of non-specific fluorescence in aged cultures therefore may be a clue as to 
the fate of PEI-PEG and the OX42-immunogene in microglia. Indeed, cultured 
microglial cells have been described to exhibit non-specific fluorescence when 
treated with extracellular material destined for intracellular degradation [439]. 
Importantly, microglia were shown to degrade only mildly oxidized protein 
efficiently while strongly oxidized proteins were accumulated intracellularly and 
exhibited  broad-spectrum auto-fluorescence [439]. Incompletely degraded 
material that caused non-specific fluorescence has been termed ‘lipofuscin’ 
[259,425,439].  
Thus, aged microglia in untreated mixed cultures presumably display 
increased non-specific fluorescence due to the accumulation of incomplete 
degraded material over time which agrees with their scavenging function as 
phagocytes. The increase in non-specific, lipofuscin-like fluorescence in 
transfected microglia therefore most likely originates from internalization and 
accumulation of incompletely degraded PEI-PEG or OX42-immunogene. The 
perinuclear localization of this vesicle-like, non-specific fluorescence suggests that 
microglia degrade the polyplexes in lysosomes [193]. 
7.4.2 Endocytic Mechanisms of PEI-PEG Internalization 
The intracellular degradation of polyplexes in vitro raises questions about the 
mechanisms that would facilitate it. The internalization of PEI-PEG can occur via 
different mechanisms that include clathrin- and caveolin-mediated endocytosis, 
fluid-phase endocytosis or macropinocytosis [190,303,510]. The internalization 
mechanism engaged in turn depends on the polyplex charge and size. 
Although the exact internalization mechanisms into microglia and astrocytes 
are unclear, differences in the uptake most certainly exist which account for 
successful transfection of astrocytes with PEI-PEG but predominantly degradation 
of PEI-PEG in microglia. The success of PEI-mediated gene delivery in other cells 
has been shown to depend on the type of cell studied and the internalization 
mechanism triggered. For instance, Rejman et al. [391] used inhibitors of specific 
endocytic internalization pathways to show that PEI-polyplexes were internalized 
via clathrin- and caveolae-mediated endocytosis in A549 pneumocytes and HeLa 
cells. However, only polyplexes internalized via the caveolae-pathway efficiently 
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transfected cells. Polyplexes that were internalized via clathrin-mediated 
endocytosis were trafficked to lysosomes and degraded. In contrast, von Gersdorff 
et al. [481] showed by using the same inhibitors that successful gene transfer with 
PEI depended on clathrin-mediated endocytosis in COS-7 cells, but in HUH-7 cells 
both, clathrin- and caveolin-mediated endocytosis contributed to gene delivery. 
Therefore, successful gene transfer with PEI-based non-viral vehicles not only 
depends on the internalization mechanism but also cell-type specific 
characteristics that remain to be investigated for transfection of microglial cells. 
7.4.3 Non-Specific Mechanisms of PEI-PEG Internalization 
Endocytosis of PEI-based non-viral vehicles is facilitated by the small size (< 150 
nm) of polyplexes [330] and the density of proteoglycans on the cell membrane. 
The uptake of PEI-PEG- via negatively charged proteoglycans requires a positive 
net charge of the PEI-PEG-DNA complex [362] which is not desired for targeted 
gene transfer with antibodies. In the present study, PEI-PEG polyplexes were 
formed at near neutral to slightly positive charge. Although zeta-potential 
measurements were not conducted here to elucidate the exact charge, PEI-PEG 
was functional in delivering genes shown by transfection of astrocytes. PEI-
polyplexes based on the same PEI as used in this study are known to completely 
bind DNA at N/P > 2 [128,330] which is in agreement to the gel retardation assays 
conducted in Chapter 6. 
However, a neutral to slightly positive charge in the range of N/P = 2-5 also 
facilitates aggregation of PEI-polyplexes in physiological salt solution and thus 
PEI-aggregates (> 500 nm) can enter the cell via other, non-specific internalization 
mechanisms such as macropinocytosis [190,294,510]. Macropinocytosis is usually 
associated with membrane ruffle formation and confined to immuno-surveillant 
cells such as macrophages and microglia [221,283,298].  
Thus, it is very likely that microglia in comparison to astrocytes internalized 
PEI-PEG by a different mechanism which is less efficient for non-viral gene 
transfer with PEI-PEG. Other unknown cell type specific characteristics such as 
limited endosomal escape may also exist that could cause low transfection 
efficiency in microglia as observed in the present study. Further work on microglial 
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transfection therefore needs to address endosomal escape as a barrier to non-
viral gene delivery into microglia. 
7.4.4 PEI-PEG Does not Cause Gene Expression in Vivo 
There were marked differences in transfection efficiencies between cultured cells 
and in vivo. PEI-PEG transfected astrocytes in vitro but did not cause gene 
expression in vivo. In contrast, PEI-PEG was taken up mainly by microglial cells in 
vivo causing non-specific fluorescence which indicated intracellular degradation. 
The unsuccessful transfection of microglia with PEI-PEG in vivo is consistent with 
a previous report that used even higher N/P-ratios (N/P = 15) [247]. The 
phagocytic/amoeboid morphology and expression of Iba1 on the cell membrane 
[347] suggested that PEI-PEG stimulated microglial activation. 
Since internalization mechanisms are dependent on the size of the 
internalized cargo [303] and the size of non-viral vehicles is dependent on the 
maturation buffer used in polyplex formation [330,345,367], differences in polyplex 
preparation could account for different internalization mechanisms in vitro and in 
vivo. PEI-PEG polyplexes were prepared in physiological salt solution. However, 
for in vitro transfections these complexes were further diluted in complete cell 
culture medium. PEI-PEG injected into rat brain was used without dilution. It has 
been reported before that FBS prevents formation of large aggregates in solution 
[345]. Therefore, larger aggregates may have been injected in vivo and this may 
have shifted the internalization of PEI-PEG aggregates to professional phagocytes 
that take up large aggregates and destroy them such as microglia.  
7.4.5 Internalization of OX42-immunogene is Receptor-Mediated 
Unsuccessful transfection of microglial cells was not only observed for PEI-PEG, 
but also for the OX42-immunogene. In contrast to non-targeting PEI-PEG, the 
OX42-immunogene was constructed to specifically target microglia via CD11b 
receptor-mediated endocytosis. In vitro transfection experiments and quantification 
of transfected cells demonstrated that incorporating the OX42 antibody into the 
PEI-PEG polyplex prevented off-target transfection of astrocytes. This suggested 
specific receptor-mediated uptake into microglia. Green fluorescence increased 
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mainly in microglia after treatment of mixed cultures with the OX42-immunogene. 
This further emphasized that the OX42-immunogene was taken up specifically by 
microglia via a receptor-mediated mechanism. However, the OX42-immunogene 
was degraded intracellularly similarly to PEI-PEG. 
7.4.6 Mechanisms of OX42-immunogene Degradation 
The degradation of PEI-PEG and the OX42-immunogene in microglia raises the 
question about the mechanisms that prevent successful gene transfer. Although 
immunogenes are designed to be internalized via receptor-mediated endocytosis 
and the OX42 antibody was found suitable for this purpose (Chapter 4), 
stimulation of certain cell surface receptors on immune cells can trigger a strong 
immune response, e.g. the respiratory burst. Stimulation of an immune response 
in microglia could therefore activate the function of immune cells to act as 
scavengers. This could lead to removal and destruction of the OX42-immunogene 
by phagocytosis and prevent successful gene transfer.  
Chapter 5 identified a role of the microglial CD11b/CR3 (complement 
receptor 3) receptor in stimulating an immune response by phagocytosis. 
However, stimulation of microglia with antibody and cross-linking of CD11b with 
OX42-F(ab’)2-beads showed that the OX42 antibody binds to a site within the 
CD11b subunit that is unable to signal the respiratory burst. Activation of reactive 
oxygen species (ROS) production involved Fcγ-receptors (FcγRs). Thus, an 
involvement of FcγRs in uptake of the OX42-immunogene needs to be examined. 
Phagocytosis of the OX42-immunogene and stimulation of an immune 
response requires that the gene vehicle is of sufficient size (> 500 nm) in order to 
trigger phagocytosis [445]. As discussed for PEI-PEG, OX42-immunogenes were 
formed at N/P = 4 which is in the range to produce a neutral to slight positive net 
charge. Although a low N/P-ratio facilitates aggregation of non-viral vehicles, a 
high positive net charge of the OX42-immunogene would most likely allow off-
target gene delivery into other cells mediated by positively charged PEI. Thus, it is 
important to determine in following experiments the size of the OX42-immunogene 
and which receptors the OX42-immunogene targets. This would determine 
whether or not the OX42-immunogene can stimulate an immune response in 
microglia. 
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7.5 Conclusion 
This study shows that the synthesis of a microglia-targeting immunogene can be 
accomplished. Evidence is given by the significant decrease in off-target 
transfection of astrocytes in vitro due to the incorporation of the OX42 antibody in 
the non-targeting PEI-PEG polyplex. However, the absence of substantial reporter 
gene expression in microglia in vitro and in vivo demonstrates that microglia are 
difficult to transfect with non-viral vehicles based on PEI. PEI-PEG and the OX42-
immunogene are both internalized into microglia but subject to intracellular 
degradation.  
The reasons for unsuccessful gene delivery into microglia thus require further 
investigation. Two potential barriers to receptor-mediated gene transfer into 
microglia are the activation of an immune response via CD11b- and/or FcγR-
stimulation and limited endosomal escape. Both barriers would be expected to 
facilitate lysosomal degradation of the OX42-immunogene. Therefore, a detailed 
investigation of these barriers was conducted in Chapter 8. The identification of 
microglia-specific barriers could lead to the development of a 2nd generation 
immunogene that successfully delivers genes into microglia. 
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8.1 Introduction 
The central role of microglial cells in mediating inflammation within the CNS and 
their involvement in virtually all neuropathologies requires a detailed 
understanding of microglial function. The development of non-viral vehicles to 
deliver genes into microglia could lead to significant advances in the investigation 
of microglial function, but specific non-viral gene transfer into microglia has not 
been achieved so far. 
Mannose-conjugated linear polyethyleneimine (jetPEI®-Macrophage) is an 
example for a non-viral gene vehicle that has been developed to deliver 
transgenes into cells expressing the mannose receptor, for instance microglia 
[290]. Indeed, mannose-conjugated PEI transfects isolated cultured microglial cells 
[225,288], but it is unknown whether gene delivery via the mannose receptor is 
specific for microglia. 
In this PhD project, a non-viral bioconjugate (OX42-PEI-PEG, ‘OX42-
immunogene’) has been developed (Chapter 6) based on the monoclonal α-
CD11b antibody OX42 and branched PEI (25 kDa) engrafted with 
polyethyleneglycol (PEG). Transfection experiments demonstrated that 
conjugating OX42 to non-targeting PEI-PEG polyplexes reduces off-target 
transfection. However, the OX42-immunogene and PEI-PEG was degraded 
intracellularly after cellular uptake and did not cause substantial gene expression 
in microglia. Therefore, intracellular barriers to antibody-mediated gene transfer 
into microglia exist that have not been described before.  
The identification and overcoming of barriers requires an understanding of 
the mechanisms of immunogene uptake and intracellular trafficking. Immunogenes 
are designed to undergo receptor-mediated internalization and endosomal-
lysosomal trafficking [395]. They are suggested to escape the endosome before 
lysosomal degradation, a property that is attributed to the ability of PEI to cause 
osmotic rupture of the endosome [10,57] and/or direct interaction of PEI with the 
endosomal membrane [46,235,454,519]. Once released into the cytosol, genes 
carried by the immunogene can enter the nucleus and be expressed. However, it 
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is unclear as yet at which stage(s) of the transfection gene delivery into microglia 
is compromised.  
The intracellular fate of material taken up by cells is dependent on the uptake 
mechanism. Aggregation of PEI-polyplexes is often observed when complexes are 
formed at a neutral charge [128,230,345] and this may influence the route of 
internalization in microglia. Immune cells can ingest extracellular material of 
sufficient size via phagocytosis receptors such as CD11b/complement receptor 3 
(CR3) and Fcγ-receptors (FcγRs). Phagocytosis via CR3 can trigger an immune 
response under certain circumstances (Chapter 5). The stimulation of an immune 
response would therefore most likely trigger functions in microglia associated with 
their role as scavengers and cause destruction of the OX42-immunogene. The 
artificial culture environment which can contain complement proteins and 
immunoglobulin G (IgG) from serum could further facilitate phagocytosis and 
degradation via the complement system or FcγRs at least in vitro [230,451]. 
Impaired endosomal escape in microglia represents another potential limiting 
factor to gene delivery into microglia which would lead to lysosomal trafficking and 
degradation of PEI-PEG and the OX42-immunogene. The endosomolytic agent 
chloroquine has been frequently used to promote endosomal escape and enhance 
transfection efficiency of non-viral vehicles [48,129,345]. Increasing the molar PEI 
to DNA ratio (referred to as N/P-ratio) has also been shown to cause the formation 
of more positively charged complexes of smaller size with increased endosomal 
escape capability and higher transfection rates [57,128,130,203,343,345].  
The modulation of polyplex sizes may further influence the gene transfer 
efficiency with PEI as has been reported in other studies, but optimal conditions 
required to achieve high transfection rates in microglia have not been reported as 
yet. Sample preparation conditions including maturation buffer choice [48,343,345] 
and complexation temperature [418] have been found to affect polyplex 
aggregation and influence gene transfer performance. 
Therefore, the aims of this study were to use an in vitro test system to 
investigate the mechanisms of and barriers to antibody-mediated non-viral gene 
transfer into microglia. A particular focus was targeted antibody-mediated transfer 
and to evaluate jetPEI®-Macrophage as an alternative vehicle for microglia-
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specific gene transfer. The size of the OX42-immunogene was determined by 
dynamic light scattering (DLS) and its ability to trigger an immune response 
investigated by measuring reactive oxygen species (ROS) production and CD11b 
exocytosis. The effect of different sample preparation conditions on polyplex sizes 
was investigated as well as the involvement of serum factors on microglial 
transfection. Transfections were performed in the presence of the respiratory burst 
inhibitor diphenyliodonium (DPI) or chloroquine which facilitates endosomal 
escape to identify limitations to antibody-mediated gene transfer into microglia. 
The identification of barriers that restrict antibody-mediated gene transfer into 
microglia could lead to the development of a 2nd generation OX42-immunogene 
capable of delivering genes specifically into these cellular agents of CNS 
inflammation. 
8.2 Materials and Methods 
8.2.1 Materials 
Chloroquine, diphenyliodonium (DPI), zymosan A (average particle diameter 
3 μm), Triton X-100, normal horse serum (NHSS) and salts to prepare Dulbecco’s 
phosphate buffered saline (DPBS), Krebs-HEPES-buffer (KHB), transfection 
buffer/HEPES-buffered saline (HBS, 20 mM HEPES, 150 mM NaCl, pH 7.3) and 
HEPES-buffered glucose (HBG, 20 mM HEPES, 5% glucose w/v, pH 7.3) were 
purchased from Sigma (Australia). Paraformaldehyde (PFA) was from Merck 
(Australia). Cell culture medium (high glucose DMEM, Invitrogen, Australia) was 
supplemented with 10% fetal bovine serum (FBS, Bovogen) and 2% penicillin-
streptomycin (Invitrogen). Fluorescence mounting medium was purchased from 
DAKO (Denmark). Enhanced green fluorescent reporter plasmid pEGFP-N1 was a 
gift from W. Kruger (RMIT University) and subcultured as outlined in Section 2.6. 
ROS-indicator CM-H2DCFDA (5-(and-6)-chloromethyl-2',7'-dichloro-dihydro-
fluorescein diacetate, acetyl ester) was obtained from Invitrogen (Australia) and 
phorbol 12,13-dibutyrate (PDBu) was purchased from Enzo Life Sciences 
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(Switzerland). jet-PEI®-Macrophage transfection reagent was from Polyplus 
Transfections (France). 
8.2.2 Antibodies 
Immunocytochemistry (ICC) was performed with antibodies and detection 
reagents according to Table 8-3. The OX42 antibody was tagged with fluorophores 
as described in Section 2.4 and used for the CD11b exocytosis assay. 
Table 8-3: Antibodies and reagents used for ICC and exocytosis assay. 
Target Antibody Tag Host Use c / DF Source 
CD11b OX42 (M) - Mouse ICC 1.25 μg/mL RMIT 
CD11b OX42 (M) FITC Mouse Exocytosis 10 μg/mL RMIT 
CD11b OX42 (M) Atto594 Mouse Exocytosis 2 μg/mL RMIT 
Iba1 α-Iba1 (P) - Goat ICC 400 Abcam 
GFAP α-GFAP (P) - Rabbit ICC 1000 DAKO 
EGFP α-GFP (M) - Mouse ICC 400 Roche 
Mouse IgG α-mouse (P) Alexa594 Donkey ICC 400 Invitrogen 
Goat IgG α-goat (P) Biotin Horse ICC 400 Vector Labs 
Rabbit IgG α-rabbit (P) Alexa594 Donkey ICC 400 Invitrogen 
Biotin Extravidin Cy3 - ICC 600 Sigma 
M: monoclonal; P: polyclonal; c: concentration; DF: dilution factor; ICC: immunocytochemistry; 
FITC: fluorescein isothiocyanate; GFAP: glial fibrillary acidic protein; Iba1: ionized calcium binding 
adapter molecule 1; EGFP: enhanced green fluorescent protein. 
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8.2.3 PEI-PEG and OX42-immunogene Preparation 
PEI-PEG and OX42-immunoporter were synthesized as decribed before (Chapter 
6). As a general procedure, maturation of polyplexes was conducted by adding the 
non-viral vehicles slowly to pDNA and incubating them for 15 minutes. Diluent was 
then added to a total volume of 0.5 mL for transfections and the solution mixed by 
pipetting up and down. 
8.2.4 Effect of Sample Preparation on OX42-immunogene 
Aggregation 
The size-distribution profile of aggregates that may be present in complete cell 
culture medium (DMEM with 10% FBS), OX42-immunoporter (10.3 μg) and pDNA 
(20 μg, to form OX42-immunogene) was recorded by adding each component in 
this order directly to the measurement vial used for Dynamic Light Scattering 
(1 mL total volume). The effect of diluent on OX42-immunogene aggregation after 
maturation was determined by adding HBS, DMEM (+ FBS) or DMEM (-) after 
polyplex maturation at RT (0.05 mg/mL OX42-immunoporter and pDNA) in HBS or 
DMEM (+ FBS).  
The influence of maturation buffer and maturation temperature on polyplex 
aggregation was investigated by forming OX42-immunogene complexes in either 
HBS or DMEM (+ FBS) at 0.5 mg/mL for OX42-immunoporter and pDNA at room 
temperature (RT) or on ice (0ºC). The reaction mixture was then made up to 1 mL 
with DMEM (+ FBS) and the size distribution of the OX42-immunogene analysed 
by Dynamic Light Scattering (DLS). 
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8.2.5 Dynamic Light Scattering (DLS) 
Raw data was acquired for 30 seconds for each measurement (three 
measurements per experiment) with a Fast DLS analyser (ALV GmbH, Germany). 
Intensity weighted size-distribution profiles were obtained from correlation 
functions using ALV-Correlator Software (ALV GmbH). The hydrodynamic 
diameter with the highest intensity for each experiment was obtained by averaging 
the values from the three separate measurements. Polyplexes were prepared 
twice for each experimental condition. 
8.2.6 Transfections of Mixed Glia Cultures 
Mixed glia cultures for transfections were prepared as outlined in Section 2.1 and 
transfected after 3 days. Plasmid pEGFP (0.5 mg/mL) was delivered by either PEI-
PEG or OX42-immunoporter (0.5 mg/mL). Complexes were formed in either HBS 
(311 mOsm/kg) or HBG (343 mOsm/kg) on ice at N/P-ratios of 4 (10.3 μg vehicle) 
or 10 (25.9 μg vehicle) and then either ice-cold DMEM (+ FBS) or DMEM (-) was 
added. Transfections with mannose-conjugated jetPEI®-Macrophage were 
performed according to the manufacturer’s instructions at N/P-ratio of 5. 
Complexes were formed with either 0.5 μg or 2 μg pDNA per well at RT (15 
minutes) in 150 mM NaCl and then topped up with DMEM (+ FBS) to 0.5 mL. 
Mixed cultures were transfected for 24 hours and then fixed (4% PFA, 10 
minutes).  
For transfections performed in the presence of either diphenyliodonium (DPI, 
1 µM) or chloroquine (100 µM), drugs were diluted in transfection medium and 
added to the cells together with polyplexes at the same time. Mixed cultures were 
then washed after 4 hours and fresh complete cell culture medium/astrocyte 
conditioned medium (1:1) was added. 
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8.2.7 Immunostaining 
Fixed mixed glia cultures on coverslips were blocked in 10% NHSS containing 
0.1% Triton-X100 (30 minutes, RT). Microglial cells were detected either by 
CD11b-immunoreactivity (IR) or Iba1-IR (ionized calcium binding adapter molecule 
1). Astrocytes were stained for glial fibrillary acidic protein (GFAP). EGFP 
expression was confirmed with an α-EGFP antibody. Primary antibody binding was 
detected with either biotinylated or fluorophore-labelled secondary antibodies. All 
antibodies were diluted in 2% NHSS and incubated for 1 hour at RT. Extravidin-
Cy3 conjugate (in DPBS) was applied to visualize binding of biotinylated 
secondary antibody (30 minutes, RT). Coverslips were then mounted on 
microscope slides with fluorescence mounting medium. 
8.2.8 Measurement of ROS Production 
The production of ROS was measured as described previously (Section 2.5.2). 
Briefly, non-viral vehicles (1 μg/well) were prepared in transfection buffer/HBS 
(N/P = 4) as above and KHB added (50 µL final volume per well). CM-H2DCFDA-
loaded microglia (1 x 104 cells/well of a 96-well plate) were stimulated to produce 
ROS at 37ºC and fluorescence was read on a plate reader (FlexStation 3) after 60 
minutes. Each condition was measured in quadruplicate wells and at least 4 
individual assays were performed. Baseline fluorescence (KHB only) was 
subtracted from fluorescence values and results expressed as percentage of the 
response to PDBu (100 ng/mL).  
8.2.9 Exocytosis of Intracellular CD11b 
Exocytosis and translocation of internal CD11b stores was detected by direct 
immunofluorescence as described in Section 2.5.3. Briefly, isolated microglial cells 
(2 x 104 cells per coverslip) were treated for 15 minutes with buffer (KHB), OX42-
immunogene (2 μg), zymosan (7.5 μg) or PDBu (100 ng/mL) and exocytosis 
stopped by cooling the cells on ice. Membrane CD11b was detected with OX42-
IgG-FITC after fixation of cells. Internal CD11b was then stained with OX42-IgG-
Atto 594 after permeabilization. 
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Three experiments were performed (2 coverslips per condition per 
experiment). At least 15 cells per coverslip were evaluated for translocation of 
internal CD11b (ImageJ). Results were expressed as the percentage of 
intracellular CD11b per cell that had not translocated to the cell membrane. 
Internal CD11b-immunoreactivity (IR) in non-stimulated microglia was interpreted 
as 100% internal CD11b.  
8.2.10 Quantification and Statistical Analysis 
Confocal images were acquired as described in Section 2.4.5. Transfection 
efficiency and specificity of PEI-PEG, OX42-immunogene and jetPEI®-
Macrophage was assessed by cell counting taking into account cell-type specific 
markers. For experiments n ≥ 3, one-way ANOVAs were performed with posthoc t-
tests with Bonferroni correction or posthoc one-sample t-tests with Bonferroni 
correction.  
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8.3 Results 
8.3.1 OX42-immunogene Forms Aggregates that can Trigger 
Phagocytosis  
Initial experiments aimed to determine the size-distribution profiles for serum 
components, the OX42-immunoporter vehicle and the OX42-immunogene. 
Complete cell culture medium (DMEM, 10% FBS) contained small aggregates of < 
100 nm in diameter (Figure 8-1 A). There was no marked difference in the size 
distribution profile when the OX42-immunoporter was added (final concentration: 
0.01 mg/mL) suggesting that the vehicle had not substantially aggregated. 
However, when pDNA was added to form the OX42-immunogene complex (N/P = 
4), large OX42-immunogene aggregates formed over a wide range (≈ 50-1300 nm, 
Figure 8-1 A). This suggested that OX42-immunogene aggregates could trigger 
phagocytosis in microglia based on aggregate sizes.  
8.3.2 The Size of OX42-immunogene Aggregates is Influenced 
by Sample Preparation 
Further experiments were designed to understand how the aggregation behaviour 
of the OX42-immunogene depended on sample preparation. The mode of OX42-
immunogene aggregate size was found to be strongly dependent on serum, either 
added after maturation of complexes in HBS or present in the maturation buffer 
(Figure 8-1 B). Although FBS caused a shift in the size distribution profile to 
smaller aggregates, it did not markedly narrow the size distribution (Figure 8-1 B). 
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Figure 8-1: OX42-immunogene forms large aggregates that can trigger phagocytosis.   
A: Size-distribution profile of OX42-immunogene formed in complete cell culture medium. 
Comparison of the size-distribution profile between complete cell culture medium (DMEM + 10% 
FBS) and the OX42-immunoporter obtained by Dynamic Light Scattering shows that the non-viral 
vehicle does not form aggregates. After adding pDNA to form the OX42-immunogene (N/P = 4), 
aggregates form over a large range (≈ 50-1300 nm). B:  Serum in the transfection medium reduces 
aggregation. Adding FBS to polyplexes after maturation in HBS and maturation of polyplexes in 
FBS-containing medium causes a shift in size-distribution to lower aggregate sizes, but it has no 
effect on the width of size-distributions. C:  Effect of sample preparation on OX42-immunogene 
aggregate sizes. The mode of aggregate sizes and the size-distribution are largely independent of 
maturation buffer and maturation temperature in the presence of FBS. The average mode of the 
hydrodynamic diameter of OX42-immunogene polyplexes prepared for in vitro transfections is 
178 nm ± 7 nm.  Values are plotted as Mean ± SEM. n = 2 experiments. FBS: fetal bovine serum; 
OX42-IP: OX42-immunoporter; HBS: HEPES-buffered saline (transfection buffer); D (+/-): DMEM 
with/without 10% FBS; RT: room temperature. 
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The maturation buffer and maturation temperature was then varied to screen for 
optimal sample preparation in order to obtain the smallest OX42-immunogene 
aggregates at N/P = 4. Polyplexes were formed at a concentration of 0.5 mg/mL 
for OX42-immunoporter and pDNA, because concentrations > 0.5 mg/mL caused 
the formation of large visible, insoluble aggregates that were mostly absent for 
concentrations ≤ 0.5 mg/mL. 
In contrast to the pronounced effect of serum components on OX42-
immunogene aggregation, the maturation buffer and temperature had no apparent 
effect on the modal hydrodynamic diameter and the size distribution profile (Figure 
8-1 C). Dynamic light scattering measurements confirmed that the sample 
preparation previously used to transfect microglia in vitro (Chapter 7) gives the 
smallest OX42-immunogene aggregates (mode of diameter: 178 nm ± 7 nm, 
Figure 8-1 C) and that changes in sample preparation do not influence 
aggregation behaviour distinctly. Although the mode of OX42-immunogene 
aggregates is in a range that allows receptor-mediated endocytosis to occur, the 
wide distribution and presence of larger aggregates could trigger phagocytosis in 
microglia. 
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Figure 8-2: Transfection medium containing FBS does not promote vehicle degradation in 
microglial cells. 
A: The presence of FBS in the transfection medium significantly increases the total number of 
transfected cells with PEI-PEG (74 ± 13 vs. 21 ± 12), but not with the OX42-immunogene (7 ± 3 vs. 
5 ± 2). B: FBS has no effect on the specificity of either PEI-PEG (14.4% ± 1.7% vs. 12.0% ± 7.4%) 
or OX42-immunogene (12.7% ± 8.0% vs. 16.1% ± 5.9%) on microglial transfection. Values are 
plotted as Mean ± SEM. n = 4-6 coverslips in 2-3 experiments. * P < 0.05; N.S.: not significant. 
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8.3.3 Fetal Bovine Serum Does not Promote Vehicle Degradation 
Previous results showed that PEI-PEG and the OX42-immunogene are degraded 
in microglia (Chapter 7). Although serum has a beneficial effect on polyplex 
aggregate formation, serum components such as complement factors and IgG 
antibodies may have attached to the complexes and facilitated PEI-PEG and 
OX42-immunogene degradation in microglia. Thus, polyplexes were prepared in 
HBS and mixed cultures were transfected in the presence and absence of FBS in 
cell culture medium (Figure 8-2).  
The presence of FBS in transfection medium caused a significant increase of 
the total number of cells transfected by PEI-PEG (21 ± 12 vs. 74 ± 13, P < 0.05, 
Figure 8-2 A) but not with the OX42-immunogene (5 ± 2 vs. 7 ± 3, Figure 8-2 A). 
There was no effect of FBS observed on the percentage of transfected microglia 
(Figure 8-2 B). For both non-viral vehicles, about 12-16% of transfected cells were 
microglia. Thus, serum did not facilitate degradation of PEI-PEG and OX42-
immunogene in microglia, it actually facilitated a higher transfection rate for the 
former. 
8.3.4 Aggregated OX42-immunogene Stimulates an Immune 
Response in Microglia 
Since serum in the transfection medium was not the reason for intracellular 
degradation of PEI-PEG and the OX42-immunogene, other explanations were 
sought. First, the consequences of microglial phagocytosis of aggregated 
polyplexes were investigated. When ROS production was measured, there was a 
significant increase in the observed fluorescence of the ROS indicator in microglia 
treated with the OX42-immunogene (37.6% ± 4.0%, P < 0.0001, Figure 8-3 A). 
Diphenyliodonium (1 μM), an inhibitor of the respiratory burst, abolished ROS 
production in microglia elicited by the aggregated OX42-immunogene (-7.02% ± 
4.49%). Non-targeting PEI-PEG did not stimulate ROS production (-0.97% ± 
3.74%) suggesting that the respiratory burst caused by the immunogene was 
mediated by specific receptors on the microglial membrane.  
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Figure 8-3: Aggregated OX42-immunogene stimulates an immune response in microglia. 
A: Quantification of ROS-indicator fluorescence after 60 minutes as a measure of ROS production 
in microglial cells. The aggregated OX42-immunogene triggers the respiratory burst (37.6% ± 
4.0%) which is inhibited by the respiratory burst inhibitor diphenyliodonium (-7.02% ± 4.49%). The 
positive control zymosan causes the release of ROS at similar levels (45.8% ± 4.7%) to the OX42-
immunogene. However, PEI-PEG (-0.97% ± 3.74%) and the OX42-immunoporter (9.83% ± 2.84%) 
do not trigger the respiratory burst. Results are expressed as% of internal standard PDBu after 
baseline subtraction. B: Intracellular CD11b-IR before stimulation of exocytosis. C: Remaining 
intracellular CD11b-IR after 15 minutes stimulation with the aggregated OX42-immunogene. The 
OX42-immunogene triggers translocation of intracellular CD11b stores to the cell membrane (white 
arrows). D: Zymosan also activates microglial cells as observed by translocation of intracellular 
CD11b stores to the cell membrane (white arrows). E: PDBu stimulates translocation of 
intracellular CD11b to the cell membrane and hardly any CD11b-IR remains inside the cell after 15 
minutes (white arrows). F: Direct comparison of intracellular CD11b-IR before and after stimulation 
with various stimuli. G: Quantification of CD11b exocytosis. Treatment of microglia with buffer 
(KHB, 104.7% ± 5.4%) does not trigger depletion of intracellular CD11b stores. Stimulation with the 
aggregated OX42-immunogene (61.3% ± 2.9%), particulate zymosan (61.7% ± 2.7%) and PDBu 
(27.0% ± 3.0%) triggers significant exocytosis of intracellular CD11b. Values are plotted as Mean ± 
SEM. ** P < 0.01 vs. control; *** P < 0.0001 vs. control; N.S.: not significant. DPI: 
diphenyliodonium; PDBu: phorbol 12,13-dibutyrate. Please note that representative confocal 
images in B, D, E and F as well as the quantification of exocytosis for KHB, zymosan and PDBu in 
G are taken from Figure 5-4 (Section 5.3.4). 
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Further, aggregation of the OX42-immunogene as seen by DLS (Figure 8-1 A) 
was crucial to trigger the respiratory burst, because the non-aggregated OX42-
immunoporter stimulated only low levels of ROS production (9.83% ± 2.84%). 
Particulate zymosan as a positive control generated significant levels of ROS 
(45.8% ± 4.7%, P < 0.01) similar to the aggregated OX42-immunogene. 
The treatment of microglia with the OX42-immunogene for 15 minutes 
(Figure 8-3 C) stimulated the translocation of intracellular CD11b stores (Figure 
8-3 B and F) to the cell membrane as did zymosan (Figure 8-3 D) and PDBu 
(Figure 8-3 E). The quantification of remaining intracellular CD11b-IR after 
stimulation (Figure 8-3 G) revealed that 61.3% ± 2.9% (P < 0.001) of intracellular 
CD11b remained when microglial cells were stimulated with the aggregated OX42-
immunogene. CD11b exocytosis was also elicited by particulate zymosan (61.7% 
± 2.7% remaining, P < 0.0001) and PDBu (27.0% ± 3.0% remaining, P < 0.0001) 
but not by buffer alone (104.7% ± 5.4%). Therefore, the aggregated OX42-
immunogene triggered a strong inflammatory response in microglia as 
demonstrated by a phagocytosis-induced respiratory burst and CD11b exocytosis. 
8.3.5 Inhibition of the Respiratory Burst with DPI does not 
Improve Transfection Efficiency and Specificity 
Whether inhibition of the respiratory burst with DPI would increase transfection 
efficiency and specificity was investigated next. In presence of DPI, the total 
number of OX42-immunogene transfected cells per coverslip did not increase (2 ± 
1 vs. 2 ± 2, Figure 8-4 A). For transfections conducted with PEI-PEG, the number 
of PEI-PEG-transfected cells even decreased (25 ± 4 vs. 53 ± 9, Figure 8-4 A). 
DPI had no apparent effect on the specificity of transfections for microglia. The 
percentage of transfected microglia ranged from 13% (PEI-PEG with DPI) to 25% 
(OX42-immunogene with DPI) with high variability due to the low number of OX42-
immunogene transfected cells (Figure 8-4 B). Phenylarsine oxide [255,521] was 
also evaluated as an alternative NOX inhibitor (data now shown). However, 
phenylarsine oxide could not be used in the ROS assay, because it apparently 
oxidized the ROS indicator dye causing green fluorescence not related to ROS 
production.  
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Figure 8-4: Inhibiting the respiratory burst does not increase transfection rate. 
A: In presence of the respiratory burst inhibitor diphenyliodonium, the number of PEI-PEG-
transfected cells decreases (25 ± 4 vs. 53 ± 9) and the number of OX42-immunogene-transfected 
cells does not increase (2 ± 1 vs. 2 ± 2). B: Diphenyliodonium has no apparent effect on specificity 
for microglial transfections conducted with either PEI-PEG or the OX42-immunogene. Less than 1 
microglial cell per coverslip on average is transfected by the OX42-immunogene. The variability of 
the data as indicated by (†) is due to the low number of OX42-immunogene transfected cells. 
Values are plotted as Mean ± SEM. Transfections were performed on two parallel coverslips. DPI: 
diphenyliodonium. 
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8.3.6 A Higher N/P-Ratio and a Different Maturation Buffer do not 
Promote Gene Expression in Microglia 
Since aggregation of the OX42-immunogene caused a phagocytosis-induced 
respiratory burst and an immune response (Figure 8-5 C) and since the size of 
polyplexes determines their internalization mechanism(s), experiments were 
performed under transfection conditions that have been reported to reduce 
polyplex aggregate sizes.  
In the first experiment, the influence of the N/P-ratio on microglial transfection 
was investigated. PEI-PEG and OX42-immunogene complexes at N/P = 4 
exhibited large insoluble aggregates that were mostly absent at N/P = 10 (Figure 
8-5 A). This suggested that a higher N/P-ratio can stabilize polyplexes and reduce 
aggregation. However, a higher N/P-ratio also caused astrocytes to acquire a 
reactive phenotype with retracted processes and increased GFAP-IR suggesting 
that a N/P-ratio of 10 is toxic to the cells (Figure 8-5 A). In contrast, the 
morphology of astrocytes at N/P = 4 looked similar to non-treated cells.  
Transfection of glia cells with PEI-PEG at N/P = 10 caused a decrease in the 
total number of transfected cells (40 ± 12 vs. 133 ± 30, Figure 8-5 B). In contrast, 
cultures transfected with the OX42-immunogene at N/P = 10 showed an increase 
in the number of transfected cells (111 ± 34 vs. 5 ± 2). However, the increase in 
the total number of transfected glia cells with the OX42-immunogene did not 
reflect an increase in the percentage of transfected cells that were microglia 10% 
of transfected cells were microglia at both N/P = 4 and 10 indicating that the 
OX42-immunogene at high N/P-ratio transfected other cells more effectively than 
microglia.  
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Figure 8-5: Increasing the N/P-ratio and changing the maturation buffer does not improve 
gene transfer into microglia. 
A: An increased N/P-ratio reduces the amount of insoluble aggregates (white arrows) in the 
transfection medium (brightfield images). However, a N/P-ratio of 10 appears to be toxic to mixed 
cultures as judged by the morphology of reactive astrocytes (retracted processes and increased 
GFAP-IR, red, confocal images). B: At N/P = 10, PEI-PEG transfects less cells (40 ± 12 vs. 133 ± 
30). In contrast, a higher N/P-ratio causes an increase in the total amount of transfected cells with 
the OX42-immunogene (111 ± 34 vs. 5 ± 2). C: At N/P = 10, the percentage of transfected 
microglia does not change (PEI-PEG: 3.9% ± 1.9% vs. 4.0% ± 2.1%; OX42-immunogene: 9.8% ± 
4.8% vs. 8.4% ± 8.4%). D: Changing the maturation buffer from HEPES-buffered saline (HBS, 
transfection buffer) to HEPES-buffered glucose (HBG, with 5% glucose) has no effect on 
transfection efficiency (PEI-PEG: 53 ± 11 vs. 56 ± 20; OX42-immunogene: 7 ± 1 vs. 9 ± 2). E:  
HBG also does not increase the percentage of transfected cells that are microglia (PEI-PEG: 
16.1% ± 4.2% vs. 14.1% ± 1.3%; OX42-immunogene: 25.0% ± 8.3% vs. 17.2% ± 2.9%). The 
variability of the data as indicated by a cross is due to the low number of OX42-immunogene 
transfected cells. Values are plotted as Mean ± SEM. Experiments were performed on two 
coverslips in parallel. N/P-ratio: molar nitrogen-phosphate ratio; HBS: HEPES-buffered saline; 
HBG: HEPES-buffered glucose. 
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Because a higher N/P-ratio was not beneficial for targeted gene transfer into 
microglia, a reduction of polyplex aggregation was then attempted by using 
HEPES-buffered glucose (HBG, 5% glucose) as maturation buffer. However, 
maturation of PEI-PEG and OX42-immunogene complexes in HBG as compared 
to HEPES-buffered saline (HBS, transfection buffer) did not have an effect on 
transfection efficiency (Figure 8-5 D) or microglial specificity (Figure 8-5 E).  
In conclusion, aggregation of the OX42-immunogene triggered an 
inflammatory immune response in microglia that may have caused destruction of 
the complex. However, neither inhibition of the respiratory burst nor interventions 
to reduce aggregate formation were successful at promoting gene transfer into 
microglia. Thus, other potential barriers for antibody-mediated gene transfer were 
examined. 
8.3.7 Endosomal Escape is Facilitated by Chloroquine 
Impaired endosomal escape was investigated as a cause of PEI-PEG and OX42-
immunogene degradation in microglia by transfecting mixed cultures in the 
presence of the endosomolytic agent chloroquine.  
Chloroquine (100 µM) had no apparent toxic effect on mixed cultures as seen 
by normal astrocyte morphology compared to non-treated cells (Figure 8-6 A). 
Choloquine treatment significantly increased the total number of cells transfected 
with PEI-PEG (424 ± 42 vs. 74 ± 13, P < 0.0001) and the OX42-immunogene (71 
± 8 vs. 8 ± 3, P < 0.0001) at N/P = 4 (Figure 8-6 B). Interestingly, chloroquine 
caused a significant increase in the percentage of transfected cells that were 
microglia for both transfectants (PEI-PEG: 20.3% ± 1.2% vs. 14.3% ± 1.7%, P < 
0.05; OX42-immunogene: 32.3% ± 2.4% vs. 12.7% ± 8.0%, P < 0.05, Figure 8-6 
C) demonstrating that endosomal escape is limiting for non-viral gene transfer into 
microglia.  
 
 
 
Chapter 8: Barriers to Antibody-Mediated Gene Transfer Into Microglia 
340 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-6: Chloroquine increases transfection efficiency and specificity. 
A: Transfection medium containing 100 μM chloroquine is not toxic to mixed cultures as judged by 
astrocyte morphology compared to untreated control (GFAP-IR, red). B: PEI-PEG (424 ± 42 vs. 74 
± 13) and the aggregated OX42-immunogene (71 ± 8 vs. 8 ± 3) transfect significantly more cells in 
the presence of chloroquine. C: Chloroquine also increases specificity for microglia when 
transfected with PEI-PEG (20.3% ± 1.2% vs. 14.3% ± 1.7%) and the OX42-immunogene (32.3% ± 
2.4% vs. 12.7% ± 8.0%). Values are plotted as Mean ± SEM. n = 6 coverslips (3 independent 
experiments). *P < 0.05, ***P < 0.0001. Cq chloroquine. 
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However, despite this increase in presence of chloroquine the majority of the cells 
transfected with the OX42-immunogene were not microglia. This showed that the 
OX42-immunogene is not specific for microglia and the data strongly suggested 
the involvement of another route in internalization of the OX42-immunogene other 
than CD11b, for instance a receptor which is shared by microglia and other glial 
cells. 
8.3.8 Mannose-Conjugated Linear PEI is not Specific for Gene 
Delivery into Microglia  
Because specific delivery of DNA into microglia was not achieved with the OX42-
immunogene, another non-viral vehicle was tested for its ability to target microglia 
in vitro. The commercially available vehicle jetPEI®-Macrophage incorporates 
linear PEI conjugated to mannose in order to target mannose receptors.  
Mixed cultures were transfected with jetPEI®-Macrophage (1 μg linear PEI) 
delivering 0.5 μg DNA per well at a N/P-ratio of 5. Under these conditions, 
astrocytes appeared to exhibit an increased GFAP-IR and shorter processes 
compared to non-treated cells and glia treated with the OX42-immunogene (1 μg 
branched PEI) suggesting toxicity of jetPEI®-Macrophage (Figure 8-7 A).  
The total number of EGFP-positive cells transfected with mannose-
conjugated linear PEI (Figure 8-7 B) was > 2500 per coverslip based on counting 
cells in 5 areas per coverslip and extrapolating the number to the area of the 
coverslip. Transfection efficiency of jetPEI®-Macrophage was about 20-30 times 
higher compared to PEI-PEG and similiar to non-PEGylated branched PEI (data 
not shown). However, an estimated 80-90% of the transfected cells were not 
CD11b-IR (Figure 8-7 B) demonstrating that jetPEI®-Macrophage is not specific 
for microglia in mixed culture. 
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Figure 8-7: Mannose-conjugated jet-PEI® is not specific for microglia. 
A: Mannose-conjugated linear PEI (jet-PEI®-Macrophage) appears to be more toxic to mixed glia 
cultures under transfection conditions (N/P = 5, 1 μg linear PEI per well) compared to the OX42-
immunogene (N/P = 4, 1 μg branched 25 kDa-PEI per well). Toxicity is judged by reactive astrocyte 
morphology (retracted processes and increased GFAP-IR, red). B: Mannose-conjugated PEI 
transfects many cells with EGFP (green) that are not microglia (white arrow heads). Only few 
CD11b-IR microglia (red) express EGFP (yellow arrow heads). Single confocal sections were taken 
with maximum pinhole and represent transfected cells from 4 coverslips (2 independent 
experiments). PEI: polyethyleneimine; EGFP: enhanced green fluorescent protein; IR: 
immunoreactivity. 
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8.4 Discussion 
This study characterised PEI-based polyplex preparations for microglial 
transfections in vitro and also identified limitations to antibody-mediated gene 
transfer into microglia. The OX42-immunogene formed large aggregates that could 
trigger phagocytosis. Serum in the transfection medium reduced OX42-
immunogene aggregation and also promoted transfection efficiency, but did not 
cause degradation of the polyplexes due to serum proteins. 
The aggregated OX42-immunogene triggered a phagocytosis-induced 
immune response in microglia resulting in respiratory burst activity and CD11b 
exocytosis which potentially caused polyplex degradation. The respiratory burst 
inhibitor DPI, however, failed to facilitate gene transfer into microglia. Modulation 
of polyplex sizes by varying N/P-ratios or choosing a glucose buffer for maturation 
had no great effect on gene transfer into microglia. 
In contrast, chloroquine promoted overall transfection efficiency and 
increased the percentage of transfected microglia with both PEI-PEG and the 
OX42-immunogene. However, most of OX42-immunogene transfected cells were 
not microglia. The evaluation of the alternative gene vehicle jetPEI®-Macrophage 
showed that despite high transfection efficiency this non-viral vehicle was not 
specific for microglia. 
8.4.1 Aggregation of OX42-imunogene Facilitates Phagocytosis 
as a Pathway for Internalization 
The influence of sample preparation on PEI-polyplex sizes and gene transfer has 
been extensively described, but not in relation to microglial gene transfer. OX42-
immunogene complexes were formed at N/P = 4, which is in the range of neutral 
overall charge [130,330], in order to promote receptor-mediated uptake rather than 
non-specific internalization mediated by positively charged PEI [395]. Dynamic 
light scattering showed that the OX42-immunogene formed a heterogeneous 
population of aggregated polyplexes from less than 100 nm to more than 1 μm 
under this condition. This suggested that phagocytosis is one of the mechanisms 
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by which the OX42-immunogene is internalized. The existence of aggregates 
< 150 nm also indicated that receptor-mediated endocytosis may occur in parallel.  
Changes in sample preparation were made in an attempt to shift the OX42-
immunogene aggregates to smaller sizes to promote receptor-mediated 
endocytosis. Serum had the most pronounced effect on polyplex aggregation and 
increasing the concentration of FBS to 10% reduced the mode of aggregate sizes 
by half to under 200 nm. This finding is in partial agreement with a study 
conducted by Ogris et al. [345] who observed the same effect of FBS on PEI-
complexes matured in HEPES-buffered glucose (HBG) but not in HEPES-buffered 
saline (HBS). However, serum had no effect on the spread of aggregate sizes in 
the present study.  
Thus, phagocytosis of the vehicles under in vitro transfection conditions could 
still occur even with 10% FBS present in transfection medium. Due to the absence 
of serum under in vivo transfection conditions (Chapter 7), polyplex aggregate 
sizes are expected to be larger than those observed for in vitro transfections and 
promote phagocytosis over receptor-mediated endocytosis. This could explain why 
smaller aggregates transfected astrocytes in vitro, but microglia almost exclusively 
internalized and degraded aggregated polyplexes of larger size in vivo (Chapter 
7). 
8.4.2 Serum Factors do not Promote Polyplex Degradation 
Although FBS reduced aggregation, serum proteins may influence the transfection 
by promoting degradation of the polyplexes via complement or FcγR. However, 
transfections conducted in presence of serum did not promote degradation of PEI-
PEG or the OX42-immunogene in this study. Instead, FBS even increased 
transfection efficiency mainly in astrocytes and other cells than microglia which 
may be attributed to the existence of smaller polyplex aggregates in the presence 
of FBS. The reduced transfection efficiency in absence of FBS may also reflect the 
lack of growth factors and other nutrients within serum that are needed for normal 
cell growth and metabolism. 
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8.4.3 The Microglial Immune Response is a Drawback for Gene 
Transfer 
The stimulation of a respiratory burst and CD11b exocytosis demonstrated that the 
aggregated OX42-immunogene but not PEI-PEG triggers a strong inflammatory 
response in microglia. The stimulation of an immune response is not desired for 
two reasons. Firstly, stimulation of the respiratory burst may exacerbate 
neurodegeneration and thus impede the application of the OX42-immunogene in 
vivo. Secondly, the stimulation of an immune response would most likely trigger 
functions in microglia associated with their role as scavengers and cause 
destruction of the OX42-immunogene. 
The inhibition of the respiratory burst with 1 µM DPI unfortunately did not 
increase transfection efficiency, although this concentration was found to be 
sufficient to abolish ROS production in the current and in another study [82]. 
Instead, a reduction in transfected cells with PEI-PEG in presence of DPI was 
observed. This suggests other non-specific effects of DPI at low micromolar 
concentrations, for instance inhibition of mitochondrial respiration [14,263] which 
may affect normal cell metabolism and function. It is therefore unclear from this 
experiment whether or not the respiratory burst prevented transfection. 
Bypassing the activation of cytotoxic effector functions in microglia was 
attempted by increasing the N/P-ratio [128,203] and using HBG as maturation 
buffer [345] to obtain smaller polyplex aggregates and circumvent phagocytosis as 
internalization mechanism. Both interventions had no great effect on microglial 
transfection. Polyplexes formed at N/P = 10 appeared to have toxic effects on the 
mixed culture system which may be related to cellular toxicity mediated by an 
excess of free PEI [52].  
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8.4.4 Degradation of the OX42-immunogene May Occur Due to 
FcγR Stimulation 
As shown previously in Chapter 5, the activation of a phagocytosis-induced 
respiratory burst in microglia requires cross-linking of appropriate cell surface 
receptors. Because the OX42 antibody was unable to trigger the respiratory burst 
even when CR3 was cross-linked (Chapter 5), the stimulation of an immune 
response by the aggregated OX42-immunogene most likely involves FcγRs. The 
non-directed conjugation of PEI-PEG to the OX42 antibody further suggests that 
both CR3 and FcγRs are targeted and that both receptors can interact in 
phagocytosis of the aggregated OX42-immunogene.  
In other immune cells, CR3 and FcγRs interact to facilitate the rate of 
phagocytosis [189,212,284,285]. The observation that lipofuscin-like 
autofluorescence due to intracellular OX42-immunogene degradation was found 
predominantly in microglia (Chapter 7) supports the assumption that CR3 also 
worked in conjunction with FcγRs in microglial phagocytosis. Therefore, the 
inability of the OX42-immunogene to cause substantial gene expression in 
microglia may be due to targeting receptors other than CR3 and directing the gene 
vehicle to a less efficient gene delivery pathway such as phagocytosis which 
involves FcγRs.  
8.4.5 Endosomal Escape is a Barrier to Non-Viral Gene Transfer 
into Microglia 
Limited endosomal escape as another obstacle for microglial gene transfer was 
investigated by using chloroquine to promote endosomal escape at N/P = 4. 
Chloroquine was used at neutral N/P-ratio, because at higher N/P-ratios non-
specific interaction of positively charged PEI with off-target cells may occur [230] 
besides promoting endosomal escape due to an excess of PEI [223,454,518].  
Chloroquine caused a significant increase in the total number of transfected 
cells and the percentage of transfected microglia with PEI-PEG and the OX42-
immunogene. Thus, the increase in transfection efficiency in the presence of 
chloroquine showed that the endosomal escape is limited in microglia. 
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Interestingly, chloroquine appears to facilitate endosomal escape of mainly 
small polyplex aggregates that undergo receptor-mediated endocytosis [48,345]. 
The increase in transfected microglia and other cells may thus be due to an effect 
of chloroquine on gene delivery with small PEI-PEG and OX42-immunogene 
aggregates that trigger receptor-mediated endocytosis rather than phagocytosis. 
Because astrocytes express FcγRs and both CR3 (Chapter 4) and FcγRs [6] can 
undergo receptor-mediated endocytosis besides phagocytosis, this further 
suggests that the uptake of the OX42-immunogene may occur via both receptors. 
8.4.6 The OX42-immunogene is not Specific for Microglia 
Although an increase in the total number of OX42-immunogene-transfected cells 
was observed in the presence of chloroquine, more than 60% of transfected cells 
were other glia. This supports the assumption that the OX42-immunogene is not 
specific for microglia. Because astrocytes and other brain cells express at least 
one FcγR subtype in vitro and in vivo [264,338,349], the transfection of non-
microglial cells underlines an involvement of FcγRs in OX42-immunogene 
internalization. Targeting the mannose receptor with jetPEI®-Macrophage did not 
provide specificity for microglial cells either possibly due to the fact that astrocytes 
express the mannose receptor as well [65]. 
8.4.7 The Activation of the Respiratory Burst and Impaired 
Endosomal Escape may be Linked 
The results from this study therefore argue for multiple limitations for microglial 
gene transfer that affect transfection efficiency and specificity. Interestingly, the 
activation of an immune response may be linked to an impaired endosomal 
escape which further limits gene transfer for OX42-immunogene aggregates that 
undergo phagocytosis. This is because the activation of the ROS producing 
enzyme NADPH oxidase (NOX) 2 in the respiratory burst is linked to a more 
alkaline phagosome in neutrophils [415] and dendritic cells [408]. NOX2 consumes 
protons to generate superoxide anions and superoxide also requires protons when 
dismutating into hydrogen peroxide [33,148] therefore causing a rise in 
phagosomal pH. This mechanism has yet not been reported for microglial cells, 
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but a more alkaline environment would interfere with the endosomal escape 
capability of PEI which requires an acidic endosomal/phagosomal pH [10,57,223]. 
Thus, the respiratory burst may not only have a direct effect on degradation of the 
OX42-immunogene, but may also modulate the phagosomal pH and impair 
endosomal escape indirectly. 
8.4.8 The Choice of PEI and PEGylation Extent may be Important 
to Deliver Genes into Microglia 
While the respiratory burst elicited by the aggregated OX42-immunogene is a 
potential reason for degradation of the non-viral vehicle, it does not explain the low 
microglial transfection efficiency of non-targeting PEI-PEG which does not 
stimulate an immune response. The inability of PEI-PEG in this study to transfect a 
large number of microglia in the presence of FBS and the successful transfection 
of astrocytes point to the ineffectiveness of branched PEI (bPEI, 25 kDa) in 
promoting endosomal escape and gene transfer in microglia. 
Indeed, the success of gene transfer with PEI depends on polyplex type 
(linear or branched PEI, molecular weight) and the cell type transfected 
[203,228,345,481]. It appears that there are other yet undefined factors at the level 
of endosomal escape that limit gene transfer into microglia. Screening of several 
types of PEI is necessary to identify the most suitable PEI-polymer that yields 
highest levels of gene expression in these cells. 
Linear PEI conjugated to mannose (jetPEI®-Macrophage) transfected more 
cells than PEI-PEG and the OX42-immunogene in the current study but similar 
numbers compared to unconjugated branched PEI (data not shown). This shows 
that linear PEI may be useful to transfect microglia. Nevertheless, PEGylation of 
branched PEI reduced the transfection rate compared to PEI alone which could be 
related to an inappropriate PEI to PEG ratio [312,344,451]. Thus, not only the 
choice of the type of PEI but also the extent of PEGylation may be important for 
microglial gene transfer. 
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8.4.9 Antibody-Mediated Gene Delivery into Microglia Requires 
Improved Vehicle Design 
The results presented here show that microglial cells are very resistant to 
antibody-mediated gene transfer. Avoiding the aggregation-induced activation of 
immune effector functions may be critical for the success of non-viral vehicles to 
transfer genes into microglia. This barrier, however, appears to be specific for 
immune cells and not for neurons, for instance, because antibody-mediated gene 
delivery has been achieved into neuronal sub-populations in vivo [29,37,395].  
Nevertheless, phagocytosis could be an appropriate internalization pathway 
for microglial transfection, because it has been employed successfully for gene 
transfer into immune cells in vitro and in vivo apparently in absence of a strong 
immune response [19,225,288,489]. Thus, further development of the OX42-
immunogene is required in order to avoid activation of the respiratory burst and 
promote endosomal escape.  
The use of OX42-F(ab’)2-fragments as targeting ligands which lack FcγR-
binding sites rather than intact OX42-IgG antibodies may confer the specificity and 
efficiency needed to successfully transfect microglial cells. The right choice of PEI 
type and PEGylation extent could further facilitate gene expression in microglia. 
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8.5 Conclusion 
Multiple barriers exist that limit non-viral gene transfer into microglia with 
antibodies. The aggregation of the OX42-immunogene represents one obstacle, 
because it favours phagocytosis and stimulates a strong immune response that 
could exacerbate inflammation in in vivo applications. Phagocytosis of the 
aggregated OX42-immunogene most likely causes the intracellular degradation of 
the targeting vehicle in the phago-lysosome. The activation of the respiratory burst 
appears to involve Fcγ-receptors (FcγRs) and therefore FcγR-stimulation has to 
be avoided. Bypassing FcγR-stimulation is also important to increase the 
specificity of the OX42-immunogene for microglia, because other CNS cells 
express FcγRs as well. Targeting the mannose receptor with jetPEI®-Macrophage 
as an alternative appears to lack specificity for microglia. 
The inability of PEI-PEG to cause substantial gene expression in microglia 
demonstrates that endosomal escape is another barrier for non-viral gene transfer 
into microglia. Branched PEI (25 kDa) may not be suitable for gene transfer into 
microglia and a thorough screening of alternative PEI-polymers and the evaluation 
of an appropriate PEI:PEG ratio is needed.  
Therefore, successful targeted gene transfer with OX42 antibody requires 
further development and a combined approach by using OX42-F(ab’)2-fragments 
that lack FcγR-binding sites to avoid stimulation of immune effector functions, a 
PEI polymer that gives the highest level of gene expression in microglia, an 
optimized PEI:PEG ratio and optimized sample preparation conditions to obtain 
small aggregates that promote receptor-mediated endocytosis. This study 
suggests that phagocytosis is not an efficient pathway for microglial transfection, 
however, it remains to be established whether phagocytosis via CD11b/CR3 in 
absence of an immune response is able to deliver genes into microglia. 
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9.1 CD11b is an Important Mediator of Microglial 
Activation 
Microglial cells express a variety of cell surface receptors that are involved in 
modulating the microglial activation state. This project focussed on the role of the 
integrin CD11b receptor (complement receptor 3, CR3) in the microglial immune 
response and its contribution to ROS production that could be toxic to neurons in 
pathology. The results presented in this work identify a previously underestimated 
central role of CD11b in mediating microglial activation from partial to full activation 
and stimulation of cytotoxic effector functions.  
Soluble CD11b agonists (eg., OX42 antibody) and particulate ligands (eg., 
beads coated with OX42 antibody) stimulated microglia to become activated. 
Integrin activation by OX42 antibody triggered internalization and trafficking of 
CD11b and its ligand and activated microglia to form macropores and membrane 
ruffles. However, this occurred in the absence of a respiratory burst. CD11b/CR3 
is also able to perform phagocytosis of particulate ligands. Importantly, 
endocytosis and phagocytosis in vitro can occur via CD11b/CR3 without co-
receptor stimulation, eg., FcγR.  
An interesting and important finding of this study is that CR3 has a dual role 
in phagocytosis and the cellular effector functions it triggers. While CR3-mediated 
phagocytosis via the complement-binding site is characterised by the absence of a 
strong, cytotoxic immune response, the interaction with FcγRs and/or the 
stimulation of the lectin-binding site in CD11b renders CR3 able to cause ROS 
production and signal CD11b exocytosis, which is typical for respiratory burst 
activity. These functions of CD11b/CR3 have not been described for microglia 
before and shed light on the pathophysiological mechanisms that can shift the 
initial neuroprotective role of microglia to a neurotoxic phenotype. 
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9.1.1 CD11b Receptor Aggregation, Trafficking and their Roles in 
Microglial Functions 
9.1.1.1 A Role for CD11b in Microglial Apoptosis 
This study has identified mechanisms that initiate and accompany CD11b-
mediated signalling in microglia, i.e. receptor aggregation, internalization and 
trafficking. Downstream consequences of CD11b signalling may be specific for 
microglia, because CD11b is specifically expressed by microglia/macrophages in 
the CNS.  
Activation of microglia with the CD11b agonist fibrinogen is known to 
stimulate the Akt and extracellular signal-regulated kinase (ERK) signalling 
pathways [4,9]. This is consistent with the role of CD11b in activating Akt and ERK 
signalling cascades in other immune cells [492]. The stimulation of these two 
pathways controls apoptosis and survival in neutrophils [97,416,522] and 
monocytes/macrophages [317,486]. 
One study reported that injected OX42 antibody can induce microglial 
apoptosis and mitosis in rat brain in vivo [390]. This suggests a similar role of 
CD11b in microglial apoptosis. The extracellular matrix (ECM) within the CNS 
provides an environment containing CD11b ligands that can modulate microglial 
functions. Intracellular adhesion molecule 1 (ICAM-1), for instance, is recognized 
by CD11b [117] and ICAM-1 expression is up-regulated in spinal cord after LPS 
injection [515], in the facial motor nucleus after axonal damage [490] and in the 
brain in an animal model of stroke [81]. In neutrophils, ICAM-1 signals cell survival 
[293,492]. However, CD11b has an opposing role in neutrophils that can also 
promote apoptosis depending on the presence of pro-apoptotic factors, for 
example tumor necrosis factor (TNF)-α and Fas [374,492].  
It remains to be investigated in detail whether CD11b plays the same role in 
cell fate determination for microglia. Further research in the mechanisms that 
regulate microglial apoptosis is crucial, because the removal of pro-
inflammatory/classically activated microglia may support the recovery of the CNS 
after neuroinflammation [251,497]. 
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9.1.1.2 Partial Activation via CD11b: Getting CR3 Ready for 
Phagocytosis 
The data presented here suggest that internalized CD11b in microglia traffics to 
membrane ruffles where it is enriched. Membrane ruffle formation is related to 
phagocytosis in microglia [347] and uptake of inactivated complement 3b (iC3b)-
coated particles in macrophages [265,360]. Thus, partial activation of microglia 
with a CD11b agonist appears to prime the cell and prepare CR3 to exert its 
phagocytic functions. 
This mechanism could be important for the removal of Aβ-fibrils, the hallmark 
of Alzheimer’s Disease (AD), from the extracellular environment, because iC3b-
mediated phagocytosis is implicated in Aβ-removal in vivo [154]. Further, 
membrane ruffles are also known to form where non-specific (i.e. not receptor-
mediated) uptake of extracellular fluid/ligands occurs by macropinocytosis [445]. 
Soluble Aβ peptides are taken up via macropinocytosis in vitro and in vivo [283] 
and this could be important to avoid Aβ-fibril formation. Thus, the function of 
CD11b/CR3 is linked to its trafficking pathway and appears to be protective for 
neuronal function. It is intriguing to speculate that dysfunctional CD11b trafficking 
affects microglial phagocytosis via CR3 and could be an underlying mechanism 
promoting chronic neurodegeneration.  
9.1.2 The Role of CR3 in Phagocytosis, Oxidative Stress and 
Phagocytosis-Induced Cell Death 
9.1.2.1 CR3 and its Involvement in Phenotype Switching 
The present study demonstrates the capacity of the microglial CR3 to perform 
phagocytosis in vitro independent of co-stimulation of other receptors. 
Phagocytosis via CD11b has profound effects on the activation of the respiratory 
burst and this depends on the CD11b ligand and the binding site ligated. Reactive 
oxygen species (ROS) are not produced in the case of complement-mediated 
phagocytosis mimicked by OX42-F(ab’)2-beads. This is consistent with the 
observation that iC3b-mediated removal of apoptotic cells is anti-inflammatory 
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[167]. Also synaptic pruning, which is facilitated by complement-mediated 
phagocytosis, does not evoke pro-inflammatory responses [409,410].  
However, the stimulation of CD11b via other binding sites or the co-
stimulation of FcγRs activates a phagocytosis-induced respiratory burst that could 
be neurotoxic if activated for an extended time. Thus, microglial CR3 could play a 
role in switching the microglial phenotype from an anti-inflammatory to pro-
inflammatory state.  
9.1.2.2 Mechanisms that could Trigger Neurotoxic Activation of CR3 
While there are many microglial receptors that could mediate the release of toxic 
molecules from microglia, eg. N-methyl-D-aspartate receptors [214,375], the 
production of ROS via neurotoxic CR3 activation could be an underlying 
mechanism that facilitates neurodegeneration in diseases where phagocytosis is a 
central component of neuroinflammation, eg., multiple sclerosis or AD [87]. 
The results of the present study strongly argue for the interaction of CR3 and 
FcγR in phagocytosis and ROS production in microglia. In peripheral immune 
cells, this interaction is well documented in the inflammatory response 
[189,212,527]. The presence of IgG in the CNS in pathology could provide a 
cross-linking agent that changes protective (anti-inflammatory) complement-
mediated phagocytosis to phagocytosis involving FcγRs associated with 
respiratory burst activity. Elevated IgG levels in the CNS are observed in chronic 
neurodegeneration [277,381] and in aged individuals due to increased 
permeability of the blood-brain-barrier [138]. In addition, changes in the expression 
profile of activating FcγRs vs. inhibitory FcγRs [277] could facilitate microglial 
phenotype switching from protective [154,279] to toxic [210] in neuropathologies. 
Arguing against this, auto-antibodies in the CNS and immunization of 
patients with Aβ or anti-Aβ antibodies support the removal of toxic protein burden 
by increasing the rate of phagocytosis [159,220]. However, different FcγR-
subtypes exist that bind IgG of diverse subclasses. The relative influence of 
activating vs. inhibitory FcγRs may therefore determine whether CR3-mediated 
phagocytosis in conjunction with FcγR-stimulation has a protective or detrimental 
outcome [337,349]. Indeed, immunization with anti-Aβ antibodies in a mouse 
model of AD can induce inflammation and cause detrimental side-effects 
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[371,383]. These effects may be attributed to an inappropriate activation of 
phagocytosis-induced ROS production. 
9.1.2.3 Phagocytosis-Induced Cell Death in Microglia 
The production of ROS via the respiratory burst may also play a role in microglial 
apoptosis and influence the progression of neurodegenerative diseases. 
Phagocytosis-induced cell death (PICD) via CR3 is one of the mechanisms by 
which neutrophils [97,293,522] and macrophages [151,226,231,357] undergo 
apoptosis This pathway of cell death requires the production of ROS via the 
respiratory burst [132,226,522]. However, PICD and apoptosis in general can be 
modulated by cytokines in the inflammatory environment, for instance TNF-α (pro-
apoptotic) and granulocyte-macrophage colony-stimulating factor (anti-apoptotic) 
[269,293,522]. 
Microglial PICD has yet not been described but if it occurs, CR3 may be 
involved in the removal of classically (M1) activated microglia and prevent chronic 
microglial activation. As discussed earlier, phagocytosis via CR3 does not trigger 
the respiratory burst and thus most likely does not trigger PICD, eg., during 
complement-mediated phagocytosis. This is reasonable considering the 
involvement of CR3 in non-inflammatory homeostatic mechanisms such as 
synaptic pruning. On the contrary, if microglia shift from an anti-inflammatory to 
pro-inflammatory phenotype involving CR3-mediated ROS production in the 
respiratory burst, then their effects may be limited due to their removal via PICD. 
Because of the presence of certain anti-apoptotic factors in the inflammatory 
environment, however, PICD may be inhibited and these classically activated 
microglia may become neurotoxic due to sustained release of ROS. 
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9.1.3 Implications of CR3-Mediated Phagocytosis, ROS 
Production and PICD for the Microglial Immune Response 
Phagocytosis, ROS production and apoptosis are interrelated events that have not 
attracted adequate attention in the study of microglial activation. The involvement 
of CD11b/CR3 in these functions of closely related immune cells in the periphery 
suggests that this receptor is crucial for an appropriate microglial function in health 
and for controlling and limiting neuroinflammation in disease. Inappropriate 
CD11b/CR3 activation could therefore promote chronic inflammation due to 
persistent ROS production facilitated by extracellular molecules such as antibodies 
or cytokines that switch the function of CD11b/CR3 from neuroprotective to 
neurotoxic. Thus, it appears that CD11b/CR3 is an ‘accidental’ promoter of 
neurotoxicity rather than a direct initiator of oxidative stress. A better 
understanding of the complex interplay between CD11b/CR3 and extracellular 
molecules that microglia encounter during neuroinflammation therefore requires 
further study. 
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9.2 Non-Viral Vehicles for Microglial Transfection 
Require further Development 
The successful development of non-viral vehicles for microglia-specific gene 
transfer could be a significant step towards understanding microglial function in 
vivo. The second aim of this project was to investigate whether antibody-mediated 
gene delivery can be achieved for microglial cells. Unfortunately, while significant 
progress was made towards this end, this approach has thus far been 
unsuccessful and the OX42-immunogene was degraded in microglia in vitro and in 
vivo. Thus, the role of hydrogen peroxide in microglial activation could not be 
examined. Instead, experiments were conducted to identify barriers to non-viral 
gene delivery into microglia which have not been reported before and to formulate 
approaches to overcoming them. 
The current study demonstrates that the transfection of microglia with non-
viral vehicles is a challenging task and this is partly due to their role as immune 
cells. The stimulation of cell surface receptors such as FcγR can initiate an 
undesired immune response that may interfere with gene delivery and also 
contribute to neuroinflammation. Further, endosomal escape in microglia appears 
to be restricted for as yet unidentified reasons. In contrast, astrocytes do not 
appear to exhibit these barriers. Thus, the search for a microglia-specific non-viral 
vehicle that transfects microglia has to continue and incorporate solutions to the 
issues identified in the present work. 
9.2.1 Receptor Function Determines the Suitability of a Target 
for Antibody-Mediated Gene Transfer 
One of the most important aspects for receptor-mediated delivery of transgenes 
into immune cells is the choice of the targeted receptor. For example, pattern 
recognition receptors may trigger an immune response and thus careful 
examination of receptor function is required. It is almost certain that receptor-
mediated gene delivery into microglia and other immune cells will initiate some 
kind of cellular response. However, the present study demonstrates that partial 
activation of microglia via CD11b, for instance, may be an acceptable side-effect 
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of CD11b-mediated gene delivery whereas a strong immune response with 
respiratory burst activity is not desired.  
Therefore, the downstream effects that a particular receptor elicits will 
determine its suitability for receptor-mediated gene transfer. Receptors such as 
CD11b and the mannose receptor that are involved in anti-inflammatory signalling 
cascades [205] are candidates to achieve non-viral gene transfer into microglia. 
While there are several studies utilizing mannose-conjugated non-viral vehicles to 
transfect immune cells other than microglia [129,142,219,489,523], the present 
work identifies for the first time the suitability of the microglial CD11b receptor as 
target for antibody-mediated gene delivery into immune cells. 
9.2.2 The OX42 Antibody is Useful for Non-Viral Gene Transfer 
into Microglia 
The data presented here argue for the use of the monoclonal α-CD11b antibody 
OX42 to specifically target and deliver genes into microglia, because OX42 
specifically binds to microglia via CD11b, stimulates receptor-mediated 
internalization, is trafficked towards the lysosomal compartment and does not 
trigger a strong immune response. However, the latter observation only holds true 
when CD11b is stimulated to undergo receptor-mediated endocytosis.  
Aggregation of the OX42-immunogene synthesized using intact OX42-IgG 
antibody facilitates receptor cross-linking causing phagocytosis and a respiratory 
burst that most likely involves both FcγRs and CR3. As discussed before, both 
receptors are known to interact in phagocytosis. In addition to aggregation of the 
OX42-immunogene, the non-directed conjugation of the DNA condensation agent 
polyethyleneimine (PEI) to the OX42-IgG antibody promotes interaction of FcγRs 
and CR3. Due to the existence of several subtypes of activating and inhibitory 
FcγRs [337], the results presented in this work suggest that the OX42-
immunogene stimulates an activating FcγR. This is consistent with the observation 
that IgG2a antibodies such as OX42 are involved in pro-inflammatory signalling 
[336]. Thus, further development of microglia-specific non-viral vehicles needs to 
bypass this FcγR-stimulation. 
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9.2.3 Future Improvements in Non-Viral Vehicles for Microglial 
Gene Transfer 
Besides unwanted stimulation of FcγRs that may limit gene transfer into microglia, 
impaired endosomal escape represents another issue that needs to be addressed 
in the further development of microglia-specific non-viral vehicles. Based on the 
data presented here, however, the development of a 2nd generation OX42-
immunogenes could result in successful microglial gene delivery.  
9.2.3.1 Development of a 2nd Generation Immunogene using 
Antibody Fragments 
The ability of CR3 to perform phagocytosis in the absence of ROS production 
suggests that an immunogene based on OX42-F(ab’)2-fragments can trigger 
endocytosis/phagocytosis, bypass FcγR stimulation and avoid activation of the 
respiratory burst. In this regard, the use of bivalent antibody fragments rather than 
single chain fragments may be beneficial, because integrin receptors of immune 
cells require receptor clustering by bivalent ligands to undergo internalization 
[139].  
Reducing immunogene aggregation would be also useful to facilitate 
endocytosis. However, the near-neutral zeta potential that is required to promote 
receptor-specific internalization and to suppress uptake of the immunogene in off-
target cells via positively charged PEI will make it difficult to achieve small polyplex 
sizes. Nevertheless, phagocytosis may still be a viable pathway for gene delivery 
[19,489]. Phagocytosis of an OX42-F(ab’)2-immunogene via CR3 may follow the 
same route and fate as parasites and bacteria that utilize complement-mediated 
phagocytosis to survive and infect host cells [172,323]. 
9.2.3.2 Other Improvements for Receptor-Mediated Gene Delivery 
While branched PEI appears to be suitable for transfecting astrocytes, the 
transfection efficiency in microglia is low. Thus, PEI of different structure may need 
to be tested in its ability to increase transfection efficiency in microglia and then 
conjugated to OX42-F(ab’)2 antibody fragments. Linear PEI conjugated to 
mannose successfully delivers genes into macrophages [128] and microglia [288] 
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in vitro. Thus, the substitution of branched PEI with linear PEI in the bioconjugate 
needs to be considered and what effect this may have on aggregation remains to 
be seen.  
In addition, the incorporation of peptides that destabilize the endosomal 
membrane [423] may further enhance transfection efficiency in microglia. 
Targeting the mannose receptor on microglia may be another strategy to achieve 
non-viral gene delivery in vivo. However, this would require the inclusion of a 
specific promoter to drive transgene expression in microglia, because astrocytes 
express the mannose receptor as well [65]. 
The present study provides a basis for further improvements of non-viral 
vehicles for microglial gene transfer by identifying barriers that limit receptor-
mediated gene transfer into microglia. The development of a vehicle based on 
antibody fragments and PEI that successfully delivers genes into microglia will 
help to elucidate microglial functions in chronic neurodegeneration. Antibody-
mediated gene delivery will also represent a new technology that allows the 
delivery of therapeutic genes specifically into microglia to treat neuropathologies in 
the future.  
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9.3 Concluding Remarks 
Our understanding of brain function has progressed tremendously in the last 20-30 
years. Although Del Rio-Hortega [111] characterised microglia almost 100 years 
ago as cells that undergo morphological changes upon injury and perform immune 
functions such as phagocytosis, it has only recently been appreciated that 
microglia are a central element to normal neuronal function.  
The plethora of tasks that microglia exert are diverse, ranging from guiding 
the establishment of synaptic networks in the developing organism to maintenance 
of synaptic plasticity in the mature CNS and orchestrating the immune response in 
pathology. Clearly, microglial cells function to protect neurons. However, microglial 
activation involves a delicate balance between protection and release of toxic 
substances that results in their role as a mediator of neuronal damage. The 
current study has exemplified this demonstrating that CD11b/CR3 has a dual role 
in exerting neuroprotective and neurotoxic functions. Although the mechanisms by 
which a shift from protective to neurotoxic microglia is still unknown, future work 
has to consider an involvement of CD11b/CR3 in this phenotypic switch. 
The involvement of activated microglia in neuropathologies can no longer be 
neglected, although there is much to be learned before successful treatments can 
be trialled. Thus, a detailed understanding of microglial function and the 
development of microglia-oriented therapies in order to modulate the immune 
response, e.g. by non-viral gene transfer, will be without doubt invaluable in the 
future. This PhD project has taken important steps towards achieving these goals. 
Subsequent work that incorporates the important findings and suggestions from 
this project will further contribute to our understanding about the role of microglia 
in health and disease. 
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